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SUMMARY 
 
 
It has been estimated that between 3000 and 4000 plant species are used for 
their medicinal properties throughout South Africa, with approximately 27 million 
South Africans making use of traditional medicines.  Of this 27 million, 3 million 
South Africans rely on traditional medicine as their primary source of health care.  
Of the 250 000 to 500 000 known plant species, very few have been investigated 
for their pharmacological qualities, and compounds of significant medicinal value 
may still remain undiscovered in many plant species.  
 
The aims of this study included investigating the antimicrobial properties of 
Geranium incanum and Artemisia afra, both plants traditionally used for their 
medicinal properties, and comparing the antimicrobial activity of the latter to that 
of Artemisia absinthium, as well as investigating the anticancer properties of G. 
incanum and A. afra, and comparing the anticancer activity of the latter to that of 
A. absinthium.  Infusions, aqueous-, methanol- and acetone extracts of the three 
plants were prepared and used for anticancer and antimicrobial screening.  Plant 
specimens used to prepare extracts for antimicrobial activity were collected and 
extracted over three seasons, while extracts used for anticancer screening were 
prepared from plants collected during the summer only.  Considerable variation 
existed in the percentage crude extract yields obtained when different extractants 
were used, while the season in which the plants were harvested and extracted 
also appeared to play a significant role in the amount of extract obtained. 
 
The plant extracts were screened for antimicrobial activity against various strains 
of Candida albicans, Escherichia coli, Pseudomonas aeruginosa, Enterococcus 
faecalis, Staphylococcus aureus and Bacillus cereus, using an agar dilution 
method.  G. incanum and A. afra possessed activity for C. albicans, while all 
three plants showed activity for S. aureus and B. cereus.  Activity was largely 
dependent on the extraction method used. 
iii 
 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay 
was used to screen for anticancer activity of the respective extracts, at varying 
concentrations, against MCF-7 (human breast adenocarcinoma) cells, HT-29 
(human colonic adenocarcinoma) cells and HeLa (human cervical cancer) cells.  
All of the extracts showed cytotoxic activity in all three cell lines to varying 
extents, depending on the extract used and cell line screened.  The acetone 
extract of A. afra proved to be the most effective inhibitor with the lowest IC50 
(2.65 ± 1.05 µg/ml) having been shown in MCF-7 cells.  A. afra and A. absinthium 
showed similar inhibitory patterns, with the methanol- and acetone extracts 
having been the most potent inhibitors of each of the respective cell lines in 
general.  Fluorescence microscopy employing 4',6-diamidino-2-phenylindole 
dihydrochloride (DAPI) and propidium iodide (PI) staining indicated that the 
acetone extract of A. afra induces apoptosis in MCF-7 cells as apposed to 
necrosis, and the results were comparable to those obtained for cells exposed to 
cisplatin. 
 
Screening of the A. afra acetone extract for toxicity in normal human cells using 
the CellTiter-Blue® assay indicated the extract to be toxic to peripheral blood 
mononuclear cells (PBMC’s) at concentrations comparable to that for MCF-7 
cells, while cell cycle analysis of MCF-7 cells exposed to the A. afra acetone 
extract indicated the extract’s ability to induce apoptosis comparable to that of 
cisplatin, with the extract exerting its activity at a point during or just prior to the S 
phase of the cell cycle. 
 
Key words: anticancer, antimicrobial, apoptosis, Artemisia absinthium; Artemisia 
afra; Bacillus cereus; Candida albicans; cell cycle; DAPI; Enterococcus faecalis; 
Escherichia coli; Geranium incanum; HeLa; HT-29; IC50; MCF-7; MTT; peripheral 
blood mononuclear cells; PI; Pseudomonas aeruginosa; Staphylococcus aureus;  
traditional medicine  
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CHAPTER 1 
INTRODUCTION 
 
 
The past two decades have witnessed a renewed interest in research in the 
field of ethnopharmacology.  The Western world acknowledges the use of 
traditional remedies by many cultures worldwide, and the need for new drug 
development has aimed the focus on an ethnobotanical approach to the 
discovery of new pharmacological agents (Light, Sparg, Stafford & Van 
Staden, 2005). 
 
The history of traditional medicinal systems is as vast and varied as the 
cultures in which they have their roots, including those originating from Africa, 
North America, Central and South America, Australia, China, India, Arabia 
and Europe.  The use of many early traditional medicines was influenced by 
irrational superstitions which, in some cases, continue today.  The belief that 
the use of human body parts in conjunction with certain medicinal plants 
increases the potency of the medicinal qualities of these plants, has led to 
numerous ritualistic murders in South Africa, with children often falling victim 
to these “muthi” murders.  However, not all traditional medicines were initially 
used based on superstitions.  Modern scientific research in the fields of 
ethnobotany and ethnopharmacology has validated the traditional use of 
many plants for their medicinal properties by different cultures.  Traditional 
African, Ayurvedic (Indian) and Chinese medicine systems are amongst the 
oldest known, and has undoubtedly influenced modern drug development and 
the isolation of novel compounds with therapeutic value (Gurib-Fakim, 2006).  
 
Pollen and flower fragments of various medicinal plants discovered in the 
grave of a 60 000 year old Neanderthal man indicates that the human race 
has recognised and has been using plants for their medicinal properties for at 
least the last 60 millennia.  Another example is the 5300 year old ice man 
discovered in the Italian Alps during 1991, whose possessions included, 
amongst other things, fragments of birch fungus, which was probably used as 
 2 
a laxative or antimicrobial agent (Elgorashi, Taylor, Maes, Van Staden, De 
Kimpe & Verschaeve, 2003; Hart, 2005).  A few plant species having been 
used by the Mesopotamian civilization for their healing properties some 4600 
years ago are still being used today to treat a variety of conditions, ranging 
from colds to infection and inflammation.  The recent development of the drug 
β-methoxypsoralen from Ammi majus (Bishop’s weed), which is used to treat 
psoriasis and T-cell lymphoma, has validated the use of this plant by the 
Egyptian civilization for the treatment of vitiligo, a skin condition (Gurib-Fakim, 
2006).   
 
Knowledge of medicinal plants was passed on from one generation to the 
next and was eventually recorded in herbal journals (Balunas & Kinghorn, 
2005).  This knowledge is important and applicable to our times for various 
reasons.  Firstly, it promotes the discovery of new alternatives to drugs 
currently being used.  Secondly, it is important from a conservation point of 
view; if over exploitation of a medicinal plant species should occur, restrictive 
measures can and should be taken to ensure survival and sustainability of the 
specific species.  From a cultural point of view, important knowledge 
regarding the traditional use of plants is lost as it is not being passed on from 
one generation to the next anymore.  Thus it is important that this knowledge 
be documented to ensure that it is at the disposal of future generations who 
may benefit from it (Thring & Weitz, 2006). 
 
It is estimated that 80% of the global population rely on plant derived 
medicines to address their health care needs (Gurib-Fakim, 2006). 
Consultation of traditional healers and the use of herbal medicine provided by 
them play an integral role in rural healthcare, with the majority of the South 
African population consulting traditional healers to address most, if not all, of 
their healthcare needs (Light et al., 2005).  This is mainly due to the high cost 
of Western medical care in developing countries such as South Africa, the 
inaccessibility of facilities rendering modern Western medical care to rural 
communities, unavailability of novel drugs and the cultural role that the use of 
traditional medicines play in these communities (Louw, Regnier & Korsten, 
2002).  Whereas modern Western medical treatment aims to treat the 
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immediate physiological processes and symptoms of a disease condition, 
traditional healers aim to restore balance and a general sense of well being of 
a patient on both a mental and physiological level.  For this reason a 
combination of plants are usually prescribed to patients by traditional healers, 
who believe that the synergistic or additive effects of the correct combination 
of plants will be more successful in treating a patient than would be a single 
drug.  The simultaneous use of traditional and modern Western medicines is 
common practice in most societies, with Western medicine being used to treat 
acute conditions, while traditional medicines are employed to provide relief 
from chronic disease conditions (Gurib-Fakim, 2006).   
 
South Africa has a remarkable botanical diversity with over 30 000 flowering 
plant species, which constitutes more or less one tenth of the global higher 
plant species.  Of the 30 000 flowering plant species, ten families are 
endemic, with 80% of the species and 29% of the genera being endemic 
(Stafford, Jäger & Van Staden, 2005; Fennell, Light, Sparg, Stafford & Van 
Staden, 2004).  It has been estimated that between 3000 and 4000 plant 
species are used for their medicinal properties throughout the country, with 
approximately 27 million South Africans making use of traditional medicines 
(Fennell et al., 2004; Mulholland & Drewes, 2004).  Of this 27 million, 3 million 
South Africans rely on traditional medicine as their primary source of health 
care (Louw et al., 2002).  Approximately 20 000 tons of plant material is sold 
on an annual basis on the South African market, be it on the street or by 
traditional healers, with 20 000 to 30 000 individuals deriving in income from 
the selling of medicinal plants in KwaZulu-Natal alone (Fennell et al., 2004; 
Mulholland & Drewes, 2004).  The number of traditional healers in the country 
is estimated at 200 000, with 60% of the population making use of their 
services (Light et al., 2005; Thring & Weitz, 2006).  Mulholland and Drewes 
(2004) estimated that the majority of South African households spend 
between 4% and 8% of their annual income on traditional medicinal plants 
and healers. 
 
South Africa’s increasing population has led to an increase in the demand and 
consumption of traditional botanical remedies during the latter part of the 
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twentieth century.  Harvesting of medicinal plants often occurs under non- 
sustainable conditions, and it is estimated that as much as 85% of medicinal 
plants harvested are non-renewable sources such as bulbs, bark and 
rhizomes (Fennell et al., 2004).  The short term financial gains from the selling 
of these non-renewable plants and their parts appear to be more compelling 
to the harvester than the long term ecological impact and availability of scarce 
plants for use by future generations.  This attitude has led to some plant 
species having become scarce and endangered.  It would appear that the 
only remedy to this predicament is the small scale farming and production of 
medicinal plant species.  However, medicinal plants cultivated and harvested 
artificially according to Western methods are often not acceptable to many 
conservative traditional healers, who claim that the plants are less effective 
and loose their potency if not grown and harvested naturally.  A decrease in 
the availability of many plant species, along with an increase in the demand 
for and price of these plants has left the majority of traditional healers no 
alternative choice but to accept that agricultural cultivation is the only 
sustainable long term solution (Fennell et al., 2004).          
 
The use of plants for the treatment of various ailments has several 
advantages.  Plant derived medicines are generally better tolerated by 
patients and have fewer side effects.  If harvested correctly, medicinal plants 
are a sustainable natural source of medicine and the cultivation and 
processing of these plants do not lead to the inevitable pollution associated 
with the industrial processes used to produce many Western drugs.  
Cultivation and selling of medicinal plants could also provide needy families 
with a small income.  The development of drug resistance is also less 
documented in plant derived medicines (Vermani & Garg, 2002). 
 
Nature continues to play an integral role in the discovery and isolation of novel 
molecules with medicinal properties, with more than 50% of chemotherapeutic 
agents currently in use having been derived from natural products (Gurib-
Fakim, 2006).  Plants constitute about 25% of the total amount of natural 
agents which have yielded useful medicinal compounds (Gurib-Fakim, 2006; 
Rates, 2001).  Eleven percent of the 252 drugs being considered by the World 
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Health Organisation as being basic and essential are of plant origin (Rates, 
2001). 
 
Detection, isolation and development of novel chemotherapeutic agents from 
plants is normally a time consuming, laborious and expensive task, with each 
new drug requiring US$ 100-360 million in investment and at least 10 years of 
development and clinical trials.  Furthermore, only 1 out of every 10 000 
compounds tested will be considered for further development, and 1 out of 
every 4 of these promising compounds eventually reaches the status of a 
novel agent for medical use.  However, of the 250 000 to 500 000 known plant 
species, very few have been investigated for their pharmacological qualities, 
with an estimated 5000 having been investigated for their medicinal properties 
(Rates, 2001).  Thus it could be safe to assume that compounds of significant 
medicinal value still remain undiscovered in many plant species which have, 
to date, not been investigated.  The rapid rate of deforestation of tropical 
areas in especially South America and Africa may lead to the extinction of 
many undiscovered plant species and the subsequent loss of compounds 
which may be the answer to some of mankind’s most devastating disease 
conditions, such as HIV/AIDS, cancer, diabetes and malaria.       
 
Examples of pharmacologically active compounds isolated from plants include 
morphine, cocaine, digitoxin, codeine, quinine, reserpine and pilocarpine. 
Catharanthus roseus (Rosy Periwinkle) has yielded two powerful anticancer 
agents, while three other major anticancer drugs were derived from plants 
traditionally used by North American Indians, including the Pawpaw (Asimina 
spp.), Mayapple (Podophyllum peltatum) and the Western Yew Tree (Taxus 
brevifolia) (Gurib-Fakim, 2006).  In 2001 and 2002, a quarter of the best 
selling drugs globally were either natural products or derivatives thereof 
(Balunas & Kinghorn, 2005). 
 
Though ethnopharmacology is progressing in South Africa, a lack of research 
that could be beneficial to traditional healers and their patients, as well as to 
Western medicine, still prevails.  Scientific research done during the last 
century has proven the pharmacological activities of many plant species 
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traditionally used for their medicinal properties, thus validating the use of 
these plants (Louw et al., 2002; Hart, 2005).  The majority of current research 
is directed toward the discovery of commercially useful compounds from 
medicinal plants (Light et al., 2005). 
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CHAPTER 2 
LITERATURE REVIEW 
 
 
2.1. Introduction 
 
In the current chapter, main subgroups of phytochemicals as the biologically 
active compounds in medicinal plants are discussed.  A brief overview of 
Geranium incanum, Artemisia afra and Artemisia absinthium is given, 
including botanical classifications and vernacular names, macroscopical 
morphology and geographical distributions.  A brief summary of the known 
major phytochemical constituents of each of the respective plant species is 
also given, as well as the ethnopharmacological application of these plants by 
various cultures, and previous scientific research conducted on the efficacy of 
these plants in treating the conditions for which they are used. 
 
The current chapter also features a brief discussion on cancer, its aetiology 
and pathogenesis on both macroscopical and molecular levels, as well as 
current plant derived anticancer agents being used in the clinical setting.   
Finally, the development of drug resistance amongst micro-organisms is 
briefly discussed, focussing on the mechanisms of the development of drug 
resistance and factors contributing to this. 
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2.2. Phytochemicals as the biologically active compounds in medicinal  
       plants 
 
In this section, an overview of some of the major phytochemical compounds 
found in plants, especially as relating to the three plants used in the current 
study, their synthesis and functions, and how they may be applied in industry 
and the clinical field, is given. 
 
2.2.1. Flavonoids 
 
Flavonoids refer to a group of phenolic compounds, the latter including a wide 
range of chemical constituents all having an aromatic ring which bears one or 
more common hydroxyl groups (Mukinda, 2005, p.27).  
 
The basic nucleus of a flavonoid contains fifteen carbon atoms arranged in a 
C6-C3-C6 configuration, which forms two aromatic rings linked by a 3 carbon 
unit.  This unit may or may not form a third ring structure.  Flavonoids exist in 
either the free aglycone form, which is a flavonoid lacking a sugar moiety, or 
the conjugated glycoside form, consisting of a flavonoid aglycone conjugated 
to one or more sugar moieties.  These glycosidic flavonoids may be one of 
two types, depending on the type of bond between the aglycone and sugar 
moiety: 
 
• Flavonoid O-glycosides, in which case an acid labile hemiacetal bond 
connects one or more hydroxyl groups to a sugar moiety, and 
• Flavonoid C-glycosides, in which case a carbon-carbon bond attaches a 
sugar moiety directly to the benzene nucleus. 
(Mukinda, 2005, p.28)  
 
Flavonoids are generally classified into three groups: 
 
• Flavonoids, being derived from 2-phenyl-1,4-benzopyrone, 
• Isoflavonoids, being derived from 3-phenyl-1,4-benzopyrone, and 
• Neoflavonoids, being derived from 4-phenyl-1,2-benzopyrone. 
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Flavonoids are further subdivided into the following groups: 
• Flavones, including the four subgroups flavones (e.g. luteolin), flavonols 
(e.g. quercetin), flavanones (e.g. hesperetin) and 3-hydroxyflavonones or 
2,3-dihydroflavonols (e.g. dihydroquercetin), 
• Isoflavones (e.g. genistein) 
• Flavan-3-ols (e.g. catechins and epicatechins), and  
• Anthocyanidins (e.g. cyanidin) 
(Flavonoid, 2007) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Flavonoid synthesis occurs during the phenylpropanoid metabolic pathway.  
During this metabolic process, 4-coumaroyl-CoA is synthesised from 
phenylalanine.  4-Coumaroyl-CoA may then be combined with malonyl-CoA to 
form chalcones (Figure 2.1), which comprise the backbone of flavonoids.   
 
Subsequent ring closure of the chalcones leads to the formation of a flavone.  
During the phenylpropanoid metabolic pathway, flavones are converted to 
flavonones, which are in turn converted to dihydroflavonols.  Dihydroflavonols 
Figure 2.1: Various flavonoids, including flavanones, flavones, 
flavonols, anthocyanidins and isoflavones are derived from the 
precursor molecule chalcone (taken from Heldt, 2005, p. 448). 
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are then converted to anthocyanins, which are the aglycones of 
anthocyanidins.  Other compounds synthesised during the phenylpropanoid 
metabolic pathway include flavonols, flavan-3-ols and tannins, also known as 
proanthocyanidins (Flavonoid, 2007).  
 
It would appear that the flavonoids possess a wide array of biological activity.  
Flavonoids are found in high concentrations in almost all green plants, and 
are responsible for the pigmentation of flowers and the protection of plants 
against microbes and insects.  The anti-inflammatory, antimicrobial and 
anticancer properties of flavonoids have also been indicated (Flavonoid, 
2007).  Quercetin (Figure 2.2) is said to be the most active flavonoid and 
imparts many of the medicinal qualities to plants used for such purposes. 
 
 
 
 
 
 
 
 
 
 
 
 
It possesses anti-inflammatory qualities, for example, by inhibiting the release 
of histamine and other inflammatory mediators of allergic reactions, and is 
thought to have a vitamin C-sparing effect as well as anticancer properties. 
Proanthocyanidins are thought to increase intracellular vitamin C levels, 
eliminates oxidants and free radicals, prevents the destruction of collagen and 
decreases capillary fragility and permeability.  Epicatechin (Figure 2.4) is said 
to improve blood flow and subsequently cardiovascular health.  Cacao is 
especially rich in epicatechin, and cacao has been shown to possess 
antioxidant activity surpassing that of red wine or even green tea.  However, a 
study conducted by the Linus Pauling Institute during 2007 (as cited in 
 
Figure 2.2: Structure of 
quercetin (taken from 
Quercetin, 2007). 
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Flavonoid, 2007) has indicated that a significant increase in the antioxidant 
capacity of blood after the ingestion of flavonoid-rich foods is not directly 
attributable to the flavonoids themselves, but rather to the increase in blood 
uric acid that occurs when these flavonoids are excreted.  Thus flavonoids 
may indirectly function as inhibitors of cardiovascular disease and 
carcinogenesis by stimulating the mechanisms responsible for the inhibition of 
tumor invasion and killing off of cancerous cells (Flavonoid, 2007; Peterson, 
1999, p.22). 
 
Apart from red wine, cacao and green tea, other food sources rich in 
flavonoids include citrus fruits, onions, berries, legumes, parsley and dark 
chocolate with a cacao content of 70% or higher (Flavonoid, 2007). 
 
2.2.2. Tannins  
 
Plants are known to accumulate a wide variety of secondary metabolic 
compounds, including phenolics.  The metabolism of phenolics is a complex 
process and yields compounds such as flower pigments and phenolics 
comprising plant cell walls.  Tannins are a group of complex polyphenols 
which are distinguished from other plant phenolics based on their chemical 
reactivities and biological activities.  They are normally divided into two 
groups: condensed tannins (proanthocyanidins) (Figure 2.5) and hydrolysable 
tannins (Figure 2.8). Geraniin (C41H28O27.7H2O) (Figure 2.11) is an example 
of a hydrolysable tannin (Hagerman, 2002).  Red wine is said to be a good 
source of condensed tannins, which is found in grape skins and seeds, as 
well as the wooden casks in which wine is sometimes matured.  
Pomegranates are thought to be rich in hydrolysable tannins, which impart 
antioxidant qualities to pomegranate juice.  Other food sources known to 
contain tannins include persimmons, cranberries, strawberries, blueberries 
and chocolate, due to its cocoa content (Tannin, 2007; Catechin, 2007).   
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2.2.2.1. Condensed tannins 
 
Condensed tannins are polymers of flavonoids, which are based on a 
heterocyclic ring system which is derived from phenylalanine and polyketide 
synthesis.  (+)-Catechin (Figure 2.3) and (-)-epicatechin (Figure 2.4), which 
are epimers, are flavan-3-ols which form the base for condensed tannins.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Figure 2.5: The general structure 
of a condensed tannin (taken from 
Heldt, 2005, p.452). 
 
Figure 2.3: Structure of catechin 
(taken from Dey & Harborne, 
1997, p.412). 
 
Figure 2.4: Structure of epicatechin (taken 
from Dey & Harborne, 1997, p. 412). 
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A wide variety of condensed tannins can be formed, depending on the carbon 
atoms involved in the carbon-carbon bonding.  The addition of a third phenolic 
hydroxyl group to catechin and epicatechin yield the compounds gallocatechin 
and epigallocatechin, respectively.  These catechin gallates are galic acid 
esters of the catechins, such as epigallocatechin gallate (EGCG) (Figure 2.6), 
which is known to be the most abundant catechin in tea (Camellia sinensis). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Studies conducted on the possible health benefits of catechins and 
epicatechins have shown that catechins bring about a reduction in 
atherosclerosis and carcinogenesis, while the occurrence of stroke, heart 
failure, cancer and diabetes appear to decrease in individuals who ingest 
epicatechins on a regular basis (Catechin, 2007).   
 
The best characterised condensed tannins are formed by bonding between 
C4 of the terminal flavonoid molecule, which may either be catechin or 
epicatechin, and C8 of the extender flavonoid molecule, which may also either 
be catechin or epicatechin.  Further cross linking between carbon atoms is 
possible to yield linear 4,8 polymers, 4,6 polymers and branched polymers 
containing both 4,8 and 4,6 linkages.  Oxidative coupling between the carbon 
and oxygen atoms of the flavonoid rings have also been described.  It should 
be noted that unlike the case with hydrolysable tannins, carbon-carbon bonds 
 
Figure 2.6: Structure of 
epigallocatechin gallate (taken from 
Epigallocatechin gallate, 2007). 
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of condensed tannins are not susceptible to hydrolysis, but may be oxidatively 
cleaved (Hagerman, 2002). 
 
2.2.2.2. Hydrolysable tannins 
 
Hydrolysable tannins are derivatives of gallic acid (3, 4, 5-trihydroxyl benzoic 
acid) (Figure 2.7), and consist of gallic acid esterified to a core polyol.  Further 
esterification or oxidative cross linking of the galloyl groups lead to more 
complex hydrolysable tannins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gallotannins are the simplest form of hydrolysable tannins, and consist of 
phenolic gallic acid esterified to the hydroxyl groups of a carbohydrate, usually 
a glucose molecule, although it is known that in some cases the core glucose 
is substituted by molecules such as glucitol, hammamelose, shikimic acid, 
quinic acid and quercitol.  Pentagalloyl glucose (PGG) (β-1, 2, 3, 4, 6- 
pentagalloyl-O-D-glucopyranose) would be a primary example of a 
gallotannin.  More complex gallotannins may be formed by the addition of 
polygalloyl ester chains to PGG.  This occurs through depside bonds involving 
the phenolic hydroxyl molecules of galloyl groups.  These depside bonds are 
more readily hydrolysed than the aliphatic ester bonds between the core 
 
Figure 2.7: Structure of 
gallic acid (taken from 
Gallic acid, 2007). 
 
Figure 2.8: General structure of a hydrolysable 
tannin (taken from Heldt, 2005, p.452). 
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carbohydrate and its primary galloyl groups.  Thus a weak acid in methanol 
may be used to methanolyse the weaker depside bonds in a mixture of 
polygalloyl esters to obtain the core carbohydrate and its esterified galloyl 
groups.  Methanolysis with a strong acid in methanol of both the depside 
bonds as well as the ester bonds yield the core carbohydrate and gallic acid 
(Hagerman, 2002). 
 
Geraniin, the tannin compound known to be found in G. incanum, is classified 
as an ellagitannin.  Ellagitannins are formed by the oxidative coupling of 
galloyl groups of gallotannins.  Initial coupling of two galloyl groups lead to the 
formation of hexahydroxydiphenic acid (HHDP) (Figure 2.9).  The simple 
ellagitannins are esters of HHDP, which will convert to ellagic acid in aqueous 
solution (Figure 2.10). 
 
 
 
 
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.11: Structure of geraniin (taken from Van Wyk, 
Van Oudtshoorn & Gericke, 1997, p.137). 
Figure 2.9: Structure of HHDP 
(taken from Goodwin & Mercer, 
1983, p.562). 
 
Figure 2.10: Structure of ellagic 
acid (taken from Goodwin & 
Mercer, 1983, p.562).  
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Intramolecular carbon-carbon coupling between different carbon atoms of the 
galloyl groups yield a variety of different compounds, depending on the 
carbon groups involved and the stability of the conformation of the polygalloyl 
glucose molecule.  Oxidative coupling of C2 with C4 and C3 with C6 will yield 
the ellagitannin geraniin.  Ellagitannins may undergo further intermolecular 
oxidative coupling with other hydrolysable tannins to form dimers, as is the 
case with geraniin, which can undergo condensation with PGG to yield 
various euphrobins (Hagerman, 2002). 
 
From a nutritional point of view, ingesting excessive amounts of tannin could 
be detrimental to the health of an individual, as tannins are known to be metal 
ion chelators.  Chelated metal ions are not absorbed by the body, which could 
lead to mineral deficiency.  Tannins are also used in a number of applications. 
The one characteristic that set tannins apart from other phenolic compounds, 
their ability to react with and precipitate proteins, is used in the tanning of 
hides to leather, with oak bark being the traditional source of tannin for this 
purpose, although industrial tannins are also employed.  Other uses of tannin 
include its incorporation into medical anti-diarrheal, hemostatic, and anti-
hemorrhoidal compounds, the reaction of iron (II)sulfate in the production of 
iron gall ink, and the use of tannin in industrial particleboard adhesive 
(Hagerman, 2002; Tannin, 2007).  
 
 
2.2.3. Saponins 
 
The term saponin is derived from the Latin word sapo, which means soap, 
and is a reflection of the tendency of aqueous solutions of saponins to froth. 
This is thought to be due to the amphiphilic nature of these molecules 
(Saponin, 2007). Ultimately, saponins are derivatives of terpenes or 
terpenoids, which is discussed in more detail in Section 2.2.4.  
 
Terpenes are compounds consisting of variable amounts of five-carbon units, 
known as isoprene units (Figure 2.12), linked together.  They are generally 
classified as hemiterpenes, monoterpenes, sesquiterpenes, diterpenes, 
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sesterterpenes, triterpenes, tetraterpenes and polyterpenes, depending on the 
amount of isoprene units present.  Triterpenoids, which are formed from 
triterpenes through biological processes such as oxidation and other 
modifications, consist of six isoprenoid units.  Squalene (Figure 2.13) is 
considered to be the parent isoprenoid of the triterpenes and triterpenoids.  
Modifications to squalene lead to the formation of different triterpenes and 
triterpenoids.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Saponins are glycosides of triterpenoids, meaning the presence of one or 
more sugar molecule.  Secondary modifications to isoprene units of 
triterpenoids lead to the formation of different sterols and steroids, in which 
case the numbers of isoprene units are not so easily distinguishable.  
Saponins may also be glycosides of steroids and steroid alkaloids.  Hydrolysis 
 Figure 2.13: Structure of squalene 
(taken from Squalene, 2007). 
 
Figure 2.12: Structure of 
an isoprene unit (taken 
from Isoprene, 2007). 
 
Figure 2.14: Glycyrrhizic acid, an 
example of a triterpenoid saponin 
(taken from Pengelly, 2004, p.75). 
 
Figure 2.15: Dioscin, an example of 
a steroidal saponin (taken from 
Pengelly, 2004, p.75). 
 
 18 
of a saponin yields the triterpenoid or steroid as aglycone (Van Wyk et al., 
1997, p.22). 
 
Saponins are said to be beneficial to human health as they may prevent or 
control hypercholesterolaemia and hyperglycaemia.  They are also believed to 
act as antioxidants and blood cleansers, and to possess anticancer and anti-
inflammatory properties due to their similarity in structure to steroids (Saponin, 
2007).  Inhibition of complement activity is said to be the anti-inflammatory 
mechanism of some saponins.  Saikosaponins present in Bupleurum 
falcatum, as well as soyasaponins and kudzusaponins are said to have 
hepatoprotective qualities.  Saponins may also be used as expectorants, 
laxatives and diuretics, and in the intestine they facilitate the absorption of 
some food and medicinal substances.  Saponins themselves are generally 
poorly absorbed by the intestine, with an exception to those produced by the 
herbs paris and corn cockle, which may cause fatal haemolysis.  Some 
saponins are sapotoxins, for example, those produced by the soapberry, and 
ingestion by humans may lead to reactions such as urticaria (Flϋck & 
Jaspersen-Schib, 1941/1976, p.10; Pengelly, 2004, pp.76-78; Peterson, 1999, 
p.22; Saponin, 2007).   
 
Apart from their health benefits, saponins are also employed in other fields.  
They may be used as detergents, and are also employed in laboratory 
procedures to permeabilise the plasma membranes of cells and intracellular 
organelles in order to facilitate the uptake of antibodies and other peptides 
during histochemical staining (Saponin, 2007). 
 
 
2.2.4. Terpenes 
 
Terpenes are one of the most important groups of active compounds in 
plants, with over 20 000 structures known (Pengelly, 2004, p.59).  Terpenes 
and terpenoids, which are also known as isoprenoids, consist of varying 
numbers of isoprene (2-methylbuta-1, 3-diene) units.  An isoprene unit is a 
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five carbon structure (Figure 2.12), and is considered to be the building block 
of terpenes and terpenoids.  During the formation of terpenes, isoprene units 
are linked to each other to form various isoprenoids, which are classified 
according to the number of isoprene units present: 
 
• Hemiterpenes – These consist of a single isoprene unit, and have the 
molecular formula C5H8.  Isoprene itself is considered to be the only 
hemiterpene.  Prenol and isovaleric acid, which are oxygen-containing 
derivatives, are called hemiterpenoids. 
• Monoterpenes – Compounds in this group consist of two isoprene units 
and have the molecular formula C10H16.   Examples are geraniol, 
limonene, menthol and iridoids. 
• Sesquiterpenes – These compounds consist of three isoprene units and 
have the molecular formula C15H24.   The bitter principles, especially 
sesquiterpene lactones, are examples. 
• Diterpenes – These compounds are composed of four isoprene units and 
have the molecular formula C20H32.  Examples include cafestol, kahweol, 
cembrene and taxadiene (the precursor of taxol).  Biologically active 
compounds such as retinol, retinal and phytol are linked to the diterpenes. 
• Sesterterpenes – Having five isoprene units and a molecular formula of 
C25H40, these compounds are rare relative to the other classes. 
• Triterpenes – These compounds consist of six isoprene units, with a 
molecular formula of C30H48.  The reductive coupling of two farnesyl 
pyrophosphate molecules lead to the formation of squalene, a linear 
triterpene.  Squalene is then processed to lanosterol, the structural 
precursor to all steroids.  The addition of a sugar moiety to a triterpene or 
triterpenoid leads to the formation of a saponin, which has been discussed 
in Section 2.2.3. 
• Tetraterpenes – Tetraterpenes consist of eight isoprene units and have 
the molecular formula C35H56.  Lycopene, gamma-carotene and α- and β- 
carotene are biologically important tetraterpenes. 
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• Polyterpenes – These compounds have variable amounts of isoprene 
units linked together to form long chains.  Rubber is an example of a 
polyterpene. 
(Terpene, 2007) 
 
In 1987 Wallach (as cited in Dey & Harborne, 1997, p.418) proposed the 
isoprene rule which was later formulated into the biogenetic isoprene rule 
proposed by Ruzicka.  This rule stated that all isoprenoids are made from a 
biologically active isoprene.  This biologically active isoprene turned out to be 
isopentenyl pyrophosphate (IPP), which is an intermediate in the 
hydroxymethylglutaryl-CoA (HMG-CoA) reductase metabolic pathway, as well 
as in the non-mevalonate pathway, where it is synthesised from (E)-4-
hydroxy-3-methyl-but-2-enyl pyrophosphate (HMB-PP) by the enzyme HMB-
PP reductase.  The latter pathway is mainly utilised by bacteria, malaria 
parasites and the plastids of higher plants (Isopentenyl pyrophosphate, 2007). 
 
.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.16: The conversion of acetoacetyl 
CoA to mevalonic acid (taken from Dey & 
Harborne, 1997, p.418). 
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During the HMG-CoA reductase pathway (Figure 2.16), two molecules of 
acetyl-CoA are combined to form acetoacetyl-CoA.  Addition of a third acetyl-
CoA leads to the formation of HMG-CoA.  HMG-CoA is converted to 
mevalonic acid through the action of HMG-CoA reductase.  During a three 
step process, mevalonic acid is converted to IPP which, through the working 
of IPP isomerase, is isomerised to dimethylallyl pyrophosphate (DMAPP).  
Either of IPP or DMAPP may be converted to a hemiterpene.  Under the 
influence of prenyl transferase, DMAPP condenses with IPP to form geranyl 
pyrophosphate (GPP).  GPP may be used for monoterpene synthesis or 
condensed with another IPP molecule to form farnesyl pyrophosphate (FPP).  
FPP, in turn, may be utilised in the synthesis of sesquiterpenes, may be 
extended in a chain fashion to form geranylgeranyl pyrophosphate (GGPP), or 
may undergo tail to tail dimerisation to form the triterpenes.  GGPP may be 
utilised in the synthesis of diterpenes, undergo chain elongation to form 
geranylfarnesyl pyrophosphate (GFPP) or dimerise to form the tetraterpenes.  
GFPP may further undergo chain extension in the formation of polyprenyl 
pyrophosphates and polyterpenes, such as rubber (Figure 2.17) (Goodwin & 
Mercer, 1983, pp.423, 425).  
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.17: The general pathway of isoprenoid 
synthesis (taken from Dey & Harborne, 1997, p.418). 
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α-And β-thujone (Figure 2.20 and Figure 2.21), 1,8-cineole (Figure 2.22), 
camphor (Figure 2.24), α-pinene (Figure 2.25) and borneol (Figure 2.23), the 
major chemical constituents of the volatile oil of A. afra (Scott, Springfield & 
Coldrey, 2004, p.209; Van Wyk et al.,1997, p.44), are monoterpene 
derivatives, as are most constituents of volatile plant oils.  Thus, for the scope 
of this study, only the monoterpenes will be briefly discussed next. 
 
 
2.2.4.1. Monoterpenes and their derivatives   
Monoterpenes are components of essential oils, and are probably ubiquitous 
in higher plants.  They are especially valued in the perfume industry and are 
also used as food flavourants (Dey & Harborne, 1997, p.419). 
As previously stated, GPP is known to be the precursor molecule of 
monoterpene synthesis.  Monoterpene cyclases (synthases), of which more 
than twenty have been identified, are the enzymes responsible for the 
conversion of GPP to cyclic, oxygenated monoterpenes during oxidation and 
reduction reactions (Dey & Harborne, 1997, p.419).    
Monoterpenes are classified according to 38 types, and are divided into four 
broad structural categories: 
 
• Acyclic 
• Cyclopentanoid, 
• Cyclohexanoid, which may either be mono-, bi- or tricyclic, and  
• Irregular monoterpenes 
(Dey & Harborne, 1997, p.419; Goodwin & Mercer, 1983, p.401) 
 
An example of a monocyclic, cyclohexanoid monoterpene would be limonene, 
which is formed during the cyclisation of GPP (Figure 2.18) (Monoterpene, 
2007).. 
 
 
 23 
 
 
 
 
 
 
 
 
Pinene is an example of a bicyclic, cyclohexanoid monoterpene, and is 
formed during two sequential cyclisation reactions of GPP (Figure 2.19) 
(Monoterpene, 2007) 
 
 
The properties of monoterpenes are dependent on the oxygen containing 
radicals bound to the carbon skeleton.  Monoterpenes may be simple 
hydrocarbons, or they may occur as oxygenated derivatives, such as ketones, 
aldehydes, alcohols, oxides or phenols (Pengelly, 2004, p.87).  Examples of 
these include: 
• Ketones – Thujone and camphor 
• Aldehydes – Geranial 
• Alcohol – Borneol 
• Oxide – Cineole 
• Phenol – Thymol 
 
Figure 2.18: The conversion of GPP to limonene (taken from Monoterpene, 
2007). 
 
Figure 2.19: The conversion of GPP to pinene (taken from Monoterpene, 
2007). 
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• Hydrocarbon - α- and β-Pinene  
 
2.2.4.1.1. Thujone 
Thujone is classified as a bicyclic, monoterpenoid ketone, i.e. it is a 
monoterpene with a carbonyl group (C=O) connected to two carbon atoms.  
Two stereoisomeric forms are known to exist; (+)-3-thujone or α-thujone 
(Figure 2.20), and (-)-3-thujone or β-thujone (Figure 2.21) (Thujone, 2007). 
 
 
 
 
 
 
 
 
 
 
 
 
Thujone is probably best known for being a chemical constituent of the 
popular alcoholic drink absinth, of which A. absinthium, also known as 
European wormwood or Grand wormwood, is a main ingredient.  The volatile 
oil of A. absinthium has been shown to contain both α- and β-thujone in 
varying ratios amongst different populations (Gambelunghe & Melai, 2002; 
Padosch, Lachenmeier & Kröner, 2006; Thujone, 2007). 
 
Up until recently, it was believed that, due to their structural similarities, 
thujone and tetrahydrocannabinol (THC), the chemical responsible for the 
euphoric sensations brought on by cannabis usage, shared the same 
mechanism of action in the brain.  Today this is known to be false.  Thujone 
blocks the γ-aminobutyric acid type A (GABAA) receptor chloride channel.   
Figure 2.20: Structure 
of α-thujone (taken 
from Van Wyk et al., 
1997, p.44). 
 
 
Figure 2.21: Structure 
of β-thujone (taken from 
Van Wyk et al., 1997, 
p.44). 
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Inhibition of GABA receptor activation leads to neurons firing more rapidly and 
consequential muscle spasms (Thujone, 2007).  This could possibly explain 
the convulsions which have been seen in individuals suffering from 
absinthism, a neurological syndrome characterised by hallucinations, 
epilepsy, convulsions and psychiatric illness, amongst others.  Absinth 
consumption and absinthism is discussed in Section 2.5.1.    
 
 
2.2.4.1.2. 1, 8-Cineole 
 
1,8-Cineole (Figure 2.22), also known as cineole, cineol, limonene oxide, 
cajeputol, 1,8-epoxy-p-menthane, 1,8-oxido-p-menthane, eucalyptol, 
eucalyptole or 1,3,3-trimethyl-2-oxabicyclo(2,2,2)octane, is classified as a 
cyclic, monoterpenoid oxide or monoterpene ether.  A secondary ring 
containing an oxygen atom is attached to the primary ring structure at 
positions 1 and 8.   
 
Cineole is a major constituent in eucalyptus oil, and has a spicy, pleasant 
aroma.  This has made it popular in flavourings, fragrances and cosmetics.  It 
also has mucolytic properties and is used as an expectorant.  It is almost 
universal in mouth washes and cough lozenges (Eucalyptol, 2007; Pengelly, 
2004, p.98). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.22: Structure of 1,8- 
cineole (taken from Van Wyk 
et al., 1997, p. 44). 
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Furthermore, cineole has been shown to possess anti-inflammatory properties 
and to relief pain.  It has also been shown to have anticancer properties 
(Eucalyptol, 2007).  Eucalyptus oil in general is known for its antimicrobial 
properties, while some are said to possess antiviral qualities as well.  Oil rich 
in cineole and terpene hydrocarbons are said to be the most effective against 
influenza, for example (Pengelly, 2004, p.99). 
 
 
2.2.4.1.3. Borneol and camphor   
 
Borneol (Figure 2.23) is classified as a bicyclic, monoterpenoid alcohol, i.e. it 
has a hydroxyl group attached to the terpene skeleton.  Alcohols rank 
amongst the most potent antimicrobial components of essential oils.  Terpene 
alcohols are generally highly valued for their fragrance, healing properties and 
gentle reactions on skin and membranes.  A well known example of a 
monoterpenoid alcohol is menthol, which is found in peppermint oil, and which 
is used in the pharmaceutical industry as well as in the food industry.  Borneol 
is easily oxidised to the monoterpenoid ketone, camphor (Borneol, 2007, 
Pengelly, 2004, pp.90-92). 
 
 
 
 
 
 
 
 
 
 
 
 
Camphor (Figure 2.24) generally occurs as a waxy, white to transparent solid 
with a strong aromatic odour.  It occurs mainly in the wood of Cinnamomum 
 
Figure 2.23: Structure of 
borneol (taken from Van 
Wyk et al., 1997, p.44). 
 
Figure 2.24: Structure of 
camphor (taken from Van 
Wyk et al., 1997, p.44). 
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camphora, and is known to be a central nervous system stimulant.  It is used 
in the medical industry for its mucolytic, antipruritic and rubifacient properties, 
and is an active ingredient in Vicks VapoRub®.  Camphor is known to be toxic 
when ingested in large amounts, and may lead to seizures, confusion, 
irritability and neuromuscular hyperactivity.  Non-medicinal uses of camphor 
include embalming, the manufacturing of fireworks, as a plasticizer for 
cellulose nitrite and as an insect repellent.  In the Orient it is used in the 
flavoring of confectionary and culinary dishes (Camphor, 2007; Pengelly, 
2004, p.97).  
 
Camphor may be biosynthetically produced through the cyclisation of linaloyl 
pyrophosphate to bornyl pyrophosphate.  This is then followed by hydrolysis 
to borneol, and oxidation to camphor (Camphor, 2007). 
 
2.2.4.1.4. α-Pinene 
 
α-Pinene (Figure 2.25) is one of two isomers of pinene, the other being β-
pinene.  It is classified as a bicyclic, monoterpenoid hydrocarbon, and lacks 
oxygen-containing functional groups.  Pinenes are produced from geranyl 
pyrophosphate via cyclisation of linaloyl pyrophosphate.  Pinenes are widely 
distributed in plants, and occur in high concentrations in oil of turpentine, 
which is derived from different species of Pinus.  Medicinally, oil of turpentine  
is used as a rubifacient and linament in rheumatic disease.  Pinene is also an 
important constituent of many culinary spices, including black pepper 
(Pengelly, 2004, p.90; Pinene, 2007).  
 
 
 
 
 
 
 
  Figure 2.25: Structure of α-pinene 
(taken from Pinene, 2007). 
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Other terpenes which are important to mention relating to the scope of this 
study with regards to being chemical constituents of A. absinthium, include 
cadinine, camphene, myrcene, phelandrene and sabinene.  These are briefly 
discussed next. 
 
 
2.2.4.1.5. Cadinene 
 
Cadinenes (Figure 2.26) are classified as bicyclic sesquiterpenes named after 
the Cade Juniper, the compound being first isolated from the oil of the wood 
(Cadinene, 2008).  The yellow or light green oily liquid is used as a flavouring 
agent in baked goods, candy and chewing gum, as well as providing 
fragrance to cosmetics and detergents (Safety data for cadinene, 2005).  The 
name cadinene has been used to describe any sesquiterpene with the 
cadalane carbon structure.  However, a large number of double bond and 
steriochemical isomers exist, and the group of compounds have subsequently 
been divided into four subclasses according to stereochemistry of the 
isopropyl group, as well as the two bridgehead carbon atoms.  These 
subclasses include cadinene, muurolene, amorphene and bulgarene 
(Cadinene, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.26: Structure of cadinene 
(taken from Cadinene, 2008). 
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2.2.4.1.6. Camphene 
 
Camphene (Figure 2.27) is classified as a bicyclic monoterpene, and is 
produced in industry by the catalytic isomerisation of α-pinene.  Camphene 
can be found in a variety of essential oils such as camphor oil, cypress oil, 
turpentine, citronella oil and ginger oil, and is used in fragrance preparation 
and as a flavouring agent in food (Camphene, 2008).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.4.1.7. Myrcene 
 
Myrcene (Figure 2.28) is classified as a monoterpene, and is a constituent of 
the essential oils of bay, verbena and myrcia.  The pyrolysis of pinene may 
also be used to synthesise this compound.  Two isomers exist, namely α-
myrcene and β-myrcene, only the latter being found in nature.  Myrcene 
possesses a very pleasant odour, and is an extremely important compound 
used in the perfume industry, as well as in the synthetic preparation of 
menthol, citral, citronellol, geraniol, nerol and linalool.   
 
 
 
 
 
Figure 2.27: Structure of camphene 
(taken from Camphene, 2008). 
 30 
 
 
 
 
 
 
 
2.2.4.1.8. Phellandrene 
 
Phellandrene refers to two compound, α-phallandrene (Figure 2.29) and β-
phallandrene (Figure 2.30), which are cyclic monoterpenes and double bond 
isomers.  α-Phallandrene possesses two endocyclic double bonds, while β- 
phallandrene has one endocyclic- and one exocyclic doulble bond.  α- 
Phallandrene is found in the essential oils of Eucalyptus radiata and 
Eucalyptus dives, while β-phallandrene is a constituent of the essential oil of 
water fennel and Canada balsam oil.  Phellandrenes are said to possess a 
pleasant aroma and are subsequently used in the fragrance industry 
(Phellandrene, 2008). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.28: Structure of myrcene 
(taken from Myrcene, 2008). 
 
Figure 2.29: Structure of α-
phellandrene (taken from 
Phellandrene, 2008). 
 
Figure 2.30: Structure of β-
phellandrene (taken from 
Phellandrene, 2008). 
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2.2.4.1.9. Sabinene 
 
Sabinene (Figure 2.31) is classified as a bicyclic monoterpene and has been 
isolated from a variety of plants.  Its chemical structure is characterised by the 
fusion of a cyclopentane ring to a cyclopropane ring.  Sabinene is a 
constituent of carrot seed oil and tea tree oil, and contributes to the spicy taste 
of black pepper (Sabinene, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Geranium incanum (Burm. f.) 
 
2.3.1. The medicinal qualities and health supporting properties of G. 
           incanum and its use as a traditional medicinal plant 
           
  
Although information regarding the use of G. incanum as a medicinal plant 
and its active chemical compounds is limited in the literature, it is known that 
the plant, as well as other Geranium species, have been used by individuals 
to address a wide array of ailments. 
 
Figure 2.31: Structure of Sabinene 
(taken from Sabinene, 2008). 
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G. incanum’s vernacular Afrikaans name of vrouebossie (vroue = women; 
bossie = small bush or shrublet) is most probably derived from its use by the 
early Dutch Cape settlers to treat ailments of the genitourinary tract, 
particularly in females.  These include bladder infections and cystitis, venereal 
diseases and menstrual related disorders.  The plant may also be useful in 
aiding in the expulsion of afterbirth and the stimulation of lactation.  G. 
incanum is also used in the treatment of various other disorders, including 
diarrhoea, colic, fever and bronchitis.  A lotion may be prepared which can be 
used to treat dry, itchy skin, while individuals whom are prone to oily hair may 
benefit from rinsing the hair with an extract of the plant.  Furthermore, the 
plant may also be effective in the treatment of dandruff and psoriasis of the 
scalp.  Its properties as an anthelmintic have also been described (Mountain 
Herb Estate, 2006a; Schwegler, 2007; Scott & Springfield, 2004a, p.3; Scott 
et al., 2004, p.192; Van Wyk et al., 1997, p.134; Van Wyk & Gericke, 2000, p. 
186; Watt & Breyer- Brandwijk, 1962, p.451) 
 
Traditionally, an infusion of G. incanum leaves is made by adding a quarter 
cup fresh leaves to 180 ml boiling water.  This is then left for ten minutes, 
strained and drunk while warm.  For the treatment of intestinal parasites, a 
teacupful is taken once daily on an empty stomach for ten days.  One 
teacupful is taken three times daily for three days to relief colic, bladder 
infections and diarrhoea, while for the treatment of dysmenorrhoea, one 
teacupful is taken three times per day for two to three days (Schwegler, 2007; 
Scott & Springfield, 2004a, p.4; Van Wyk et al., 1997, p.134).  
 
During a study conducted by Scott et al. (2004, p.198) on the 
pharmacognostical properties of several plants used as traditional medicines 
in South Africa, it was found that the aqueous extract of G. incanum 
expressed inhibition to the growth of Staphylococcus aureus, but no 
significant results were obtained regarding the inhibition of Pseudomonas 
aeruginosa, Candida albicans or Mycobacterium smegmatis.  A separate 
study conducted by Treurnicht (as cited in Scott et al., 2004, p.208), showed 
cytotoxicity at all concentrations of aqueous extracts of G. incanum to HeLa 
(human cervical cancer) cells, Vero (African Green monkey kidney epithelial) 
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cells, Jurkat E6.1 (human T-cell lymphoblast) cells, AA-2 (human CD4+ 
lymphocyte) cells and CEM-SS (human T-lymphoblast) cells.  This may have 
been due to the presence of tannins.  Similar extracts also exhibited a 
reduction in the infectivity of both Coxsackie B2 virus and Herpes Simplex 
Virus 1 during an antiviral cell culture assay. 
 
This, in conjunction with the historical use of the plant by the early Dutch 
Cape settlers as well as the use of the plant by indigenous South African 
peoples such as the Southern Sotho, warrants further investigation into the 
medicinal properties of G. incanum (Mountain Herb Estate, 2006a; Schwegler, 
2007; Watt & Breyer- Brandwijk, 1962, p.450). 
 
 34 
2.3.2. Botanical classification and vernacular names 
 
The botanical classification of G. incanum is as follows: 
 
Kingdom : Plantae 
Phylum : Magnoliophyta 
Class  : Magnoliopsida  
Order  : Geraniales 
Family : Geraniaceae 
Genus : Geranium 
Species : G. incanum 
 
Vernacular names: Carpet Geranium [English]; Vrouebossie, Amarabossie, 
Bergtee, Horlosies [Afrikaans]; Ngope-sethsoha, Tlhako [Sotho]; Tlako 
[Xhosa]; Mlako [Tswana]. 
(Scott & Springfield, 2004a, p.1; Van Wyk et al., 1997, p.134) 
 
It should be noted that many individuals often refer to different species of the 
genus Geranium as Pelargoniums and vice versa.  When botanical collectors 
from the United Kingdom collected different species of the genus 
Pelargonium, which are indigenous to South Africa, a few centuries ago, it 
was noted that the South African Pelargoniums were in many aspects similar 
to the different species of Geranium being cultivated in Europe at the time. 
This led to the South African plants being erroneously referred to as 
Geraniums.  This miss-nomenclature seems to have endured, and today one 
may walk into a nursery enquiring about Geraniums, only to be shown a 
South African Pelargonium.  Thus, in the South African context, Geraniums 
are almost always in truth Pelargoniums.  However, G. incanum, which is 
indigenous to South Africa, is classified as a true Geranium, and should not 
be confused with the genus Pelargonium (Geranium or Pelargonium, n.d.). 
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2.3.3. Macroscopical morphology 
 
G. incanum is a low spreading, 
multiple branching, perennial 
shrublet, roughly 10-25 cm in 
height.  The plant possesses a 
long, thickened tap root, while 
stems are slender.  The leaves are 
borne on slender petioles, each up 
to 5 cm wide and up to 7 cm long.  
Leaves have 3 to 7 lobes, each 
lobe being pinnatisect and covered 
in fine silver hair which lies flat 
against the leaf surface, unlike other Geranium species in which case the hair 
is spreading.  The plant normally flowers between September and November, 
with flowers being white to pale pink with dark veins or light violet to magenta 
in colour, and up to 4 cm in diameter.  Flowers are borne on slender pedicels 
which are also covered in fine silver hair.  The characteristic fruit is an 
elongated capsule which resembles the bill of a stork.  Due to the similarities 
between different species of Geranium, confusion has arisen in the past as to 
the medicinal records of the different species.  Subsequently, G. incanum has 
been divided into two varieties; var. incanum, which possesses the white to 
pale pink flowers, and var. multifidum, which bears the violet to magenta 
coloured flowers (Scott & Springfield, 2004a, p.1; Van Wyk et al., 1997, p. 
134). 
 
 
 
 
 
Figure 2.32: G. incanum 
(taken from Scott & Springfield, 
2004a, p.1). 
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2.3.4. Geographical distribution 
 
G. incanum commonly occurs on flats, hill 
slopes and dunes along the Southern 
coasts of the Western and Eastern Cape 
provinces of South Africa.  Although both 
var. incanum and var. multifidum have 
been recorded from the Cape peninsula 
eastwards towards Knysna, only the latter 
occurs in the Eastern Cape as far as Port 
Alfred (Scott & Springfield, 2004a, p.2).  
 
2.3.5. Major chemical constituents 
 
According to Van Wyk et al. (1997, p.137) as well as Watt and Breyer- 
Brandwijk (1962, p.451), the leaves of G. incanum are said to contain tannins, 
of which geraniin (Figure 2.11) is the best known example, while Scott et al. 
(2004) detected the presence of saponins.  Different flavonoids have also 
been detected in Geranium species, but other than this, very little or no 
published information on the phytochemistry of G. incanum seems to be 
available (Van Wyk et al., 1997, p.137).  These and other phytochemicals 
have been discussed in Section 2.2. 
 
 
2.4. Artemisia afra (Jacq. ex Willd.) 
 
2.4.1. The medicinal qualities and health supporting properties of A.     
          afra and its use as a traditional medicinal plant 
 
 
A. afra is one of the oldest, most well known and widely used traditional 
medicinal plants, not only in South Africa, but in many parts throughout Africa.  
It is popular amongst indigenous tribes of Africa up to this day, and early 
European colonists also recognised its healing qualities.  This may have been 
Figure 2.33: South African geographical 
distribution of G. incanum, the orange 
area indicating the regional occurrence 
(taken from Van Wyk et al., 1997, p.134). 
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due to the plant’s resemblance to European wormwood (A. absinthium), which 
is also known to have various medicinal properties.  Jan van Riebeeck is said 
to have recorded the use of A. afra in his diary to treat an array of ailments 
ranging from jaundice to gout. (Mountain Herb Estate, 2006b; Roberts, 1999, 
pp.226-227; Van Wyk & Gericke, 2000, p.142; Van Wyk et al., 1997, p.44; 
Watt & Breyer-Brandwijk, 1962, pp.199, 201). 
 
Current literature indicates that A. afra is used to treat a diverse and great 
amount of ailments.  These include coughs, colds, bronchitis, croup, 
whooping cough, sore throat, earache, gum- and mouth ulcers, toothache, 
indigestion and constipation, poor apatite, colic, heartburn, flatulence, 
menstrual- and childbirth related pains, neuralgia, inflammation, sprains and 
strains, haemorrhoids, measles, fever, rashes, bites and stings, pimples and 
boils, amongst others (Herbal Africa, n.d.; Jäger, 2003, p.596; Roberts, 1999, 
pp.226-227; Scott & Springfield, 2004b, p.3; Thring & Weitz, 2005, p.265; Van 
Wyk & Gericke, 2000, p.142; Van Wyk et al., 1997, p.44; Vincent, Mabusela, 
Folk, Weitz, Rottinghaus, Mawhinney, Khan, Lee, Wenzel, Applequist, 
Gqaleni & Johnson, n.d.; Watt & Breyer-Brandwijk, 1962, pp.199, 201). 
 
Furthermore, McGaw, Jäger and Van Staden (2000) found ethanol extracts of 
A. afra to be inhibitory to the growth of Bacillus subtilis and S. aureus, while 
Rabe and Van Staden (1997, p.84) found similar results when methanol 
extracts were used.  Gundidza (as cited in Herbal Africa, n.d.) found the 
essential oil of A. afra to be inhibitory to the growth of Aspergillus ochraceus, 
Aspergillus niger, Aspergillus parasiticus, C. albicans, Alternaria alternate, 
Geotrichum candidum and Penicillium citrium.  A. afra is also used by 
individuals in the treatment of diabetes mellitus (Thring & Weitz, 2005, p.265; 
Van Wyk & Gericke, 2000, p.142; Vincent et al., n.d.; Watt & Breyer-
Brandwijk, 1962, pp.201) and is said to possess activity against Plasmodium 
falciparum (Scott & Springfield, 2004b, p.3; Vincent et al., n.d.), 
Mycobacterium tuberculosis (Mukinda & Syce, in press; Scott & Springfield, 
2004b, p.3; Vincent et al., n.d.; Watt & Breyer-Brandwijk, 1962, pp.201) and 
Human Papilloma Virus (Vincent et al., n.d.). 
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Van Wyk and Gericke (2000, p.142), Hutchings, Scott, Lewis and 
Cunningham (as cited in Mukinda & Syce, in press) as well as Scott and 
Springfield (2004b, p.3) all state A. afra to possess anti-histamine, narcotic 
and analgesic qualities.  The Medical Research Council and SA Health Info 
(as cited in Mukinda & Syce, in press) and Guantai and Addae-Mensah (as 
cited in Herbal Africa, n.d.) claim A. afra to have a hypotensive effect and thus 
may be useful in the treatment of hypertension.  Burits (as cited in Herbal 
Africa, n.d.) found A. afra essential oil to be an effective hydroxyl radical 
scavenging agent, while Stafford et al. (2005) found A. afra to have anti- 
convulsive properties and GABAA – benzodiazepine receptor-binding activity.  
 
Finally, SA Health Info (as cited in Mukinda & Syce, in press) report an 
aqueous extract of A. afra to be cytotoxic to HeLa cells in vitro, while a study 
conducted by Treurnicht (as cited in Scott et al., 2004, p.210) found aqueous 
extracts of A. afra to be cytotoxic to HeLa, Vero, Jurkat E 6.1, AA-2 and CEM-
SS cells. 
 
The methods in which the plant is utilised for its medicinal qualities are as 
varied as the conditions for which it is used.  Infusions or decoctions are often 
made, which is sweetened with sugar or honey and drunk as a tea or used as 
a mouthwash or gargle.  An infusion may also be used as a wash for skin 
ailments.  The Tswana are reported to roll fresh leaves and insert these into 
the nose to relief headache and congestion, while some tribes are said to 
smoke the leaves to relief respiratory conditions (Roberts, 1990, p.226).  
Some individuals place a fresh, rolled leaf onto a tooth to relief toothache 
(Watt & Breyer-Brandwijk, 1962, p.201).  The Zulus are reported to use the 
plant as an enema for the treatment of intestinal worms (Roberts, 1990, p. 
226).  The Xhosa inhale the vapours after adding leaves to boiling water to 
relief colds and flu (Bhat & Jacobs, 1995, p.8).  Females may also use the 
vapour as a steam in the genital area to relief menstrual and childbirth related 
pains (Watt & Breyer-Brandwijk, 1962, p.201).  Furthermore, a poultice is 
sometimes made using heated leaves, which is then applied to strains, 
sprains and areas of inflammation (Scott & Springfield, 2004b, p.3).  Roberts 
(1990, p.227) as well as Watt and Breyer-Brandwijk (1962, p.201) report that 
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brandy, sugar, ginger, thyme, rosemary, mint, chamomile, Osmitopsis 
astericoides or Eucalyptus globulus are added to preparations of A. afra and 
is then used as a tincture for the relief of respiratory- and gastrointestinal 
ailments.   
 
There does not appear to be any precise traditional method regarding the 
preparation of an infusion of A. afra.  Rather, these vary depending on the 
strength required and the condition which is to be treated.  Roberts (1990, p. 
226) states that one quarter cup of fresh leaves should be added to one cup 
of boiling water, left for 5 minutes and then strained.  Scott and Springfield 
(2004b, p.4) states that 14 g fresh leaves should be infused in 1 litre boiling 
water and strained when cold.  
 
From the above information it is clear that A. afra plays a very important role 
in the traditional indigenous medicinal knowledge of South Africa, and 
deserves further investigation. 
 
 
2.4.2. Botanical classification and vernacular names 
 
The botanical classification of A. afra is as follows: 
 
Kingdom : Plantae 
Phylum : Magnoliophyta 
Class  : Magnoliopsida   
Subclass : Asteridae 
Order  : Asterales 
Family : Asteraceae 
Genus : Artemisia 
Species : A. afra 
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Vernacular names:  Wild wormwood, African wormwood [English]; Wilde als, 
Als, Alsem [Afrikaans]; Zengana [Southern Sotho]; Lengana [Sotho & 
Tswana]; Mhlonyane [Zulu]; Umhlonyane [Xhosa & Zulu]  
(Roberts, 1990; p.226; Van Wyk et al., 1997, p.44; Van Wyk & Gericke, 2000, 
p.142)    
 
2.4.3. Macroscopical morphology 
 
A. afra is an erect perennial shrub 
which may reach a height of up to 
two meters, and may be easily 
identified by its characteristic, highly 
aromatic odour.  The aerial parts of 
the plant are deciduous in areas 
experiencing cold winter months and 
die back, but rapidly regenerate from 
the base during spring.  The finely 
divided feathery, ovate leaves are up 
to 8 cm long and 4 cm wide, and are 
silver-green in colour due to the presence of fine hairs.  Each possess a 
pectinated midrib, and have a smooth or glandular punctated upper surface 
and canescent lower surface.  Petioles may be up to 2 cm long and dilated 
towards the base, where a pair of simple or divided stipules are found.  The 
ultimate segments are described as being linearly shaped with a smooth or 
toothed margin, and may be up to 1 cm long and 0.2 cm wide.  The plant 
normally flowers between January and June, with the flowers being small and 
inconspicuous, and yellow in colour.  These flowers are borne on the end of 
branches in globose capitula which are approximately 0.3 cm in diameter.  
The fruit is approximately 0.1 cm in length, slightly curved and three-angled, 
and have a silver to white coating (Komperlla, 2004, p.4; Scott & Springfield, 
2004b, p.1; Van Wyk et al., 1997, p.44).  
 
 
Figure 2.34: A. afra   
(adapted from Mukinda, 
2005, p.21). 
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2.4.4. Geographical distribution 
 
A. afra is widespread throughout most of Africa, and is recognised and used 
by many African people for its medicinal qualities, including individuals from 
South West Africa (Namibia), Southern Rhodesia (Zimbabwe), Kenya, 
Tanganyika and Uganda (Watt & Breyer- Brandwijk, 1962, p.201).  A. afra is 
widespread throughout South Africa, except the Northern Cape province, and 
may also be found in Lesotho and Swaziland and further North as far as 
Ethiopia in East Africa.  The plant is usually found in 
mountainous habitats along streams and forest 
margins (Scott & Springfield, 2004b, p.2; Van Wyk et 
al., 1997, p.44).  
 
 
2.4.5. Major chemical constituents 
  
The known chemical constituents that have been 
identified in A. afra can be divided into two groups, 
those present in plant material, and those which are 
found in the essential oils.  Microchemical tests 
conducted by Scott et al. (2004, p.209) indicated the 
presence of tannins and saponins in plant materials.  
Silbernager, Spreitzer and Buchbauer (as cited in 
Scott et al., 2004, p.209) identified the triterpenes α- and β-amyrin and 
friedelin, as well as ceryl cerotinate and n-nonacosane, which are alkanes, 
from the leaves of A. afra.  Ten guaianolides and five glaucolides have also 
been detected during an analysis of the sesquiterpene lactones of A. afra by 
Jakupovic, Klenmeyer, Bohlmann and Graven (as cited in Scott et al., 2004, 
p.209).  
Furthermore, Wollenweber, Mann and Valant-Vetschera (as cited in Scott et 
al., 2004, p.209) indicated the presence of two luteolin methyl ethers from the 
leaf exudate flavonoids, while Waithaka (as cited in Komperlla, 2004, p.5) 
indicated the presence of flavonoids such as luteolin and apegenin (both 
Figure 2.35: South African 
geographical distribution of 
A. afra, the orange area 
indicating the regional 
occurrence (taken from Van 
Wyk et al., 1997, p.44). 
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flavones), kaempferol and quercetin (both flavonols) as well as hesperetin (a 
flavanone), which have been linked to the medicinal qualities of the Artemisia 
species.  Examples of this include the in vitro GABAA-benzodiazepine 
receptor activity of the flavonoids hispidulin and cirsilineol, which have been 
isolated from Artemisia herba-alba Asso traditionally used in Turkey (Stafford 
et al., 2005), and the antimicrobial activity of flavonoids from Artemisia annua 
(Komperlla, 2004, p.6).  Flavonoids isolated from Artemisia copa exhibited 
anti-inflammatory, analgesic and antitumour activities, while the anti-oxidant 
properties of A. annua are associated with the flavonols contained in the 
aerial parts of the plant (Mukinda, 2005, p.27).   
 
The geographical variability of phytochemical compounds is a well known fact. 
From the results of various studies, Scott et al. (2004, p.209) concluded that 
the analysis of essential oils of A. afra leaves from different South African 
populations vary considerably in composition, with the major components 
being α- and β-thujone (Figure 2.20 and Figure 2.21, respectively), 1,8-
cineole (also known as eucalyptol, Figure 2.22), camphor (Figure 2.24) and α-
pinene (2.25).  Van Wyk et al. (1997, p.44) stated borneol (Figure 2.23) to be 
another major component of the essential oil of A. afra, while other 
compounds present, but whose contribution to biological activity remains 
unknown, include terpenoids of the eudesmadien and germacratien types, 
coumarins and acetylenes.  Goodson (as cited in Watt & Breyer-Brandwijk, 
1962, p.202) further isolated triacontane (an alkane), scopoletin (a coumarin 
derivative), quebrachitol (methyl 1-inositol) and a wax ester, which he though 
to be ceryl cerotate.  Other minor compounds present in the essential oil of A. 
afra include δ-cadinene, α-terpineol, e-chrysanthenyl acetate, camphene 
(Figure 2.27), β-pinene, trans-β-ocimene and myrcene (Figure 2.28) 
(Artemisia afra, 2007). 
 
Flavonoids, tannins and saponins, as well as the major chemical constituents 
which have been isolated from the essential oil of A. afra, being α- and β- 
thujone, 1, 8-cineole, camphor, α-pinene and borneol, have been discussed in 
Section 2.2.   
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2.5. Artemisia absinthium 
 
2.5.1. The medicinal qualities and health supporting properties of A.  
           absinthium and its use as a traditional medicinal plant 
   
A. absinthium, also commonly known as wormwood, has been recognised 
since ancient times for its medicinal qualities.  It was believed by the ancient 
people that wormwood could counteract the poisonous effects of hemlock and 
mushrooms, and could be used to treat the bite of the seadragon (Grieve, 
2008).  Wormwood has also been used as an antihelmintic for centuries, and 
reference to the extremely bitter plant was made in Egyptian papyri, early 
Syrian texts, and can also be found in many parts of the Bible, e.g. 
Deuteronomy 29:18, Proverbs 5:4, Jeremiah 9:15 and 23:15, Lamentations 
3:15, Amos 5:7 and Revelation 8:11 (Quinlan, Quinlan & Nolan, 2002; 
Williamson, 2003, p.460).  
 
Apart from its use as a vermifuge, wormwood is probably best known as the 
major constituent in the controversial alcoholic drink absinth.  For a long time 
it was believed that the chronic consumption of absinth and more specifically 
the thujones present in the drink, gave rise to the syndrome absinthism.  
Thujones have been discussed in Section 2.2.4.1.1.  Popular in the 19th 
century throughout Europe and enjoyed by famous individuals such as Arthur 
Rimbaud, Toulouse-Lautrec, Degas, Monet, Baudelaire, Picasso, Hemingway, 
Oscar Wilde and Vincent van Gogh, absinth was banned in many European 
countries and the USA for this reason.  Other countries imposed limits on the 
allowable amount of thujone present in the drink.  Absinthism is mainly 
characterised by addiction, acute visual and auditory hallucinations, 
gastrointestinal problems, insomnia, brain damage, epilepsy, convulsions, 
psychiatric illness and coma (Gambelunghe & Melai, 2002; Padosch et al., 
2006; Thujone, 2007).   
 
Gambelunghe and Melai (2002), and Padosch et al. (2006), concluded that 
absinthism is probably not related to the thujone content of absinth, but rather 
to the extremely high alcohol content, which in some forms of absinth may be 
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as high as 50%.  Padosch et al. (2006) stated that absinthism can not be 
exactly distinguished from the effects of chronic alcoholism.  Adulterants 
which were often used in historical cheaper version of the liquor, such as 
copper sulfate and antimony chloride, are also believed to have contributed to 
the observed symptoms (Padosch et al., 2006).  Absinth is currently 
experiencing resurgence in popularity amongst young people, to whom it is 
being advertised as having spiritual elucidation and aphrodisiac stimulation 
properties, and has been legalised in many countries from which it was 
previously banned (Gambelunghe & Melai, 2002; Lachenmeier, Emmert, 
Kuballa & Sartor, 2006; Padosch et al., 2006; Van Wyk & Gericke, 2000).  
 
Today, wormwood is used in many cultures around the world in the treatment 
of various maladies.  Usage of the plant as a vermifuge or antihelmintic is still 
popular (Artemisia absinthium, 2007; Gambelunghe & Melai, 2002; Grieve, 
2008; Guarrera, 1999; Guarrera, 2005; Quinlan et al., 2002; Uzun, Sariyar, 
Adsersen, Karacok, Ötük, Oktayoglu & Pirildar, 2004; Williamson, 2003, 
p.459).  Other uses include the treatment of dyspepsia (Langone Medical 
Center, 2008), colds and rheumatism (Williamson, 2003, p. 453), esophageal 
reflux (Langone Medical Center, 2008), irritable bowl syndrome (Langone 
Medical Center, 2008), indigestion, flatulence and gastric pain (Artemisia 
absinthium, 2007; Gambelunghe & Melai, 2002; Grieve, 2008), inflammation 
and joint pain (Guarrera, 2005; Langone Medical Center, 2008), anorexia 
(Guarrera, 2005; Langone Medical Center, 2008) hypertension and cardiac 
disease (Eddouks, Maghrani, Lemhadri, Ouahidi & Jouad, 2002; Williamson, 
2003, p.453), as well as diabetes mellitus (Andrade-Cetto & Heinrich, 2005; 
Eddouks et al., 2002), insomnia, epilepsy and menstrual problems (Langone 
Medical Center, 2008).  Wormwood is also used as a tonic (Artemisia 
absinthium, 2007; Grieve, 2008; Williamson, 2003, p.453), antiseptic 
(Artemisia absinthium, 2007; Langone Medical Center, 2008; Williamson, 
2003, p.453), carminative and febrifuge (Artemisia absinthium, 2007; 
Williamson, 2003, p.453), antispasmodic (Williamson, 2003, p.453) and to 
relief pain during childbirth (Williamson, 2003, p.453).   
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A study conducted by Omer, Krebs, Omer and Noor (2007) showed 
wormwood to have a steroid sparing effect in patients with Crohn’s disease, 
and could be used as a supplement in the treatment of the disorder.       
Furthermore, wormwood extract has been shown to exhibit antiviral activity 
towards Herpes Simplex virus 1 & 2, Epstein-Barr virus, Cytomegalovirus, 
Varicella-Zoster virus and Human Herpes virus 6 in monkey kidney cells 
(Vero-cells) and human epithelial type 2 (HEp-2) cells (Omer et al., 2007).  
Other studies showed wormwood aqueous extract to be antipyretic in rabbits, 
exhibit choleretic effects in humans, have anticholinesterase activity in vitro as 
well as having hepatoprotective properties against toxicity caused by 
paracetemol in rats (Williamson, 2003, p.459).  The methanol extract of A. 
absinthium has also exhibited antimicrobial activity, ranging from 51.5% to 
25.0% inhibition of growth, against strains of Escherichia coli, Shigella sonnei, 
Shigella flexneri and Salmonella spp., with an aqueous extract showing 
weaker antimicrobial activity (Alanis, Calzada, Cervantes, Torres & Ceballos, 
2005).  
 
A wide array of methods employed in the preparation of wormwood extracts 
for medicinal use by humans have been reported, and it would appear that the 
mode of use is dependent on geographical location and culture it is being 
used in, as well as the ailment for which it is used.  Flϋck and Jaspersen-
Schib, (1941/1976, p.162) states that for the treatment of anorexia, poor 
digestion and colic, an infusion can be prepared by adding 1-2 teaspoons full 
of chopped plant material to one litre of cold water.  Grieve (2008) states that 
wormwood tea, prepared by infusing 28 g of the plant material in 
approximately 500 ml water for 10 to 12 minutes and taken in wineglassful 
doses, will relieve melancholia and jaundice, in addition to being a good 
stomachic.  The addition of a fixed alkaline salt to the infusion confers strong 
diuretic properties to the preparation.  The people of central Italy consume an 
infusion prepared from the leaves of wormwood to stimulate apatite, while a 
decoction made from the aerial parts of the plant is used as an antiemetic.  
The aerial parts of the plant are also used, after prolonged decoction, to 
prepare a poultice which is applied to inflamed tendons.  In Turkey, the aerial 
parts of the plant are infused and drunk as a tea, which is said to provide relief 
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from stomach disorders and flu.  The infusion also acts as a tonic, vermifuge 
and apatite stimulant, and is believed to strengthen the immune system after 
flu.  It is also used to ease childbirth as it causes uterine contractions (Uzun et 
al., 2004).      
 
The use of A. absinthium through the centuries by many cultures across the 
globe for the treatment of various ailments is an indication of the plant’s well 
recognised medicinal properties.  However, further scientific investigation into 
the therapeutic potential of the plant needs to be made which, judging by 
previous studies done and indication of the usage of the plant in the literature, 
may very well produce promising results. 
 
2.5.2. Botanical classification and vernacular names 
 
The botanical classification of A. absinthium is as follows: 
 
 
Kingdom : Plantae 
Phylum : Magnoliophyta 
Class  : Magnoliopsida 
Subclass : Asteridae 
Order  : Asterales 
Family : Asteraceae 
Genus : Artemisia 
Species : A. absinthium 
 
Vernacular names: Wormwood; Absinthe; Absinthe Wormwood; Grand 
Wormwood; True Wormwood; Madderwort; Green Ginger; Absinthium 
[English];  Lapsent [Dominica]; Ascenzo, Scenzo, Ascenza or Ascenze [Italy]; 
Pelin Otu (Turkey), Ajenjo [Spain & Mexico](Andrade-Cetto & Heinrich, 2005; 
Gambelunghe & Melai, 2002; Guarrera, 1999; Guarrera, 2005; Quinlan et al., 
2002; Uzun et al., 2004; Wormwood, n.d.)   
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2.5.3. Macroscopical morphology 
 
A. absinthium is a herbaceous 
perennial growing to a height 
of 0.8-1.2 meters, and rarely 
exceeds 1.5 meters.  The root 
system is hard, woody and 
rhizomatous.  The stems 
appear silver-green in color 
and are straight, grooved and 
branched.  Leaves are spirally 
arranged and covered in fine 
silky silver-white hair, with a 
grey-green appearance on top 
and white below.  They may be 
obovate or lanceolate, entire or 
toothed and are pinnately divided, possessing tiny oil producing glands.  
Basal leaves may be bipinnate or tripinnate and up to 25 cm long with long 
petioles, while cauline leaves are less divided, 5-10 cm long and with shorter 
petioles.  The uppermost leaves may be simple or sessile.  Flowers are small, 
greenish-yellow and tubular without a pappus and clustered in globular bent-
down capitulae.  These are clustered on leafy and branched panicles.  The 
fruit is described as a small achene.  The plant carries flowers from summer 
to early autumn, and pollination is anemophilous (Artemisia absinthium, 2007; 
Williamson, 2003, p.459).   
 
 
2.5.4. Geographical distribution 
 
A. absinthium is not indigenous to South Africa, but can be found growing 
naturally throughout many regions of the world.  Native to Europe, it was first 
introduced to the United States of America in 1841, and today it is naturalised 
across the USA and Canada.  The plant is also found in North Africa and 
Figure 2.36: A. absinthium (taken 
from Colorado Noxious Weeds ID 
Guide, 2006). 
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Western Asia, but may grow as far East as Siberia.  It primarily grows in 
disturbed sites in grasslands and pastures, as well as in uncultivated places, 
on walls, dry rocks and on roadsides (Carey, 1994; Flϋck and Jaspersen-
Schib,1941/1976, p.162; Grieve, 2008).     
 
2.5.5. Major chemical constituents 
 
With both A. absinthium and A. afra being of the same genus of Artemisia, 
similarities exist within the major chemical composition of both plants.  
Grieves (2008) states the major chemical constituents of the essential oil of A. 
absinthium to comprise of thujones, thujyl alcohol, cadinene, phellandrene 
and pinene, while absinthin, absinthic acid and tannins can be found within 
the plant material itself.  Anabsinthin has also been found in plant materials 
(Gambelunghe & Melai, 2002).  Kordali, Aslan, Çalmaşur and Cakir (2006) 
describes the essential oil as comprising of 1,8-cineole, camphor, borneol, 
terpinen-4-ol, ρ-cymen-8-ol, α-terpineol, β-selinene, geranyl isobutyrate, (Z)-
sesquisabinenehydrate, caryophyllene oxide, chamazulene, nuciferol 
propionate and nuciferol butanoate.  Lopes-Lutz, Alviano, Alviano and 
Kolodziejkzyk (2008) investigated the chemical composition of the essential 
oil of A. absinthium and found the major constituents to be myrcene, trans-
thujones and trans-sabinyl acetate.  A detailed description of the chemical 
composition of A. absinthium is also given by Williamson (2003, p.459), 
including the volatile oil consisting of α- and β-thujones, thujyl alcohol, 
azulenes, bisabolene, cadinene, camphene, sabinene, trans-sabinylacetate, 
pinene and phellandrene.  Sesquiterpene lactones to be found in the plant 
include artabsin, artabin, absinthin, anabsinthin, artemetin, arabsin and 
artemolin.  Other compounds include various acetylenes, flavonoids, phenolic 
acids and lignans.     
 
Thujones (Figure 2.20 and Figure 2.21), 1,8-cineole (Figure 2.22), camphor 
(Figure 2.24), borneol (Figure 2.23) and pinene (Figure 2.25), cadinene 
(Figure 2.26), camphene (Figure 2.27), myrcene (Figure 2.28), phellandrene 
(Figure 2.29 and Figure 2.30), and sabinene (Figure 2.31), which are the 
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major chemical constituents of A. absinthium, have been discussed in Section 
2.2.4.1. 
 
 
2.6. Cancer 
 
It is well known that cancer is second only to cardiovascular disease as a 
natural cause of death, with an incidence of over 6 million cases reported 
annually across the globe (Srivastava, Negi, Kumar, Gupta & Khanuja, 2005).  
The World Cancer Report of 2003 (as cited in World Health Organisation, 
2007a) stated that during the year 2003, of the 56 million fatalities that 
occurred worldwide during the year 2000, cancer was responsible for 12% of 
these, with 5.3 million males and 4.7 million females developing neoplasms, 
which claimed the lives of 6.2 million of these individuals.  The World Health 
Organisation (WHO) (World Health Organisation, 2007b) reports that fatality 
due to cancer accounted for 7.6 million, or 13%, of the 58 million total fatalities 
worldwide during 2005.  According to the WHO (World Health Organisation, 
2007b), the main types of cancer responsible for the highest death rates are, 
in order of decreasing mortality rates, cancer of the lung (1.3 million deaths 
per annum), stomach (about 1 million deaths per annum), liver (662 000 
deaths per annum), colon (655 000 deaths per annum) and breast (502 000 
deaths per annum).  In males, in order of decreasing frequency of occurrence,  
lung cancer, stomach cancer, liver cancer, colorectal cancer, oesophageal 
cancer and cancer of the prostate are the most commonly occurring types of 
cancer, while in females, in order of decreasing frequency of occurrence, 
breast cancer, lung cancer, stomach cancer, colorectal- and cervical cancer 
are the most commonly occurring types of cancer. 
 
The WHO (World Health Organisation, 2007b) further states that during the 
year 2005, more than 70% of cancer related fatalities occurred in low- to 
middle income countries.  Cancer related fatalities are projected to increase 
during the coming years, with 9 million cancer related deaths during 2015, 
and a further increase to 11.5 million cancer related deaths during 2030. 
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The literature often defines cancer simply as an uncontrolled proliferation of 
abnormal cells.  Although correct, this very general definition does not do 
justice to the extremely complex and involved pathological state that is 
cancer.  Cancer is not a simple molecular event, but a multifunctional and 
dynamic one, requiring changes that effect the neoplastic cell, the interaction 
between the neoplastic cell and its surrounding stroma, as well as the immune 
system (Carbone & Pass, 2004).  Hanahan and Weinberg (as cited in 
Workman & Kaye, 2002) characterised cancer according to the following six 
hallmark traits: 
 
• Cancer is self sufficient in proliferative growth signals. 
• Cancer is insensitive to growth inhibitory signals. 
• Cancer has the ability to evade apoptosis. 
• Cancer has the potential to replicate in a limitless manner. 
• The induction of angiogenesis is an important trait of cancers. 
• Cancer has the potential to invade tissues and metastasise.  
 
 
2.6.1. Aetiology and risk factors 
 
Under normal circumstances, the somatic cells of an organism continue to 
divide and multiply until the organism has reached maturity, at which point the 
majority of cells enter a quiescent, non proliferative and metabolically active 
state which corresponds to G0 of the cell cycle.  Examples of such cells 
include neurons and myocytes.  However, certain cells are required to remain 
in a proliferative, renewing state and do not enter senescence.  Examples of 
such cells include intestinal epithelial cells, dermal cells and germ cells.  The 
proliferation of cell populations is subject to the stringently controlled growth 
mechanisms of the cell cycle (O’Conner & Browder, 1998). 
 
The growth mechanisms of the cell cycle maintain homeostasis within a cell 
under normal circumstances, and determine whether a cell will continue to 
proliferate, enter into a quiescent state, or undergo programmed cell death, 
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also known as apoptosis.  Mutations of the intracellular signal pathways of a 
cell, which usually occur at the deoxyribonucleic acid (DNA) level, leaves such 
a cell independent of the growth control mechanisms of the cell cycle, 
enabling it to proliferate at an uncontrolled rate (Foster, in press).  Mutations 
of cellular DNA may be due to the direct effect of environmental agents on the 
DNA as well as a cell’s inherited genetic predisposition to certain mutations. 
 
2.6.1.1. Environmental/external carcinogens and co-carcinogens   
 
When discussing the environmental factors which may cause genetic 
mutations allowing a cell to overcome the various checkpoints of the cell cycle 
and continue to proliferate in an uncontrolled fashion, it is important to 
distinguish between carcinogens, co-carcinogens and promoters.  
Carcinogens, or initiators, are those factors which cause molecular alterations 
leading to the development of cancer.  Co-carcinogens and promoters are 
factors which are not carcinogenic on their own, but which enhance the 
activity of carcinogens.  Co-carcinogens may, however, at high amounts or in 
the presence of other co-carcinogens, become carcinogenic.  A genetic 
predisposition may also lead to co-carcinogens having a carcinogenic effect 
(Carbone & Pass, 2004). 
 
The environmental- or external factors which may act as carcinogens or co-
carcinogens are classified as follows: 
 
• Physical- examples are ultraviolet- (UV) and ionizing radiation. 
• Chemical- examples include asbestos and tobacco smoke. 
• Biological- examples are infection by Hepatitis B virus (HBV), Human 
Papilloma virus (HPV), Helicobacter pylori and Aspergillus fungae. 
(World Health Organisation, 2007b)   
 
A fourth group of external factors which may lead to the development of 
cancer may be classified as related to diet and exercise habits, and include 
 52 
factors of both the physical and chemical groups.  This fourth group is 
discussed separately.   
 
 
2.6.1.1.1. Physical carcinogens and co-carcinogens 
 
It is a well known fact that solar UV radiation causes mutations in the genetic 
makeup of cells via the formation of cyclobutane pyrimidine dimers, leaving 
the cells prone to becoming neoplastic (Migliore & Coppedè, 2002).  UV 
radiation may give rise to any type of skin cancer.  The risk of developing skin 
cancer for individuals suffering from the hereditary condition of xeroderma 
pigmentosum (XP), which is mainly characterised by the body’s inability to 
repair UV induced DNA damage, is 2000 times greater than in healthy 
individuals.  Individuals suffering from XP also run a much higher risk of 
developing various other neoplasms (Voet & Voet, 1995, p.1048).  The 
importance of limiting exposure to solar radiation, using sunscreen and 
wearing protective clothing could not be emphasised enough where 
prevention of UV induced DNA damage is concerned.   
 
Ionizing radiation is also known to cause certain types of cancer (World 
Health Organisation, 2007c).  Radioactive decay of uranium in the crust of the 
earth leads to the formation of radon gas which, when inhaled, may lead to 
the development of lung cancer.  Uranium miners and survivors of the 
Japanese nuclear holocaust have been shown to be at a higher risk of 
developing lung cancer, as well as cancer of the breast and thyroid, 
respectively.  Excessive diagnostic radiology exposure, such as the 
performance of fluoroscopies to monitor iatrogenic pneumothoraces in 
women, has been shown to lead to the development of breast cancer.  The 
use of thoratrast as a contrast agent in medical procedures has led to the 
development of tumours of the hepatobiliary tract and nasal sinuses.  
Furthermore, therapeutic irradiation of the breast, thyroid and skin leads to an 
increased incidence of tumour development in these respective sites (Neal & 
Hoskin, 1994, p.6). 
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2.6.1.1.2. Chemical carcinogens and co-carcinogens 
 
The WHO (World Health Organisation, 2007a) reports that the consumption of 
tobacco products is the main avoidable risk factor for developing cancer.  
During the twentieth century, 100 million people died of illnesses related to 
tobacco use.  Half of regular smokers die as a result of tobacco use, and a 
quarter of smokers die prematurely during their middle ages as a result of the 
habit.  The relative risk of developing lung cancer amongst smokers is 
between twenty and thirty times that of non-smokers.  In countries where 
tobacco consumption is high, 90% of lung cancer in both men and women is 
attributable to the use of tobacco products.  Although lung cancer is the 
malignancy most often associated with tobacco use, smoking also increases 
the relative risk of developing a multitude of other malignancies.  The relative 
risk of developing cancer of the oral cavity, pharynx, larynx and oesophagus 
(squamous cell carcinoma) as a result of smoking, is greater than six, while 
the relative risk for developing malignancy in the pancreas is between three 
and four.  A relative risk factor of between two and three for the development 
of other malignancies as a result of tobacco smoking has also been 
described.  These malignancies include cancer of the stomach, liver, cervix, 
nasal cavities and sinuses, kidneys, oesophageal adenocarcinoma and 
myeloid leukaemia (World Health Organisation, 2007a).   
 
Under normal circumstances genetic damage caused by UV radiation is noted 
during the cell cycle, and the cell will attempt to correct this damage.  If repair 
of the damaged DNA is not possible, the cell will undergo programmed cell 
death, also known as apoptosis, which is discussed later.  Sugano, Minegishi, 
Kawamoto and Ito (2001) conducted a study on the effects of nicotine on UV 
induced apoptosis.  They found that levels of nicotine normally obtained in the 
lungs of smokers inhibit UV induced apoptosis, allowing pre-neoplastic and 
neoplastic cells to proliferate in an uncontrolled fashion, which may ultimately 
lead to the development of cancer. 
 
Cessation of smoking has been shown to have enormous benefits, with the 
best results obtainable if cessation occurs early in the third decade of life.  
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However, a risk reduction of 60% is possible if cessation occurs after the fifth 
decade of life (World Health Organisation, 2007c). 
 
Apart from those present in tobacco smoke, exposure to a variety of 
chemicals often present in the occupational setting have also been linked to 
the development of various malignancies.  As mentioned earlier, uranium 
miners are known to be at high risk of developing lung cancer.  Dockers, 
plumbers, builders, engineers and miners are often exposed to asbestos, 
which is associated with lung carcinoma and mesothelioma of the pleura and 
peritoneum.  Cancer of the renal pelvis, ureters and bladder is associated with 
exposure to β-naphthylamine and azo-dyes.  Individuals in the rubber product 
and aniline dye industry are known to be exposed to these chemicals.  
Inhalation of hardwood dust by furniture workers is associated with 
adenocarcinoma of the nasal sinuses (Neal & Hoskin, 1994, p.4). 
 
Occupational exposure to vinyl chloride is associated with hepatic 
angiosarcoma, while exposure to aromatic amines is associated with cancer 
of the bladder.  Inhalation of arsenic is associated with the development of 
lung cancer, while ingestion of this compound leads to basal- and squamous 
cell carcinoma of the skin.  Other metals such as cadmium, nickel and cobalt 
have been associated with an increased risk in the development of lung 
cancer (Migliore & Coppedè, 2002).  
  
 
2.6.1.1.3. Biological carcinogens and co-carcinogens  
 
The WHO (World Health Organisation, 2007a) reports that infectious agents 
are responsible for up to 23% of malignancies in developing countries, while 
this figure is decreased to only 8% in developed countries.  This is mainly due 
to the availability of better healthcare services in developed countries as 
compared to those in developing countries. 
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External biological agents acting as carcinogens and co-carcinogens are 
mostly viral in nature.  Viruses generally reproduce by integrating their genetic 
material with that of the host cell, which may lead to mutations in genes 
whose products normally act as regulators during the cell cycle.  This may 
cause an infected cell to escape apoptotic signals of the cell cycle, allowing it 
to transform and enter into unchecked proliferation.   
 
Ten percent of individuals infected with HBV develop chronic infection, which 
is known to lead to cirrhosis and hepatocellular carcinoma (Bishop, Duben-
Engelkirk & Fody, 2000, p.364-365).  Infection with certain strains of HPV, 
especially strains 16 and 18, is known to lead to the development of cervical 
and anogenital warts, occasionally leading to the development of cervical- and 
anogenital cancers (Neal & Hoskin, 1994, p.7).  Infection with Epstein-Barr 
virus (EBV) is associated with the development of Burkitt’s lymphoma in areas 
where malaria is endemic (Jensen, Wright & Robison, 1997, p.403).  There 
also appears to be strong evidence that EBV might be the causative agent of 
nasopharyngeal carcinoma in Southeast Asia (Neal & Hoskin, 1994, p.7).  
Human T-cell lymphotrophic virus type 1 (HTLV-1) has been strongly 
associated with adult T-cell lymphoma leukaemia in endemic areas of Japan 
and the Caribbean, where positive viral serology results were obtained in 
more than 95% of the cases (Neal & Hoskin, 1994, p.7).  Kaposi’s sarcoma-
associated Herpes virus is thought to be the causative agent of Kaposi’s 
sarcoma, a rare malignancy seen mostly in AIDS patients (Jensen, et al., 
1997, p.406). 
 
Infection by a number of larger microbes is also associated with the 
development of neoplasms.  Examples are H. pylori infection, which is thought 
to play an important role in the development of stomach cancers, 
schistosomiasis, which is thought to increase the risk of developing bladder 
cancer, and liver fluke infection, which is said to increase the risk of 
developing cholangiocarcinoma of the bile ducts (World Health Organisation, 
2007c). 
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It should be mentioned at this point, however, that precautionary measures 
and early detection and intervention may be key to preventing the 
development of neoplasms associated with microbial infection.  HBV 
vaccination has been shown to prevent hepatocellular carcinoma in high 
incidence countries (World Health Organisation, 2007a).  The Pap-test, which 
is used to detect cervical dysplasia and neoplastic lesions of the cervix, has 
been the most effective preventative measure in cancer prevention up to date 
(Carbone & Pass, 2004).  An effective HPV vaccine could become a reality 
within the next 3-5 years (World Health Organisation, 2007a). 
 
 
2.6.1.1.4. Diet and exercise as factors in the development of malignancy 
 
The 20th century has brought about a turnaround in human dietary 
consumption habits.  Industrialisation has caused the migration of agrarian 
societies to urban centres, where industrialised societies were formed.  This 
subsequently led to the industrialisation and commercialization of large scale  
non-organic food production, employing industrialised methods of food 
processing and distribution.  These changes in food production methods have 
led to the turnaround in human dietary habits, with the consumption of animal 
fats and proteins increasing by more than three fold.  Although the 
consumption of fruits and vegetables has also increased, most of it is not 
consumed fresh (Grandics, 2003).  Japan demonstrates the lowest incidence 
of the major cancer types.  This is possibly due to the Japanese custom of 
consuming food in a fresh or raw state.  Even though the Japanese have 
adopted many aspects of the Western lifestyle and have the same risk factors 
for cancer development such as alcohol and tobacco consumption, obesity, 
which is another known risk factor for cancer development, is relatively low.  
This is attributable to Japanese dietary habits.  Evidence suggests that dietary 
manipulations may be protective against 10-70% of cancer types (Grandics, 
2003).  
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Diets rich in highly saturated fats and proteins may contribute to the 
development of colon cancer, while consumption of fibre in the form of fresh 
fruit and vegetables may be preventative (Grandics, 2003).  Heterocyclic 
amines which form during the cooking of meat have been associated with the 
development of colorectal cancer (Migliore & Coppedè, 2002).  Folate 
deficiency has been shown to cause nucleotide pool imbalance, DNA strand 
breaks, hypomethylation of DNA, increased gene expression, altered 
chromatin conformation and altered cellular proliferation.  These have all been 
associated with carcinogenesis.  Thus high dietary intake of folate may be 
protective in the prevention of malignancy.  In the USA, breast cancer has 
been shown to be prevalent in areas where iodine consumption is low.  
Fibrocystic breast disease, which is a known risk factor for breast cancer 
development, may be prevented by proper iodine intake (Grandics, 2003). 
 
Physical activity plays just as important a role as dietary habits when cancer 
prevention is considered.  Diets rich in saturated lipids, proteins and refined 
carbohydrates, in conjunction with low- or no levels of physical activity, are 
known to contribute to the development of various disease states, including 
obesity, diabetes, cardiovascular disease and malignancy.  The obesity 
epidemic prevalent in especially developed countries is commonly associated 
with poor dietary habits and little physical activity.  This Western lifestyle is 
strongly linked to the development of various malignancies.  Examples are 
colorectal cancer, endometrial carcinoma, oesophageal adenocarcinoma and 
cancers of the breast, gall bladder and kidneys (World Health Organisation, 
2007a). 
 
From the aforementioned, the maintenance of a healthy body by maintaining 
a healthy weight through regular physical activity and proper diet is paramount 
in the prevention of not only malignancy, but also diabetes and cardiovascular 
disease, two of the major health problems of our times.   
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2.6.1.2. Internal factors in carcinogenesis 
 
As stated earlier, carcinogenesis is a complex pathology.  It should not be 
classified as a single disease state, but rather a multifunctional and dynamic 
event involving a wide array of factors, including the internal cellular state, the 
cell’s interaction with its environment and the immune system.  The events 
leading up to a cell turning malignant often involve the mutagenic actions of 
carcinogens and co-carcinogens from the external environment, such as 
tobacco smoke, industrial chemicals and pollutants, and microbes.  An 
individual’s lifestyle may also contribute to the development of malignancy, as 
outlined in the previous section. 
 
The following section will focus on what will be referred to as internal factors 
of carcinogenesis, i.e. those factors related to the individual’s genetic makeup, 
immune system and endocrine function. 
 
 
2.6.1.2.1. A genetic predisposition to cancer 
 
Whether a cell proliferates, enters senescence or undergoes apoptosis is 
tightly regulated by the protein products of chromosomal DNA transcription 
and translation.  Mutations in gene sequences that regulate these processes 
often lead to cellular transformation, immortalisation and uncontrolled growth.  
In fact, it would appear that all forms of cancer are due to genetic aberrations 
(Voet & Voet, 1995, p.1186), whether inherited or acquired due to the action 
of environmental carcinogens.  
 
Cellular growth and proliferation is a function of the highly regulated cell cycle 
(Figure 2.37), a sequence of events occurring during the lifetime of a 
eukaryotic cell.  The cell cycle is divided into the following stages: 
 
1. G1 phase: During this phase, which is normally the longest phase of the 
cell cycle, normal cellular growth occurs while the cell prepares for DNA 
synthesis.  During the G1 phase, the cell may enter into the quiescent G0 
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phase, depending on the type of cell.  Terminally differentiated cells such 
as myocytes and neurons usually assume this state permanently, while 
other non-terminally differentiated cells which have entered the G0 phase 
will remain in such state in the case of insufficient nutrients or contact 
inhibition.  Cells which do not enter the G0 phase, or quiescent cells 
coming out of the G0 phase, are compelled to enter the next phase of the 
cell cycle, during which DNA is copied.  The cell cycle time of different 
cells may vary greatly depending on the type of cell, from 8 hours to 100 
days and more, with the majority of this variation occurring during the G1 
phase.  Cells in culture, however, normally complete the cycle within 16 
hours to 24 hours. 
2. S phase: Upon completion of the G1 phase, the growing cell enters the 
next stage of the cell cycle, being the S phase, as a result of cytoplasmic 
factors stimulating DNA replication.  Other factors that may stimulate a cell 
to enter the S phase and commence DNA replication include carcinogens 
and/or tumour viruses, surgical removal of tissue resulting in loss of 
contact inhibition and subsequent tissue regeneration, as well as mitogens 
binding to the cell surface receptors and inducing cellular division.  Before 
the cell is able to continue to the third phase of the cycle, the newly 
replicated DNA is inspected by DNA-replicating enzymes such as DNA 
polymerase for any errors which might have occurred during replication.  
Once these errors have been rectified the cell moves into the third phase 
of the cycle, being the G2 phase. 
3. G2 phase: During this phase the now tetraploid cell prepares for mitosis 
and cell division which occurs during the M-phase, the final stage of the 
cell cycle. 
4. M phase: During this final stage of the cell cycle, the tetraploid parental 
cell undergoes mitosis and gives rise to two identical daughter cells, each 
entering the cell cycle again at the G1/G0 phase. 
(Voet & Voet, 1995, p.1038) 
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Cyclins and cyclin dependent kinases (CDK’s) are two molecules which play 
key roles in the regulation of the cell cycle.  Cyclins, which are regulatory 
molecules, combine with and activate CDK’s to form active heterodimers, 
which phosphorylate proteins guiding the cell to the next level of the cell cycle.  
The type of protein activated is dependent on the combination of the type of 
cyclin and its CDK.  While CDK’s are constitutively expressed, cyclins are 
synthesised and broken down in the cell according to various cellular signals.  
A variety of cyclin-CDK complexes are active in the regulation of the cell 
cycle.  G1 cyclin-CKD’s are active during the G1 phase of the cell cycle, and 
regulate the expression of transcription factors which promote S phase cyclin 
expression, the synthesis of DNA replication enzymes as well as the 
ubiquitination of S phase inhibitory molecules.  A pre-replication complex 
formed during the G1 phase is further activated by S cyclin-CDK which forms 
during the S phase.  Activation of this complex prevents new complexes of the 
same type from forming, ensuring that only one copy of the genome is made 
during the S phase.  Additionally, mitotic cyclin-CDK complexes which form 
during the S phase and G2 phase activate a crucial complex, anaphase 
promoting complex (APC), further downstream.  APC is responsible for the 
Figure 2.37: A graphical representation of the cell cycle 
(taken from Physiomics, 2008). 
 61 
breakdown of structural proteins of the chromosomal kinetochore, enabling 
mitosis as well as the degradation of mitotic cyclins (Cell Cycle, 2008).    
 
Two families of tumour suppressor genes, tumour suppressor genes being 
discussed later in this section, which play a crucial role in cell cycle regulation 
and prevention in the formation of malignancy by preventing cell cycle 
progression, are the cip/kip and INK4a/ARF families.  The cip/kip family 
includes p53, which is activated by DNA damage and in turn activates the p21 
gene, as well as transforming growth factor β (TGFβ) which activates the p27 
gene.  Activated p21 and p27 in turn binds to and inactivates cyclin-CDK’s 
during the G1 phase of the cell cycle, inhibiting further cellular growth and 
replication. The INK4a/ARF family of genes include p16INK4a, which bind to 
CDK4 and halts the cell cycle during the G1 phase and p14arf, which prevents 
the degradation of p53 (Cell Cycle, 2008).  P53 is discussed in more detail 
later in this section.      
 
External carcinogens as discussed in Section 2.6.1.1., however, occasionally 
cause mutations in the genes coding for the proteins which regulate the cell 
cycle, resulting in cells with abnormal growth patterns being allowed to 
proliferate unchecked, and cancer to develop. 
 
Two types of genes that play important roles in the cell cycle and control of 
cellular growth and proliferation are proto-oncogenes and tumour suppressor 
genes.  Proto-oncogenes are normal genes whose translational protein 
products stimulate cell division, while tumour suppressor genes generally 
inhibit cellular growth and transformation by regulating the expression of 
proto-oncogenes.  Normal activity of these genes take place during somatic 
growth, regeneration and repair, occurring during phase G1/G0 of the cell 
cycle.  A highly controlled homeostatic balance is maintained between the up- 
and down-regulation of these two groups of genes.  Any alteration in this 
balance favouring the expression of proto-oncogenes result in cellular 
proliferation and potential cancer (Macfarlane, Reid & Callander, 2000, p. 
151).   
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Oncogenes are the result of mutations occurring in normal proto-oncogenes.      
The activation (transcription and translation) of oncogenes lead to the 
formation of neoplasms in various ways: 
 
• The transcription and translation of oncogenes may give rise to protein 
products, including growth factors, growth factor receptors and 
intracellular signal transductors, whose activities are anomalous relative to 
the corresponding products of proto-oncogene activation.  This may 
potentially lead to malignancy. 
• Malignant transformation may arise due to an oncogene product being 
degraded at a slower rate than the corresponding normal proto-oncogene 
product, leading to an inappropriately high intracellular concentration of 
the anomalous protein. 
• Chromosomal rearrangement may lead to the inappropriate transcription 
of an oncogene under a foreign regulatory sequence.  The translocation of 
a proto-oncogene to a highly active regulatory sequence may also lead to 
an inappropriately high concentration or untimely expression of the protein 
product, which is a major factor in cellular transformation. 
• The multiple replication of an oncogene (gene-amplification), either as 
sequentially repeated chromosomal copies or extra-chromosomal 
particles, may give rise to malignancy. 
• Insertion of a viral genome into the host genome may lead to a proto-
oncogene being brought under the transcriptional control of a viral 
regulatory sequence, leading to the inappropriate expression of the gene 
product.  
• The loss or inactivation of a tumour suppressor gene that normally 
regulates the expression of a proto-oncogene or oncogene, may lead to 
the uncontrolled transcription of these genes, resulting in inappropriately 
high concentrations of their products and uncontrolled cellular 
proliferation.   
(Voet & Voet, 1995, pp.1186-1187) 
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Examples of proto-oncogenes whose mutation or up-regulation may lead to 
the development of cellular proliferation and potential malignancy, include 
Ras, Raf, Myc, Neu, Src and Sis (Neal & Hoskin, 1994, p.2).  Anti-apoptotic 
genes of the Bcl-2 family of genes, which include genes coding for anti-
apoptotic survival proteins as well as genes coding for pro-apoptotic death 
proteins, include Blc-2, Bcl-xL, Mcl-2, Bfl-1, Bcl-w, A1 and Ced-9 (Bowen, 
Bowen & Jones, 1998, p.73).  The Bcl-2 family is discussed in more detail 
later. 
 
Normal cells contain one of a pair of tumour suppressor genes on each 
homologous chromosome.  Individuals from families in which cancer is 
prevalent often inherit only a single copy of this gene, have a normal 
phenotype and act as carriers.  However, deletion or mutation of the single 
inherited tumour suppressor gene may lead to cancer in such a person.  For 
cancer to develop sporadically in an individual not genetically predisposed to 
it, both copies of a tumour suppressor gene must be mutated or deleted.  The 
most commonly altered gene in human malignancy has been shown to be 
p53, a tumour suppressor gene which is altered in 50% of cancers (Voet & 
Voet, 1995, p.1188).  In fact, it is considered that alteration or loss of p53 is 
crucial to the development of most, if not all, malignancies (Lohrum & 
Vousden, 2000).  P53 may be activated by many types of stress, including 
UV- and gamma irradiation, chemical-induced genetic damage, hypoxia, 
oncogene activation and loss of normal growth- and survival signals.  This 
leads to the cell entering cell cycle arrest in the G1 phase, allowing damaged 
DNA to be repaired before the cell enters the S-phase of the cell cycle.  
Irreparable DNA damage leads to p53-directed apoptosis of the cell.  Both 
these responses prevent the replication of cells undergoing oncogenic 
changes, and thus possible tumour formation (Ryan, Phillips & Vousden, 
2001).   
 
Rb (retinoblastoma gene) is another well known tumour suppressor gene that 
plays a vital role in regulating cell cycle progression.  Retinoblastoma is a 
malignancy affecting mostly infants and children, and is the result of the 
deletion of the Rb gene from chromosome 13 of retinoblasts.  This leads to 
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uninhibited cellular proliferation of retinoblasts, and subsequent 
retinoblastoma.  Offspring of individuals who survive retinoblastoma also have 
a high incidence of the disease as well as other forms of malignancy (Voet & 
Voet, 1995, p.1187).  Rb protein normally binds and inactivates the E2F 
transcription factors, which normally function to regulate the expression of 
genes required for cell cycle progression into the G1 phase.  Loss of Rb leads 
to cellular proliferation, but also apoptosis, through the exogenous expression 
of E2F which, through a complex pathway, leads to apoptogenic Bax-
mediated cytochrome C release.  In this way a tumour suppressor molecule 
which directly contributes to cellular proliferation also transactivates 
components of the apoptosis mechanism, indicating the complexity of cell 
cycle regulation and cancer (Makin & Dive, 2003). 
 
2.6.1.2.2. Telomeres   
 
The Hayflick limit refers to the finite replicative potential of mammalian cells.  
Upon reaching this limit, cells enter senescence, a state of replication 
cessation and changes associated with ageing.  The ability of a cell to escape 
senescence and proliferate in an uncontrolled fashion is a prerequisite for 
malignancy.  Thus senescence is seen as a means of inhibiting 
tumourigenesis (Neumeister, Albanese, Balent, Greally & Pestell, 2002).   
 
This state of replicative senescence is thought to be due to the shortening of 
telomeres during each cycle of DNA replication.  Telomeres are nucleoprotein 
structures capping the ends of chromosomes.  These non-coding DNA 
sequences consist of up to 25 000 base pairs and protect chromosomes 
against degradation, rearrangement and interchromosomal fusion.  The 
normal lagging strand method used by DNA polymerase to transcribe DNA 
makes transcription of the ends of linear DNA impossible, leading to the loss 
of between 50 and 200 base pairs of telomeric DNA per round of DNA 
replication.  This erosion of telomeres is thought to trigger cellular senescence 
and form the basis of ageing (Neumeister et al., 2002).   
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Telomerase is an enzyme with reverse transcriptase activity, present in self- 
renewing cell populations of the body such as germ cells, epidermal basal 
cells, lymphocytes and heamatopoetic cells, but down-regulated in most other 
somatic cells.  Its function is to replicate telomeres and thus to counteract the 
progressive shortening of telomeres that normally occur during DNA 
replication.  Although normally absent or present in very low levels in normal 
somatic cells, 70% of immortalised somatic cell populations and between 90% 
and 95% of cancer cells express telomerase activity, leading to the 
stabilisation of telomeric lengths and subsequent escape from senescence.  A 
strong correlation appears to exist between the maintenance of telomere 
length and cellular immortalisation and tumour formation (Liu, Lai, Andrews & 
Tollefsbol, 2004).  This may explain the absence of telomerase function in 
somatic cells.  The entering of cells into the senescent phase as a result of 
telomere shortening and absence of telomerase contributes to the prevention 
of immortalisation of these cells and eventual malignancy (Voet & Voet, 1995, 
p.1045).  Thus it would appear that ageing is the price multicellular organisms 
pay in exchange for protection against malignancy.   
 
  
2.6.1.2.3. Immune factors in malignancy 
    
The favourable prognostic indicator of lymphocytic infiltration in tumours such 
as seminomas and melanomas, spontaneous regression in hypernephroma 
and melanoma, as well as the objective responses observed during cytokine 
stimulation of T-cells, are thought to be evidence of the immune system’s 
ability to mount a response in the presence of cancer cells.  
Immunosupression leads to the development of certain types of malignancy 
which, in some cases, are virally mediated (Neal & Hoskin, 1994, p.8).  
Nowhere is this more evident than in the case of AIDS.  Up to 40% of 
individuals with AIDS will develop a malignancy, most notably Kaposi’s 
sarcoma, which is thought to be caused by Kaposi’s sarcoma associated 
Herpesvirus (Jensen et al., 1997, p.406), and non-Hodgkin’s lymphoma (Neal 
& Hoskin, 1994, p.8). 
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An increase in the incidence of Kaposi’s sarcoma, non-Hodgkin’s lymphoma 
and skin cancer is also observed in transplant recipients receiving steroids, 
azothioprine or cyclosporin (Neal & Hoskin, 1994, p.8). 
  
2.6.1.2.4. Endocrine factors in malignancy 
 
Over-stimulation of cellular hormone receptors by endogenous- or exogenous 
hormones may lead to hyperplasia, resulting in adenomatous change and 
occasionally cancer.  An example of this is the predisposition of the 
endometrium to the development of well differentiated endometrial 
adenocarcinoma, through excessive stimulation from endogenous steroids, 
such as oestrogen secreting ovarian granulosa cell tumours, or stimulation 
from exongenous steroids, as in hormone therapy.  A further example is the 
rise in thyroid stimulating hormone (TSH), subsequently leading to goitre and 
possible follicular carcinoma in cases of chronic severe iodine deficiency 
(Neal & Hoskin, 1994, p.8). 
 
  
2.6.2. Cell death: necrosis versus apoptosis 
In order to maintain the homeostatic balance of the body, around 10 billion 
cells die on any given day in order to counter the amount of new cells arising 
through mitosis.  Programmed cell death, or apoptosis, is a vital link in this 
life-death cycle.  It sculpts the body during development and gives rise to 
organs, fingers and toes.  Both the immune- and nervous systems arise from 
an overproduction of cells.  Those cells that respectively fail to produce 
antigen specificities or form functional synaptic connections are removed via 
apoptosis.  Furthermore, apoptosis is necessary for the elimination of 
pathogen infected cells from the body, as well as activated- or auto 
aggressive immune cells (Heemels, 2000, p.769).  Another important function 
of apoptosis is the elimination of cells that have acquired genetic mutations 
which can not be repaired during the cell cycle.  Failure of these cells to be 
eliminated through apoptosis may lead to their immortalisation and possible 
malignancy (Evan & Littlewood, 1998). 
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Apoptotic cells undergo morphological cellular changes which distinguish 
them from necrotic cells.  These changes occur on cytoplasmic-, plasma 
membrane- and nuclear levels.  Apoptotic cells round up, condense and loose 
contact with neighbouring cells.  This is accompanied by loss of microvilli and 
desmosomes.  Dilation of the endoplasmic reticulum and outer nuclear 
envelope is observed in the cytoplasm.  Vacuoles and vesicles are formed 
due to swelling of the reticulum cisternae.  The cell has a characteristic 
spongy appearance due to the fusion of these vacuoles and vesicles with the 
plasma membrane.  Other cytoplasmic organelles generally remain intact.  
Compaction of the cytoplasm due to loss of water and shrinkage leads to an 
increase in cell density.  Convolution of the plasma membrane leads to 
budding or blebbing and the formation of several membrane-bound spheres 
known as apoptotic bodies, which are rapidly phagocytosed by neighbouring 
cells and macrophages.  This inhibits the launch of an inflammatory response 
in the tissue.  On a nuclear level, chromatin condensation and margination is 
usually observed.  Convolution of the nuclear membrane may lead to the 
budding off of several fragments and the forming of apoptotic bodies.  
Apoptotic cells or apoptotic bodies that are shed into lumina loose their 
membrane integrity and undergo apoptotic changes known as secondary 
necrosis (Bowen et al., 1998, pp.17-18). 
 
Necrosis is the term donating passive cell death as a result of lethal trauma 
and pathology.  Unlike apoptotic cells, necrotic cells swell instead of shrink.  
Calcium and sodium loss as a result of plasma membrane damage leads to a 
loss of water balance, acidosis and shock.  The drop in pH causes chromatin 
precipitation and a subsequent pyknotic nucleus.  In the mitochondria, 
distension of both the inner- and outer compartments is observed, as well as 
dense deposits of lipoprotein.  Swelling and bursting of both the endoplasmic 
reticulum and lysosomes is further observed. The latter of these two 
organelles contain digestive enzymes which contribute to further autolysis of 
the cell and its final disintegration.  This releases cellular debris which elicits 
the inflammatory response that normally accompanies necrosis (Bowen et al., 
1998, p.23).   
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2.6.2.1. Pathways in apoptosis 
 
In general, initiation of apoptosis occurs through the activation of the extrinsic 
pathway (death receptor pathway), intrinsic pathway (mitochondrial pathway), 
or both (Perik, De Vries, Gietema, Van der Graaf, Sleijfer, Suurmeijer & Van 
Veldhuisen, 2005). The common denominator in both these pathways is a 
family of evolutionary highly conserved cysteine proteases known as the 
caspases.  It could be said caspases are the central executioners of 
apoptosis, as elimination of these enzymes significantly slows down and may 
even inhibit apoptosis (Hengartner, 2000, p.770).  
 
Caspases function by cleaving their respective target proteins at one or more 
locations, always after an aspartate residue.  Cleavage by a caspase 
inactivates a protein in most cases, however the cleaving off of a negative 
regulatory domain or the cleaving of a regulatory subunit may also activate 
some target proteins.  Caspases themselves occur as enzymatically inert 
zymogens that need to be activated in order to carry out their catalytic 
activities.  Three models of caspase activation have been proposed.  These 
are: 
 
• Autocatalytic activation through cleavage of pro-caspase molecules by 
previously activated caspases.  This suggests a caspase activation 
cascade which is known to be utilised by cells to activate caspases 3, 6 
and 7.  However, this cascade does not account for the activation of the 
initiator caspase. 
• The induction by proximity model proposes the cleavage and activation of 
pro-caspase molecules that are in close proximity to each other.  During 
the extrinsic pathway of apoptosis, which is discussed later, death 
receptor molecules on the plasma membrane recruit several molecules of 
pro-caspase 8.  The high localized concentration of zymogen is thought to 
initiate induction by proximity, leading to the formation of active caspase 8, 
which may then continue in the activation of pro-caspases further along 
the caspase cascade. 
 69 
• A third means of caspase activation, particularly activation of caspase 9, 
which plays an important role in the intrinsic apoptotic pathway discussed 
later, is via the association with a regulatory subunit.  Activation of 
caspase 9 requires the association of pro-caspase 9 with two protein co-
factors; Apaf-1 and cytochrome C.  This haloenzyme complex is known as 
the apoptosome, and may well contain various other proteins. 
(Hengartner, 2000, p.771) 
 
It appears that all three above models may be utilised by the cell to facilitate 
caspase activation and apoptosis.  Effector caspases are normally activated 
proteolytically by a caspase further up the caspase cascade, while initiator 
caspases are activated through interaction between different proteins, such as 
the case with caspase 8 and caspase 9 activation. 
 
Although the extrinsic- and intrinsic pathways of apoptosis are initiated 
through different mechanisms, both these pathways seem to converge at the 
activation of pro-caspase 3, which in turn activates pro-caspases further along 
the caspase pathway that ultimately leads to apoptosis of the cell.   
 
2.6.2.1.1. Extrinsic apoptotic pathway 
 
Although much more complex, the basic principle of the activation of the 
extrinsic pathway involves the binding of death signal ligands such as 
apoptosis related cytokines to their respective receptors, such as the Fas 
receptor (FASR), tumour necrosis factor receptor 1 (TNFR1) and CD95 on the 
plasma membrane.  The binding of a ligand to example FASR causes its 
death domain to bind to that of the cytosolic adaptor molecule Fas associated 
death domain protein (FADD) (Bowen et al., 1998, p.98).  FADD then 
continues to recruit pro-caspase 8, resulting in the formation of a death 
inducing signalling complex (DISC).  Activation of pro-caspase 8 occurs at this 
point through induced proximity.  However, caspase 8 activation can be 
blocked at this point through the recruitment of the degenerate caspase 
homologue, c-FLIP (Hengartner, 2000, p.773).  Activated caspase 8 may 
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catalytically activate caspase 1, which in turn activates caspase 3, or it may 
directly cleave nuclear poly-(ADP-ribose) polymerase (PARP), an enzyme 
related to the repair of DNA strand breaks (Bowen et al., 1998, p.95).  
Caspase 8 may also cleave and activate Bid, a pro-apoptotic member of the 
Bcl-2 protein family which acts as a mediator between the extrinsic- and 
intrinsic apoptotic pathway.  Activated Bid migrates to the mitochondria, where 
it facilitates the release of cytochrome C, which is vital to the successful 
completion of apoptosis via the intrinsic pathway (Hengartner, 2000, p.773). 
 
 
2.6.2.1.2. Intrinsic apoptotic pathway 
 
The Bcl-2 protein family is a group of related proteins that have important 
functions in the intrinsic apoptotic pathway.  Members of this family are 
ordered into three groups based on their structural similarities and functions.  
Group 1 include anti-apoptotic proteins such as Bcl-2 and Bcl-XL, while group 
2 include pro-apoptotic proteins such as Bax, Bcl-XS, Bak and Bad.  Group 3 
includes a large and diverse group of proteins which may be structural 
homologues of proteins from both groups 1 and 2.  Examples of proteins in 
this group include Bik and Bid (Hengartner, 2000, p.774). 
 
The intrinsic pathway of apoptosis is activated by DNA damage caused by 
factors such as carcinogenic chemicals and irradiation.  DNA damage causes 
the activation of the tumour suppressor gene p53, which is mutated in 50% of 
malignancies (Voet & Voet, 1995, p.1188).  Activation of p53 in turn leads to 
the transcription of various apoptotic genes, including PUMA, Bax, NOXA, 
Bid, PIG3, CD95, DR5 and p53AIP1 (Yu, 2006).  Bax, a pro-apoptotic Bcl-2 
protein, migrates to the mitochondrial surface along with other pro-apoptotic 
Bcl-2 proteins.  Here they compete with anti-apoptotic Bcl-2 proteins such as 
Bcl-2 and Bcl-XL for the regulation of the release of cytochrome C from the 
mitochondria.   
 71 
The mechanism of exit of cytochrome C from the mitochondria is not known, 
although Hengartner (2000, pp.772-774) has suggested three scenarios.  
These include: 
 
• The insertion of Bcl-2 proteins into the outer mitochondrial membrane 
where, after conformational change, they form pores to facilitate the exit 
of cytochrome C. 
• The recruitment of other mitochondrial outer membrane proteins such as 
the voltage dependant anion channel (VDAC) by pro-apoptotic Bcl-2 
proteins, to aid in the formation of a large pore channel. 
• Alteration of mitochondrial physiology by apoptotic signals, resulting in 
rupture of the mitochondrial outer membrane and leakage of cytochrome 
C to the cytoplasm.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.38: The basic mechanisms of the extrinsic- and intrinsic- 
apoptotic cellular pathways (taken from Hengartner, 2000, p. 773). 
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After release from the mitochondria, cytochrome C and Apaf-1 bind pro-
caspase 9, forming the apoptosome protein complex.  The apoptosome is 
thought to be responsible for the conversion of pro-caspase 3 to its active 
form, which may then carry on activating other pro-caspases further down the 
caspase cascade (Hengartner, 2000, p.773). 
 
The release of cytochrome C from the mitochondria is accompanied by the 
simultaneous release of other mitochondrial proteins, including apoptotic 
inducing factor (AIF), Smac/DIABLO and various pro-caspases, including pro-
caspases 2, 3 and 9.  Mammalian DNA codes for inhibitor of apoptosis (AIP) 
proteins, which function to inhibit the activation of pro-caspase 3 in the 
intrinsic pathway.  Smac/DIABLO functions as an inhibitor of AIP’s, thus its 
release from the mitochondria prevent AIP’s from interfering with the apoptotic 
mechanism (Hengartner, 2000, p.774). 
 
As mentioned earlier, caspase 8 is responsible for the cleavage and 
subsequent inactivation of the DNA repair protein PARP.  Various other 
caspases possess similar functions, including: 
 
• The cleavage of PARP by caspases 1 to 7 and caspase 9.  
• Cleavage of DNA dependant kinase by caspase 3. 
• Attack of nuclear ribonucleo-proteins by caspases 3, 6 and 7. 
• Cleavage of nuclear lamins by caspase 6, which facilitates the packaging 
of condensed chromatin into apoptotic bodies. 
• Cleavage of the cytoskeletal protein fodrin by caspase 3, which may 
account for the blebbing characteristically observed in apoptotic cells. 
(Bowen et al., 1998, p.96) 
 
2.6.3. Apoptosis as a target for cancer therapy 
 
A cell that has accumulated sufficient genetic damage to escape cell cycle 
checkpoints and apoptosis has the potential to transform and proliferate in an 
uncontrolled manner and ultimately lead to the development of cancer.  Thus 
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a chemotherapeutic agent that has the potential to reactivate the apoptotic 
pathway in cancer cells may be an effective anticancer agent. 
 
Current chemotherapy is toxic to healthy cells and often fails in destroying 
malignant cells.  Thornberry and Lazebnik (1998) proposed an alternative 
strategy of designing chemotherapeutic drugs that activates target caspases 
directly.  One way of achieving this is the activation of death receptor 
complexes of the extrinsic apoptotic pathway which in turn activates the 
caspase cascade.  Death receptor complexes, however, occur on normal cells 
as well as healthy cells.  Thus this approach should include a strategy for 
targeting death receptor complexes of cancer cells only. 
 
Furthermore, it has been observed that certain oncoproteins that deregulate 
the cell cycle are responsible for the activation of the caspases and 
subsequent apoptosis.  Thus this oncogenic transformation acts as a pro-
apoptotic signal present only in transformed cells.  Uncoupling of this signal 
with caspase activation leads to the survival of the transformed cell and 
cancer.  Knowledge about the mechanism of recoupling this signal may be 
another target for cancer therapy (Thornberry & Lazebnik, 1998). 
 
 
2.6.4. Phytotherapy in cancer treatment and plant-derived anticancer   
           agents 
 
The search for anticancer agents from natural sources can be dated back to, 
at least as far as, the Ebers papyrus of 1550 BC.  This search has only been 
pursued in more earnest during the 1960’s, initiated by research into the 
anticancer potential of podophyllotoxin and its derivatives (Srivastava et al., 
2005). 
 
Plant products have been used by many individuals globally either to prevent 
or cure cancer, or to alleviate the accompanying symptoms.  In South Africa, 
the best example of a plant traditionally used to treat internal cancer would 
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probably be Sutherlandia frutescens, better known as the cancer bush.  
Another well known South African plant which has a long history of traditional 
use as a medicine is the African potato, a common name for an indigenous 
Hypoxis species.  The African potato has shown remarkable effects in 
prostate cancer, and may be used to reduce the side-effects of radiation- and 
chemotherapy.  Furthermore, the well known illegal narcotic dagga (Cannabis 
sativa) has been used as a folk remedy in the form of a tea for various 
ailments, including cancer.  Dagga is also used medicinally to treat nausea 
caused by chemotherapy (Fairall, 1999, pp.72-74).  Scott et al. (2004, p.193) 
report that Elytropappus rhinocerotis is traditionally used in South Africa to 
treat cancer, while Thring and Weitz (2006, p.266-267) report the traditional 
use of Leonotis leonurus, better known as wilde dagga, in the treatment of 
cancer, as well as the use of Agathosma betulina in the prevention of cancer.  
Ginseng, usually in combination with other herbs, is traditionally used by the 
Chinese in the treatment of cancer.  Other herbal preparations used by 
individuals from different cultures include iscador, lapacho, cat’s claw and 
chapparal (Fairall, 1999, pp.74, 76-77). 
 
Sarath, So, Won and Gollapudi (2007) conducted a study on the anticancer 
properties of Artemisia princeps var. orientalis, and found that smoke and 
water soluble extracts of the plant induced apoptosis in MCF-7 (human breast 
adenocarcinoma) cells via the mitochondrial pathway.  Another example of an 
Artemisia species exhibiting promising results in cancer studies is the 
traditional Chinese medicinal plant, A. annua.  Various articles report on the 
anticancer- and antimalarial effects of artemisinin (Figure 2.39), a 
sesquiterpene lactone isolated from the plant, as well as its synthetic 
derivatives, artesunate, artemether and dihydroartemisinin.  Artemisinin 
contains an endoperoxide bridge as the active moiety of the molecule.  Upon 
reaction with free iron, peroxides form highly reactive, oxygen based free 
radicals.  The Plasmodium parasite, the causative agent of malaria, infects 
iron rich red blood cells.  While the body normally stores iron in a bound state, 
excess iron accumulates in the parasite.  This accumulation allows excess 
iron to spill from the parasite and become free.  When artemisinin comes into 
contact with this free iron, free radicals are released, and the parasite is 
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destroyed along with the infected cell (Rowan, 2004; Li, Lam, Roos, 
Zdzienicka, Kaina & Efferth, 2008).   
 
Based on this knowledge, Singh and Lai (2004) conducted research on the 
effects of dihydroartemisinin on Molt-4 (human acute lymphoblastic 
leukaemia) cells.  The rapid generation time of cancer cells imply that they 
need relatively more iron in order for DNA replication to be carried out.  
Subsequently, malignant cells express relatively more transferrin receptors on 
their outer membranes than do their normal counterparts.  Lai stated that 
leukaemia cells may have a concentration of iron 1000 times more than 
normal cells (as cited in Denver Naturopathic Clinic, 2005).  Singh and Lai 
(2004) found that addition of dihydroartemisinin to Molt-4 cells induced 
apoptosis and significantly reduced the number of viable cells in vitro.  
Addition of dihydroartemisinin and halotransferrin, which enhances iron supply 
to cells, had even more significant results.  Similar results were observed 
when HTB 27 (human breast cancer) cells were treated with combinations of 
halotransferrin followed by artemisinin.  Artemisinin exhibited high selectivity, 
being toxic to HTB 27 cells, but having only a marginal impact on normal 
breast cells (Singh & Lai, 2001).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.39: Structure of artemisinin (taken 
from Artemisinin, 2008).  
 76 
Zheng (1994) investigated the cytotoxic effects of compounds isolated from A. 
annua on various human tumour cells lines, and found artemisinin and 
quercetagetin 6,7,3',4'-tetramethyl ether to express cytotoxicity towards P-388 
(human lymphocytic leukaemia) cells, A-549 (human lung carcinoma) cells, 
HT-29 (human colonic adenocarcinoma) cells, MCF-7 cells and KB (human 
oral tumor) cells.  Chen, Zhou and Fang (2003) found artesunate and 
dihydroartemisinin to exhibit varying levels of toxicity towards HeLa cells, JAR 
(human uterus chorion cancer) cells, RD (human embryo transversal cancer) 
cells and HO-8910 (human ovarian cancer) cells.  A study conducted by 
Efferth (2007) further indicated that cancer cells expressing genes which 
confer resistance to current chemotherapeutic drugs were not resistant to 
artesunate.  Artesunate and dihydroartemisinin have also been shown to be 
potent inhibitors of angiogenesis, a process which is vital to neoplastic 
formation, growth and metastasis (Chen et al., 2003).   
 
With A. afra and A. absinthium being of the same species as A. annua, and 
artemisinin and its derivatives possessing anticancer activities as discussed 
above, one might assume that A. afra and A. absinthium might contain these 
compounds and express anticancer activity as well.  According to Klayman et 
al. (as cited in Van der Kooy, Verpoorte & Meyer, 2008, p.186), however, no 
other species of Artemisia possess artemisinin.  Van der Kooy et al. (2008, 
pp.186-189) conducted a study in which they screened A. afra leaves 
collected from four different plants for the presence of artemisinin, concluding 
that A. afra does in fact not contain any trace of the compound or its 
derivatives.  Artemisinin not only possesses anticancer activity, but is also 
currently used in the treatment of malaria (Christen & Veuthey, as cited in Van 
der Kooy et al., 2008, p.186).  If A. absinthium and A. afra, the latter having 
been traditionally used to treat malaria (Scott & Springfield, 2004b, p.3), does 
in fact not contain artemisinin and additionally expresses toxicity towards 
malignant cells, it could strongly suggest the presence of one or more 
unknown compounds other than artemisinin present in A. afra and A. 
absinthium with both anticancer- and antimalarial activity that needs to be 
identified. 
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An increasing interest in novel plant-derived drugs have been witnessed in 
recent years, largely due to the fact that conventional medicines are often 
ineffective and cause side effects, the inaccessibility by a large proportion of 
the global population to conventional drugs, and the apparent safety of 
traditional medicine.  Smith, Pharms and Boon (as cited in Bungu, 2005, p.13) 
report that as many as 86% of cancer patients use some form of traditional 
medicine.  Ernst (as cited in Bungu, 2005, p.13) found that 25% of Canadian 
breast cancer patients make use of traditional medicine.  By the year 1992, 
the National Cancer Institute (NCI) had screened 33 000 plants for anticancer 
activity (Rates, 2001).  Various chemical compounds isolated from plants 
have lead to the development of effective anticancer agents used today in the 
clinical setting.  Plant-derived anticancer drugs are divided into four classes: 
 
• Vinca alkoloids – Vinblastine and Vincristine were isolated from 
Catharanthus roseus, and have been used clinically for over 40 years. 
• Epipodophyllotoxins – Podophyllotoxin was originally isolated from 
Podophyllum peltatum and found to be too toxic.  However etoposide and 
teniposide, two analogues, are used in the treatment of lymphomas, 
acute leukaemia, testicular cancer, small cell lung cancer, ovarian-, 
bladder- and brain cancers. 
• Taxanes – Taxol was first isolated from Taxus brevifolia and is used in 
the clinical setting for the treatment of refractive ovarian cancer as well as 
metastatic breast- and lung cancer and Kaposi’s sarcoma.  Analogues 
include Paclitaxel and Taxotere. 
• Camptothecin – This anticancer agent was first isolated from 
Camptotheca acuminata. Analogues include Topotecan, Irinotecan and 
Rubitecan.  These drugs show activity against cancers of the colon, 
breast, liver, prostate and pancreas. 
(Balunas & Kinghorn, 2005; Srivastava et al., 2005) 
 
A fifth group of anticancer molecules are the combretastatins, particularly 
combretastatin A-4, which was isolated from the South African tree 
Combretum caffrum.  Combretastatin A-4 demonstrates activity against lung 
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cancer, colon cancer and leukaemia, and is said to be the most cytotoxic 
phytochemical isolated thus far (Srivastava et al., 2005). 
 
Although nature has provided mankind with a number of effective 
chemotherapeutic drugs which are utilised in the fight against cancer, an 
anticancer drug that is safe, economic to develop and site-specific is still 
elusive (Srivastava et al., 2005).  Many plant species still remain to be 
screened for their anticancer properties, and might hold the key to the 
development of this elusive molecule.   
 
 
2.7. Infection and the role of microbial drug resistance in infectious  
            pathology 
 
History has born witness to humanity’s suffering as a result of various 
pandemics, including cholera, plague, typhoid, influenza, and tuberculosis, to 
name but a few.  Other infections which, by today’s standards, would seem 
trivial, such as skin, ear and throat infections, often lead to deafness, 
disfigurement and death.  The average life expectancy for 19th century 
Europeans and North Americans is said to have been around 50 years.  The 
likelihood of dying prematurely as a result of infectious disease was as high 
as 40% and women routinely succumbed to child birth related infections which 
are easily treatable today (Brundtland, 2000). 
 
In 550 A.D., the first major documented plague pandemic, also known as the 
Black Death, claimed the lives of 100 million people.  The next major 
pandemic occurred in the 14th century, which wiped out 25% of the European 
population (Jensen et al., 1997, p.340).  This, in conjunction with successive 
outbreaks of smallpox and typhus during the 14th and 15th centuries 
diminished the European population by 50% (Brundtland, 2000).  It was, 
however, not only Europeans who suffered plague pandemics.  It is estimated 
that between 1896 and 1948, 12.5 million people succumbed to plague on the 
Indian subcontinent alone.  Cholera has also greatly contributed to infection 
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related mortalities over the centuries.  In 1783, it claimed the lives of 20 000 
pilgrims on the way to the Indian holy site of Hardawar, while nearly half of all 
individuals participating in the Hajj to Mecca and Medina during 1831 were 
infected with cholera.  It rapidly spread to Istanbul and Alexandria, and from 
there radiated outward as far as Hungary, devastating populations and 
economies (Brundtland, 2000).   
 
Peurperal sepsis, a streptococcal infection, was responsible for the death of 
more than 70% of post partum mothers lying in at various hospitals across 
Europe during the early 1800’s, with one Italian infirmary having reported not 
a single mother to have survived childbirth for a period of a year.  This death 
rate only declined once health workers adopted proper hand washing 
procedures.  The global influenza pandemic of 1918, which is said to have 
claimed the lives of more than 30 million people, devastated entire 
economies, and is thought to have had a higher mortality rate than the First 
World War.  Another example of an epidemic which may very well have 
altered the course of European history is the louse-borne typhus infection 
which struck the army of Napoleon Bonaparte on its way to Moscow, and 
reduced it from 655 000 to 93 000.  Those who returned home spread the 
infection amongst family and friends, leading to the death of a further 2 million 
people (Brundtland, 2000). 
 
During the Spanish invasion of the Americas in 1495, it was not their 
firepower or horses which lead to their conquests of the natives, but the 
introduction of smallpox, influenza and measles by the Spaniards to these 
previously unexposed communities.  Over a time span of only ten years, 
Mexico’s population declined by 74% as a result of epidemics (Brundtland, 
2000).  As if in some ironic retaliation by the Native Americans, Spaniards 
returning home carried with them the beginnings of a new epidemic which, 
until then, was unknown in Europe, and characterised by genital ulcers, rash, 
dementia and death.  Today the condition is known as syphilis (Brundtland, 
2000). 
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Many of the maladies of previous centuries still pester mankind today, 
especially in impoverished communities of developing nations.  Malaria,  
acute respiratory infections, diarrhoea and tuberculosis have lead to the 
deaths of many people over the centuries, and continue to do so today in 
various developing nations where sanitation is poor, and adequate healthcare 
and drugs is inaccessible or simply too expensive.  The advent of HIV and 
AIDS during the last 25 years has struck a further blow to these communities. 
 
2.7.1. The discovery of antimicrobial agents 
 
In 1928 Gerhard Domagk demonstrated that Prontosil can successfully be 
used to treat heomolytic streptococcal infections, including puerperal fever. 
The discovery of penicillin by Alexander Fleming in 1928 revolutionised 
medical science, and has since saved the lives of millions.  In 1938 A.J. 
Evans developed the drug sulphanilamide, which also proved to be successful 
in treating streptococcal and pneumococcol infections.  In 1948 Selman 
Waksman developed the tuberculosis drug streptomycin, and when isoniazid 
was later developed, the world thought that finally tuberculosis might be 
something of the past.  However, the development of resistance to these 
drugs necessitated the development of yet another tuberculosis drug.  This 
came in the form of rifampicin, developed by Piero Sensi.  Untill recently, a 
combination of these three drugs proved to be successful in treating 
tuberculosis.  Subsequent discoveries include tetracycline, quinolones, 
antifungals, antiparasitics and antivirals, which saved the lives of millions of 
people, prevented disabilities such as deafness, blindness and disfigurement 
as a result of infection, and allowed invasive surgical procedures to be 
performed which, in the pre-antibiotic era, would have proven fatal due to 
post-operative infections (Brundtland, 2000).     
 
A radical change in the way mankind viewed, understood and subsequently 
treated infectious disease only occurred during the 20th century.  The 
discovery and development of antimicrobial agents and vaccines has lead to 
the drastic decline in occurrence of infections which often had fatal outcomes 
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as little as 100 years ago, for example measles, typhoid fever, rubella, 
diphtheria, tetanus, yellow fever, pertussis and polio, while some previously 
fatal afflictions have now been eradicated, e.g. smallpox.  Apart from the 
smallpox vaccine, quinine and penicillin, the discovery of most modern day 
antimicrobial agents and vaccines was not an accidental occurrence, but the 
result of many decades of intensive research and vast amounts of money 
(Brundtland, 2000). 
 
The last 30 years have seen the development of acyclovir, which is used to 
treat herpes related infections, the anti-retroviral drug zidovudine (AZT), used 
in the treatment of HIV, and the development of the first protease inhibitor 
used in the clinical setting.  Currently, the number of antimicrobial drugs used 
to combat infection and infection-related disorders amounts to more than 150, 
with the cost of researching and developing each new drug amounting to 
about US$500 million per drug (Brundtland, 2000).  The discovery of 
antimicrobial agents and subsequent development of various agents used in 
the clinical setting has certainly greatly improved the life expectancy of the 
current generation and individuals privileged enough to have access to quality 
drugs, compared to that of generations of the previous century.  However, 
humanity is currently faced with another crisis, one which, if not dealt with 
swiftly and efficiently, could very well see future generations plummeted into a 
post-antibiotic era which may be similar to pre-antibiotic times.  Infectious 
diseases which were until recently curable are becoming harder to treat, such 
as typhus and gonorrhoea, while tuberculosis and malaria continue to exhibit 
an increasing amount of resistance to drugs which were formerly effective 
(Brundtland, 2000).  
 
2.7.2. Microbial resistance    
 
The development of antimicrobial resistance amongst microbes does not 
appear to be a phenomenon of the last decade.  Only a few years after 
penicillin was introduced to the market, a penicillin-resistant strain of S. 
aureus was discovered, followed in the next 20 to 25 years by resistant strains 
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of Gonorrhoea spp., Shigella spp. and Salmonella spp.  Since then the 
problem of microbial resistance has grown to one with tremendous economic, 
social and political implications.  Multi-drug resistant tuberculosis (MDR-TB) 
strains are no longer exclusively associated with individuals infected with HIV, 
poor living conditions and poverty.  It has infiltrated Europe, Asia and Africa, 
and may be found amongst the general population and healthcare workers.  
Penicillin-resistant pneumococci are spreading rapidly, while resistant strains 
of the malaria parasite kill millions of individuals on an annual basis.  As 
recently as a decade ago all strains of cholera collected around New Delhi, 
India, were shown to be susceptible to the first line drugs furazolidone, 
ampillin, co-trimoxazole and nalidixic acid.  Today, however, these drugs have 
no effect on the previously susceptible organisms (Brundtland, 2000).     
 
In Southeast Asia, 98% of all gonorrhoea cases are multi-drug resistant, while 
60% of all cases of visceral leishmaniasis in India are reported to be resistant 
to first line antimicrobials.  In the industrialised world, as much as 60% of 
nosocomial infections are caused by drug resistant organisms, the most 
recently identified being Vancomycin Resistant Enterococcus (VRE) and 
Methicillin Resistant S. aureus (MRSA).  The development of microbial 
resistance may be attributed mainly to overuse of antibiotics by developed 
nations and the under-use of effective antibiotics by developing nations, as a 
result of ignorance, poverty and poor healthcare services (Brundtland, 2000).  
It has now become necessary to develop and implement second- and third 
line drugs which are considerably more expensive to fight off infectious 
disease such as MDR-TB, which exacerbates the problem of poor individuals 
in developing nations often not being able to access these drugs. 
 
2.7.2.1. Major problematic organisms expressing antimicrobial        
              resistance 
 
Although humanity has been plagued by a myriad of infectious diseases 
throughout the ages, ranging from bacterial and fungal infections to viral and 
parasite related ailments, some of which have been brought under control or 
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even eradicated, a number of infectious diseases continue to devastate many 
populations around the globe.  In her infectious disease report of 2000, Dr Gro 
Harlem Brundtland, Director General of the WHO, included a list of infectious 
related pathologies that are becoming increasingly more difficult to treat as 
resistance to current antimicrobials develops in the causative organisms.  The 
list includes: 
 
• Pneumonia – Including Streptococcus pneumoniae and Haemophilus 
influenzae as the primary pathogens. 
• Diarrhoeal diseases – Including Shigella dysenteriae and Salmonella 
typhi as the primary pathogens. 
• Tuberculosis – Including Mycobacterium tuberculosis and the 
development of MDR-TB and XDR-TB as the main causes of concern.   
• Malaria – The development of resistance in P. falciparum against 
cloroquine and other 2nd and 3rd generation antimalarial drugs is 
increasingly becoming a concern.  
• AIDS –The major obstacles in combating the disease remain ignorance, a 
lack of education, poor health service delivery in developing nations and 
the inaccessibility of antiretroviral drugs (ARV’s) and diagnostic tests to 
individuals in rural areas. 
• Hepatitis viruses – Including Hepatitis B virus (HBV) and hepatitis C 
virus (HCV) as the primary causes of concern. 
• Gonorrhoea – The development of resistance to penicillin and 
ciprofloxacin in Neisseria gonorhoea, as well as the apperarance of MDR 
strains is particularly worrying.  
• Nosocomial infections – MRSA and VRE are increasingly becoming 
bigger health risks in hospitals.  Vancomycin, the only drug available to 
successfully treat MRSA, is itself becoming less effective in the face of the 
emergence of Vancomycin Intermediate Staphylococcus aureus (VISA). 
(Brundtland, 2000) 
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2.7.2.2. Factors contributing to the development of resistance 
 
The development of antimicrobial resistance is the result of a combination of 
various factors, and occurs through a process of natural selection by which 
susceptible organisms are killed by a specific drug, while resistant ones 
survive and subsequently pass on their genes either by replication or 
conjugation.  The latter is a natural process entailing the exchange of DNA-
containing plasmids between bacteria (Brundtland, 2000).  
 
Antimicrobial drugs are categorised into several general groups according to 
their mode of action: 
 
• Drugs that selectively target and inhibit microbial cell wall synthesis. 
• Drugs that inhibit prokaryotic translation and protein synthesis. 
• Drugs that disrupt the cytoplasmic membrane. 
• Drugs selectively inhibiting prokaryotic metabolic pathways. 
• Drugs which inhibit nucleic acid synthesis. 
• Drugs preventing microbial recognition of- or attaching to- its host. 
(Bauman, 2007, p.289) 
 
Antimicrobial-resistant microbes have developed and employ various 
strategies which circumvent the above listed mechanisms of antimicrobial 
action.  Many bacteria possess porin proteins which act as channels into the 
cell for a variety of substances, as well as cytoplasmic penicillin-binding 
proteins (PBP’s) which are vital for cell wall synthesis (Hopley & Van 
Schalkwyk, 2006).  Beta lactams such as penicillin function by entering the 
cell via the porin and binding to PBP’s, hampering cell wall synthesis and thus 
destroying the organism.  Bacteria may, however, avoid this process by 
employing one of the following strategies: 
 
• Some bacterial cells loose their porin proteins, a process which would, 
under normal circumstances, be disastrous for the cell as it would loose its 
competitive edge.  In the presence of penicillin, however, the cell survives 
as penicillin does not enter it. 
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• Bacteria may possess specialised “pumps” which are used to pump out 
penicillin and other beta lactams as soon as they enter the cell. 
• The beta lactam binding site on PBP’s may be altered, resulting in the 
inability of the beta lactam to bind and subsequently inactivate PBP’s. 
• Enzymes capable of inactivating a wide variety of antimicrobials are 
employed by some bacteria, including beta lactamases capable of 
inactivating beta lactams, as well as enzymes which inactivate 
aminoglycosides, chloramphenicol etc.  Several substances which are 
able to inhibit beta lactamases have been used, including clavulinic acid.  
(Hopley & Van Schalkwyk, 2006) 
 
Beta lactamases may be classified into the following groups: 
 
1. Cephalosporinases, not inhibited by clavulanic acid. 
2. Penicillinases, inhibited by clavulanic acid. 
3. Penicillinases, not inhibited by clavulanic acid. 
4. Metallo-beta-lactamases 
(Hopley & Van Schalkwyk, 2006) 
 
A wide variety of Gram negative bacteria possess group 1 enzymes.  Amp C 
cephalosporinases are common and occur in the plasmids of organisms such 
as Klebsiella pneumoniae and E. coli.  They are resistant to 1st, 2nd, and 3rd 
generation cephalosporins, as well as penicillins, cephamycins, monobactams 
and combinations of beta lactams and beta lactamase inhibitors.  Group two 
enzymes include TEM-1 beta lactamases and extended spectrum beta 
lactamases.  They show resistance to a wide variety of cephalosporins and 
aztreonam.  Group 3 enzymes are capable of hydrolysing carbapenems such 
as imipenem, and are found in Aeromonas, Bacteroides and P. aeruginosa, 
while group 4 enzymes are uncommon.   
 
A fifth means of antimicrobial resistance involves the antimicrobial 
trimethoprim and its role in the inhibition of folic acid synthesis by bacteria.  
Bacteria synthesise their own folic acid with the aid of dihydrofolate reductase.  
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Trimethoprim inhibits this enzyme and subsequent folate synthesis, which is 
crucial for DNA formation.  However, some organisms acquire plasmid-borne 
enzymes capable of bypassing the dihyrofolate reductase step, escaping the 
inhibiting effects of trimethoprim. 
 
Fungi employ similar mechanisms in the development of antifungal 
resistance, which is observed at an increasing rate, especially in the intensive 
care units of hospitals (Hopley & Van Schalkwyk, 2006).  Various factors have 
contributed to the stance of antimicrobial resistance observed today.  These 
include:  
 
• Poverty and drug access – Poverty remains one of the major forces 
indirectly driving the alarming development and spread of antimicrobial 
resistance currently observed.  Many individuals in developing nations can 
simply not afford, or do not have access to effective drugs, while those 
who can afford single doses start on treatment and continue to use the 
medication only until they feel better.  The infecting organism is not 
necessarily eliminated, however, which greatly contributes to the 
development of resistance.  Treatment with 2nd and 3rd line drugs is 
relatively more expensive than 1st line drugs, is more toxic to the patient 
and is becoming less effective due to the rapid rate at which microbes 
mutate and develop resistance to new drugs. 
• Misdiagnosis – Often a result of poor healthcare systems in developing 
nations, overworked and ill-informed physicians and healthcare workers 
are unable to give adequate attention to all patients.  A lack of diagnostic 
laboratory services and tests further increases the pressure on physicians 
to make an accurate diagnosis.  This may lead to healthcare workers 
often having to “guess” the diagnosis based on the symptoms, 
subsequently leading to the wrongful prescription of medication. 
• Counterfeit drugs – Being a US$21 billion industry and comprising 5% of 
all antibiotics sold worldwide, counterfeit drugs lead to the death of those 
whose lives might have been saved had they been administered the 
proper medication.  The abuse, misuse and administration of antimicrobial 
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drugs at lower levels than treatment guidelines dictate, contribute to the 
phenomenon of natural selection amongst microbes, leading to the 
elimination of only those in a population susceptible to a specific drug, and 
allowing resistant ones to flourish.  As many as 51% of the counterfeiting 
cases uncovered by the WHO between 1992 and 1994 revealed 
counterfeit drugs to contain no active ingredients.  A further 17% 
contained the wrong active ingredient, while 11% contained active 
ingredients lower than the dictated dose.  Furthermore, some of these 
drugs showed to contain fatal poisons.   
• Corruption – In countries where physicians earn less than what the 
global trend dictates, unethical pharmaceutical companies offer these 
healthcare workers commission on prescribing more expensive, broad- 
spectrum antimicrobials to their patients, while cheaper, narrow-spectrum 
drugs would have been adequate.  This leads to a smaller, more 
expensive pool of drugs used to treat infectious disease, and greatly 
contributes to the development of drug resistance amongst microbes. 
• Media and advertising – Pressure on physicians from their patients 
requesting specific drugs seen advertised in the media has lead to many 
physicians prescribing drugs which would otherwise not have been 
necessary.  As many as 70% of American physicians questioned admitted 
to succumbing to patient pressure and prescribing drugs they would have 
otherwise avoided.  Patient ignorance and misinformation creates a 
further problem.  In the Philippines many parents believe isoniazid to be a 
“lung vitamin”, with which they dose their children.  The sub-therapeutic 
administration of this anti-tuberculosis drug directly contributes to the 
development of resistant organisms.   
• Lack of education – The shortage of qualified healthcare workers in 
developing nations leads to many patients having to rely on their own 
judgement regarding the use of antimicrobials.  Additionally, many drug 
dispensers in developing nations are under-qualified and dispense drugs 
without a physician prescription or consulting with the patient.  In 
developed countries, the topic of antimicrobial resistance enjoys little 
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attention in medical schools, and is rather dealt with as a subject of 
expertise.  
• Role of hospitals – A study of 10 training hospitals worldwide showed 
that between 40% and 91% of antibiotics prescribed were inappropriate, 
and that healthcare workers disregarded basic hygiene procedures such 
as hand washing and the changing of gloves in between patient visits.  In 
a separate study of clinics in Tanzania, researchers demonstrated that 
40% of reusable needles which were supposed to be sterile were 
contaminated.  Inadequate training and monitoring of proper hygiene 
procedures by healthcare workers can have dire consequences for both 
clinician and patient. 
• Use of antimicrobials as growth promoters in food production – Only 
50% of antimicrobials produced are consumed by humans.  The other 
halve is used in the treatment of sick livestock, as growth promoters in 
these animals and to rid and protect cultivated foods from infecting 
organisms.  This low-level prophylactic use of antimicrobials greatly 
contributes to the development of resistance amongst organisms in 
livestock, and creates the possibility of a resistant strain jumping the 
species to humans, such as VRE. 
• Globalisation and travel – The current rate of international travel means 
that microbes originating from Africa or Asia may arrive in North America 
in less than a day.  The possibility of unknowingly aiding in the spread of 
resistant microbes across continents is all too real, as was shown when 
two Canadian cases of MRSA were traced back to India.          
(Brundtland, 2000) 
 
In an effort to curb the current trend in the development of antimicrobial 
resistance amongst microbes, Brundtland (2000) has proposed to following 
guidelines and suggestions to be implemented by governments: 
 
• Adoption of WHO strategies and policies 
• Education of health workers and the public on the proper use of 
medications. 
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• The containment of resistance in hospitals and the prevention of the 
spread of resistant organisms to the public. 
• A reduction in the use of antimicrobials in livestock as growth promoters 
and substitutes for high-quality animal hygiene practices. 
• Increased efforts for the research and development of new drugs and 
vaccines. 
• The forging of alliances between governments, international 
organisations, non-government organisations (NGO’s) and the private- 
and public sectors to increase access to antimicrobials. 
• An increase in the availability of essential drugs. 
• Increasing the accessibility of effective quality drugs to the poor.  
 
The employment of more effective treatment strategies, immunisation- and 
vaccination programmes, better nutrition, enhanced vector control and 
initiatives aimed at the impoverished have greatly contributed towards 
controlling the spread of drug resistance amongst microbes.  However, 
individuals, governments, NGOs, large pharmaceutical companies and 
private- and public organisations need to invest time, money, effort, flexibility, 
cooperation, philanthropy and personal commitment if the growing problem of 
antimicrobial resistance is to be halted.  If quality antimicrobials are not used 
wiser and made more accessible, current effective drugs may soon be 
rendered useless against the increasing population of drug-resistant microbes 
(Brundtland, 2000). 
 
 
2.7.3. Phytomedicinal sources of antimicrobial agents 
 
The medicinal qualities of plants have been known to and exploited by man 
for centuries.  Historic texts are rich in information regarding the medicinal 
applications of plants.  The previously mentioned Ebers papyrus contains 
information on nearly a thousand different medicines, most of which are of 
plant origin.  Of the hundreds of plants mentioned in the Bible, 25 to 30 have 
been identified as medicinal, while ancient Chinese scripts refer to thousands 
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of phytomedicinal remedies.  Hippocrates, who is widely considered to be the 
father of modern medicine, mentioned about 400 drugs, 91% of these 
originating from plants (Lev, 2007). 
 
Al-Bakri and Afifi (2007) claim that the fast majority of modern drugs are 
derived from traditional herbal remedies.  Indeed, more than 50% of drugs 
currently used are products of or derived from higher plants.  Seventy eight 
percent of drugs of natural origin approved by the United States Food and 
Drug Administration between 1983 and 1994 were of antibacterial type (Du 
Toit, Elgorashi, Malan, Mulholland, Drewes & Van Staden, 2007).  Higher 
plants produce thousands of chemical compounds with a wide array of 
functions, including acting as pollinator attractants and defending the plant 
against insects, herbivores and microbes.  Many phytochemicals acting as 
antimicrobial agents in the plant’s defence are likewise active against human 
pathogenic organisms, and various studies report on the antimicrobial 
activities of crude plant extracts (Rojas, Bustamante, Bauer, Fernández, 
Albán & Lock, 2003).  Although the majority of current antimicrobials are 
derived from soil-borne microbes, higher plants have also proven to be a 
valuable source of antibiotics, such as the isoquinoline alkaloid emetine 
obtained from the underground parts of Cephaelis ipecacuanha, as well as 
the antiplasmodial agent quinine, obtained from the bark of the Cinchona tree.  
The bacteriostatic and antifungal properties of lichens, the antibiotic action of 
the garlic (Allium sativum) compound allinin, and the antimicrobial action of 
berberines in goldenseal (Hydrastis Canadensis) have also been described.  
Other examples of plants with the potential of producing novel antimicrobial 
agents include Garcinia cola, Aframomum melegueta, Xylopia aethiopica, 
Cryptolepis sanguinolenta, Chasmanthera dependens, Nauclea latifolia and 
Araliopsis tabouensis, all of which exhibit various forms of antibacterial-, 
antifungal- and antiviral activities (Janick, 1999, 457-461).   
 
The alarming increase in the incidence of new and reoccurring infectious 
diseases, as well as the continued evolving of antimicrobial resistance 
amongst a wide array of pathogenic microbes, highlights the dire need for 
novel, effective antimicrobial agents.  Of the 250 000 to 500 000 known plant 
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species, very few have been investigated for their pharmacological qualities, 
with an estimated 5000 having been investigated for their medicinal properties 
(Rates, 2001).  The emergence of multiple-drug-resistant organisms 
necessitates the exploration of all available avenues by man in the search for 
novel antimicrobial agents, including plants and traditional phytomedicines.  
Plant-derived drugs not only have fewer negative side-effects in general, but 
are also cheaper and more accessible than modern Western drugs to the 
impoverished in developing nations, who appear to be the worst off 
concerning infectious diseases.  G. incanum, A. afra and A. absinthium have 
traditionally been used in the treatment of a wide variety of maladies, as 
mentioned in Sections 2.3.1, 2.4.1. and 2.5.1., respectively.  Most of these 
ailments are of an infectious nature, and the traditional use of these plants in 
the treatment and relief of infectious disease is an indication of their 
antimicrobial qualities. 
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CHAPTER 3 
INTRODUCTION TO THE PRESENT STUDY 
 
 
3.1. Aims and objectives 
The present study had two main aims, and it was attempted throughout the study 
to reach these in as scientific a manner as possible.  The main aims of the study 
were: 
 
1. To scientifically determine the antimicrobial properties of two plants, being 
Geranium incanum and Artemisia afra, these traditionally having been used 
in South Africa for their medicinal properties, and comparing the antimicrobial 
properties of A. afra to those of its European counterpart, Artemisia 
absinthium, and 
2. To scientifically determine the anticancer properties of G. incanum and A. 
afra, and comparing the anticancer properties of A. afra to those of A. 
absinthium. 
 
Through the use of well established scientific methods and research materials, 
the present study aimed to fulfill the following objectives: 
 
1. Collection and identification of plant materials used in the study. 
2. Preparation of both traditional and non-traditional plant extracts using various 
extractants and solvents. 
3. Determination of the inhibitory qualities of plant extracts against selected 
strains of microbes representing both Gram positive and Gram negative 
organisms as well as yeasts, using an adapted agar dilution method. 
4. Determination of the IC50 values of the various plant extracts after exposure 
of three cancer cell lines to these extracts, using the 3-[4,5-dimethylthiazol-2-
yl]-2,5-diphenyl tetrazolium bromide (MTT) assay. 
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5. Determination of the mode of cell death induced (apoptosis or necrosis) in 
any one of the three cancer cell lines expressing the highest level of 
sensitivity to a specific extract through the use of fluorescence staining and 
fluorescence microscopy. 
6. Determination of the degree of sensitivity of peripheral blood mononuclear 
cells (PBMC’s) to the plant extract which show the highest degree of toxicity 
towards any one of the three plant extracts screened, using the Cell Titer-
Blue® assay. 
7. Determination of the percentage of apoptotic cells present in a sample of 
cancer cells from the line most susceptible to a specific extract following 
exposure to that extract, comparing these results to the percentage apoptotic 
cells present in the same cell line after exposure to cisplatin, and determining 
which phase of the cell cycle is most affected by the specific extract using the 
Beckman Coulter FC 500 cytometer and Coulter® DNA Prep™ Reagents Kit. 
 
 
3.2. Collection, preparation and extraction of plant materials 
 
The three plants G. incanum, A. afra and A. absinthium have long been used 
both in South Africa and beyond its borders for their medicinal properties, as 
outlined in the previous chapter, and were selected based on this literature. 
 
For the purposes of antimicrobial screening, plant materials were collected and 
extracted over three seasons, having been winter, spring and summer.  It is a 
well established fact that the phytochemical profile of plants and their potency as 
medicinal plants are influenced by various factors such as seasonal changes, 
geographical distribution, climatic variations and other environmental factors 
(Fennell et al., 2004), and for this reason the extraction yields obtained for 
antimicrobial screening form the three plants were compared according to the 
season in which they were prepared.  Due to time limitations, the same could not 
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be done for extracts used in anticancer studies, with one set of extracts having 
been prepared for anticancer studies during the summer.   
 
Furthermore, the medicinal properties of plants are dependent on the extractant 
used, with variation in the biological activities of plants having been observed for 
different extractants used.  The literature reports on various extractants used to 
extract biologically active compounds from plants, including water, ethanol, 
methanol, hexane, chloroform, petroleum ether, methylene dichloride, ethyl 
acetate and methanol-chloroform-water mixture (Eloff, 1998; Eloff, 1999; George, 
Laing & Drewes, 2001; Lin, Opoku, Geheeb-Keller, Hutchings, Terblanche, Jäger 
& Van Staden, 1999; Martini & Eloff, 1998; Shale, Stirk & Van Staden, 1999), 
with relative variation in the amount of active compounds extracted when 
different extractants are used.  George et al. (2001) has stated it essential for 
preparation of medicinal plant extracts according to traditional methods to be 
taken into account when the extractant is chosen.  Therefore, it was decided to 
employ water, which is reported to be routinely used by traditional healers as 
extractant (Lin et al., 1999; Shale et al., 1999), as well as two other extractants, 
including methanol and acetone.  Infusions of G. incanum and A. afra were 
prepared according to the traditional methods described by Scott & Springfield 
(2004a, p.4) and Scott & Springfield (2004b, p.4), respectively.  As the medicinal 
properties of A. afra were to be compared to those of A. absinthium, an infusion 
of the latter was prepared in the same manner as for A. afra.  Aqueous-, 
methanol- and acetone extracts of all three plants were further prepared 
according to a method adapted from Eloff (1998) and Lin et al. (1999).  
 
3.3. Screening of plant extracts for antimicrobial activity 
   
An agar dilution method adapted from Alanis et al. (2005), Kumar, Chauhan, 
Padh & Rajani (2006), Tshikalange, Meyer & Hussein (2004) and Weckesser, 
Engel, Simon-Haarhaus, Wittmer, Pelz & Schempp. (in press), was employed in 
the screening the plant extracts for antimicrobial activity towards various 
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microbial strains of C. albicans, E. coli, P. aeruginosa, Enterococcus faecalis, S. 
aureus and Bacillus cereus.  Screening was performed in triplicate, with a new 
set of extracts having been prepared for each round of screening, at an extract 
concentration of 100 mg/ml agar.  A Mast Diagnostics® (UK) multipoint inoculator 
was used to inoculate agar plates containing the extracts, and plates were 
visually inspected after 48 hours incubation.  Where a specific strain of any one 
of the test organisms was found to be resistant to an extract for two out of the 
three rounds of screening, that specific strain was reported as being resistant to 
inhibition of growth by the relevant extract.  Likewise, where a specific strain of 
any one of the test organisms was found to be inhibited by an extract for two out 
of the three rounds of screening, that specific strain was reported as being 
susceptible to growth inhibition by the relevant extract.  Three control plates were 
simultaneously run and compared to test plates following incubation in order to 
establish the validity of the results.  
 
3.4. Screening of plant extracts for anticancer activity 
 
The 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) assay, a 
quantitative means of determining mammalian cell survival and proliferation in 
vitro, was adapted from Mosmann (1983, pp.55-63) and used to screen for the 
anticancer activities of the various plant extracts towards MCF-7 (human breast 
adenocarcinoma) cells, HT-29 (human colonic adenocarcinoma) cells and HeLa 
(human cervical cancer) cells, at initial extract concentrations ranging between 
500 µg/ml and 10 µg/ml.  Variation in the degree of toxicity expressed by the 
various extracts in the three cancer cell lines was observed, depending on the 
extractant used, with some extracts, especially those for which acetone was used 
as the extract, showing higher degrees of toxicity in the malignant cells.   
 
Where extracts appeared to significantly inhibit cell growth or induce cell death, 
screening of the specific extract on the respective cell line was repeated using 
lower concentrations of the extract.  Cells cultured in cell growth media lacking 
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extract served as an extract blank and negative control for each of the extracts 
screened against each of the three cancer cell lines, while cisplatin, a known 
anticancer agent, was serially diluted and served as a positive control.  
Screening of various dilutions of each extract against the three malignant cell 
lines was performed in triplicate, and cell viability, as well as inhibition of cell 
growth/cell death was expressed as a mean percentage ± standard deviation of 
the mean negative control absorbance.  Dose response curves were constructed 
from this data, and IC50 values for each of the extracts on each of the three cell 
lines was determined through regression analysis.   
       
It was decided to investigate the mode of cell death induced in the cell line most 
susceptible to inhibition by any one of the twelve plant extracts prepared, i.e. the 
extract expressing the highest degree of toxicity at the lowest concentration for 
any one of the three cell lines, as determined from the results obtained during the 
MTT assay.  Fluorescence microscopy, using 4',6-diamidino-2-phenylindole 
dihydrochloride (DAPI) and propidium iodide (PI) as fluorescent dyes, was 
employed for this purpose.  Due to structural differences between cells 
undergoing apoptosis as apposed to necrosis, DAPI is able to penetrate and 
stain apoptotic and living cells, while PI is excluded.  PI, however is capable of 
entering and staining the nuclei of necrotic cells (Darzynkiewicz et al., as cited in 
Bungu, 2005, p.50). 
  
Cells were separately stained with DAPI and PI using a combined, modified 
method of Moongkarndi, Kosem, Kaslungka, Luanratana, Pongpan & Neungton 
(2004), Bungu (2005, p.51) and Botha (2003, p.80), and observed under a 
fluorescence microscope for staining patterns and hallmarks specific for 
apoptosis or necrosis.  As a positive control, the same type of cells were exposed 
to cisplatin, which induces apoptosis in malignant cells, for 48 hours, and 
separately stained with DAPI and PI, followed by observation through a 
fluorescence microscope.  Cells undergoing apoptosis as a result of exposure to 
cisplatin were compared to cells treated with the extract to establish the 
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possibility of apoptosis induced by the extract.  As a negative control, cells 
cultured in media lacking any extract or cisplatin were separately stained with 
DAPI and PI and observed through a fluorescence microscope.  Photographs 
were taken of both cells exposed to cisplatin and cells exposed to the extract, 
and examined for correlations.   
 
The toxicity of the extract tested during fluorescence microscopy on normal, non- 
malignant human cells was determined using the CellTiter-Blue® assay as 
outlined in the Promega Technical Bulletin (2006), where it is described as a 
flourometric method for the estimation of the amount of viable cells present in a 
sample, based upon the principle of viable cells being able to reduce the 
indicator dye resazurin, which possesses very little intrinsic fluorescence, to the 
highly fluorescent resorufin, with an excitation wavelength of 544 nm and 
emission wavelength of 590 nm.  Although the MTT and CellTiter-Blue® assays 
are in principle similar, it was decided to use the latter in the screening of 
peripheral blood mononuclear cells (PBMC’s) as apposed to the former assay.  
During the MTT assay, formazen crystals are retained inside the viable malignant 
cells adhering to the bottom of the microtitre plate well, which is then dissolved 
using DMSO following removal of the growth medium by vacuum, and the 
absorbance measured spectrophotometrically.  During the CellTiter-Blue® assay  
fluorescent resorufin, formed from the conversion of resazurin by viable cells in 
suspension, precipitates into the surrounding growth medium, eliminating 
removal of growth medium (as this would also remove the resazurin formed) and 
dissolving with DMSO as in the MTT assay.  It would have been possible to use 
the CellTiter-Blue® assay instead of the MTT assay in the general screening for 
toxicity of plant extracts in the three cancer cell lines, although this would 
essentially have been financially less viable and unnecessary, as both assays 
are similar. 
 
PBMC’s were isolated from a healthy, consenting adult male and exposed to 
various concentrations of the extract, which ranged between 500 µg/ml and 2.65 
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µg/ml, for 48 hours, followed by the addition of the assay reagent and 
measurement of the fluorescence using a Flouroskan Ascent® fluorometer.  
Three controls, including a control consisting of PBMC’s cultured in growth media 
only, a negative control consisting of growth media lacking PBMC’s or extract, 
and a test compound control consisting of various concentrations of the extract 
tested, having ranged between 500 µg/ml and 2.65 µg/ml, in growth media 
lacking PBMC’s, were run simultaneously.  The purpose of this third control was 
to exclude any fluorescence emitted by the extract itself or fluorescence 
produced as a result of interaction between the chemistry of the extract and 
assay reagent.   
 
Screening was performed in triplicate, and fluorescence and possible 
interference of the extract itself was excluded by subtracting the mean values of 
any fluorescence emitted by each of the extract dilutions from the third control 
from the fluorescence readings obtained for the PBMC’s treated with the 
respective dilutions of the extract.   The percentage of PBMC viability, as well as 
the percentage cell death was determined by expressing the final fluorescence 
values for PBMC’s treated with the extract as a mean percentage ± standard 
deviation of the mean fluorescence readings recorded for the vehicle control.  
This data was used to construct a dose response curve of the extract for 
PBMC’s, and compared to that constructed for the same extract on malignant 
cells.  Regression analysis was also done in order to determine the IC50 of the 
extract for PBMC’s.   
 
Finally, the effect of the extract screened against PBMC’s on the cell cycle of the 
malignant cell line used during fluorescence microscopy was investigated by 
exposing the cells to the IC50 of the extract as determined during the MTT assay, 
lysing and staining of the cells with a lysis buffer and PI, respectively, which were 
both included in the Coulter® DNA Prep™ Reagents Kit, and analysing the cell 
cycles of the cells using the Beckman Coulter FC 500 cytometer.  As a positive 
control, the same cell line was exposed to cisplatin, while untreated cells were 
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used as a negative control.  Both cisplatin treated cells and untreated cells were 
lysed and stained as was the case with the cells exposed to the extract, their cell 
cycles were analysed and the percentage apoptotic cells present in the cell 
sample exposed to the extract was compared to the percentage apoptotic cells 
present in the sample exposed to cisplatin as well as in the untreated cell 
sample, respectively.  Screening was performed in triplicate. 
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CHAPTER 4 
METHODS AND MATERIALS 
 
 
4.1.   Introduction 
 
The current chapter discusses the materials and methods used in the harvesting 
of G. incanum, A. afra and A. absinthium plant materials, the preparation of 
infusions, aqueous-, methanol- and acetone extracts of the three respective 
plants, as well as the performance of antimicrobial activity screening of the 
respective infusions and extracts.  Maintenance of cell cultures and anticancer 
activity screening of the respective infusions and extracts, as well as assays 
performed to determine whether apoptosis or necrosis were induced in selected 
cell lines, are also discussed.  
 
 
 
4.2.   Antimicrobial activity studies 
 
4.2.1. Collection and preparation of plant materials 
 
Antimicrobial screening assays were done in triplicate.  Fresh plant materials 
were harvested and fresh extracts prepared for each round of antimicrobial 
screening.  Due to large extraction volumes, freeze drying of infusions and 
aqueous extracts were lengthy, which resulted in plant materials being collected 
under different seasonal and environmental conditions between the triplicate 
antimicrobial screenings.  Furthermore, due to an inconsistency in the availability 
of G. incanum, fresh plant material was collected from three different locations for 
each round of antimicrobial screening. 
 
The harvesting and preparation of fresh plant materials occurred during June 
2007, September 2007 and January 2008 for each round of antimicrobial 
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screening, respectively.  For the initial round of antimicrobial screening, G. 
incanum plant material was obtained from the garden of Mrs. E. Baxter of the 
Nelson Mandela Metropolitan University (NMMU).  In September 2007, G. 
incanum plant material was harvested from the horticultural service department 
of the NMMU, while fresh plant material of G. incanum was collected from the 
garden of Dr. N. Smith of the NMMU in January, 2008.  G. incanum plants were 
identified and authenticated by Mr. Clayton Weatherall-Thomas from the Botany 
department of the NMMU, and a voucher specimen was submitted to the NMMU 
Ria Olivier herbarium.  A. afra plants were obtained from New Plant Nurseries in 
George, Western Cape, in June 2007, and nursed at the horticultural service 
department of the NMMU, from where fresh plant material was collected in June 
2007, September 2007 and January 2008, respectively.  A. afra plants were 
identified and authenticated by Mrs. Cornelia Garner from the Botany department 
of the NMMU, and a voucher specimen was submitted to the NMMU Ria Olivier 
herbarium.  Fresh plant material of A. absinthium was obtained from the garden 
of Dr. M van de Venter of the NMMU during aforementioned months for the 
initial-, second- and third rounds of antimicrobial screening, respectively.  A. 
absinthium plants were identified and authenticated by Mrs. Estelle Brink from 
the Botany department of Rhodes University, Grahamstown, and a voucher 
specimen was submitted to the Selmar Schonland herbarium at Rhodes 
University, Grahamstown.  
 
Fresh leaves were separated from the stems of the respective plants and 
separately rinsed in distilled water in order to remove dust, soil and insects.  The 
washed leaves were allowed to dry at room temperature, separately weighed and 
used immediately for the preparation of infusions, while the leaves used in the 
preparation of aqueous-, methanol- and acetone extracts were first dried 
overnight in an oven at 40°C.  
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Figure 4.1: Dried G. incanum plant material. Figure 4.2: Dried A. afra plant 
material. 
Figure 4.3: Dried A. absinthium plant 
material. 
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4.2.2. Extraction of plant materials 
 
4.2.2.1. Preparation of infusions 
 
Infusions of G. incanum were prepared according to the traditional method 
described by Scott & Springfield (2004a, p.4).  A quarter teacup full of fresh 
leaves (approximately 6 g) was added to a teacup full (180 ml) of boiling distilled 
water and left to infuse for ten minutes.  The infusion was filtered using Whatman 
No 1 filter paper to remove insoluble plant material and the filtrate frozen at -20°C 
in clean, pre-weighed 50 ml centrifuge tubes (Eppendorf®, Germany).  Samples 
were freeze dried (VirTis® freeze-dryer, USA) and weighed in order to determine 
the percentage yield. 
  
Infusions of A. afra were also prepared according to a traditional method 
described by Scott & Springfield (2004b, p.4).  Approximately 14 g of fresh 
leaves were added to 1 litre of boiling distilled water and left to infuse until cool.  
Samples were then dried as described above.  A. absinthium was included in this 
study to compare its biochemical effects to those of A. afra.  For this reason, the 
infusion and extracts of A. absinthium were prepared in the same manner as that 
of A. afra.  
 
As mentioned previously, fresh extracts were prepared for each round of 
antimicrobial screening, which was done in triplicate.  Thus the above procedures 
for the preparation of infusions of the three test plants, including the amount of 
fresh leaves and extraction medium used, were also done in triplicate for each of 
the respective rounds of antimicrobial screening.  However, due to the lengthy 
time required for the freeze drying of the large volumes of A. afra and A. 
absinthium infusions and aqueous extracts, as well as time constraints, the 
above method was slightly modified upon the third round of infusion preparation.  
For the third round, infusions were not freeze dried immediately, but were instead 
concentrated in a laminar air flow cabinet (Labscheme Allchem®, South Africa) 
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by evaporation in a hot water bath for 48 hours at 40°C to 50 ml.  This 
significantly reduced the volume of infusions and aqueous extracts of A. afra and 
A. absinthium, and subsequently the time required for freeze drying.  Freeze 
dried extracts were stored at room temperature in the dark until required. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G. incanum 
infusion: 6 g fresh 
leaves to 180 ml 
boiling distilled 
water.  Infused for 
10 minutes. 
A. afra infusion: 
14 g fresh leaves 
to 1litre boiling 
distilled water.  
Infused till cool. 
A. absinthium 
infusion: 14 g 
fresh leaves to 1 
litre boiling 
distilled water.  
Infused till cool. 
Filtration of infusions through Whatman no.1 filter paper. 
Third round only: 
Concentration of 
infusions in air flow 
cabinet for 48 hours at 
40°C in hot water bath, to 
50 ml. 
Freezing at -20°C, freeze drying and weighing of extracts 
Storage of extracts at room temperature in the dark. 
Figure 4.4: Schematic representation of the preparation of infusions for antimicrobial 
screening. 
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4.2.2.2. Preparation of aqueous-, methanol- and acetone extracts   
 
An extraction method adapted from Eloff (1998) and Lin et al. (1999) was used to 
prepare the aqueous-, methanol- and acetone extracts of G. incanum, A. afra 
and A. absinthium, respectively.  The remaining fresh leaves of the three test 
plants were separately weighed, dried over night in an oven at 40°C and weighed 
again the following morning in order to determine the percentage yield of dry 
plant material.  The dried leaves of each of the three respective plants were then 
divided into three equal amounts from which aqueous-, methanol- and acetone 
extracts were prepared.   
 
For the preparation of aqueous extracts, 4.47 g of dry G. incanum leaves, 12.15 
g of dry A. afra leaves, and 12.46 g of dry A. absinthium leaves were separately 
and equally divided into 50 ml centrifuge tubes.  The centrifuge tubes were then 
filled to 40 ml with distilled water at room temperature (RT), shaken vigorously for 
3 minutes and centrifuged in an Eppendorf® 5810 centrifuge (Germany) at 1811 
x g for 15 minutes.  After centrifugation, the supernatants were decanted 
separately into clean, pre-weighed 50 ml centrifuge tubes.  This process was 
repeated two more times for each of the three test plants.  The respective 
aqueous extracts were then frozen at -20°C in pre-weighed centrifuge tubes and 
freeze dried, followed by storage in the dark at room temperature until required.  
This procedure was followed for the initial- and second rounds of preparation of 
aqueous extracts.  However, it was decided to further adapt this method in order 
to decrease the amount of time required for freeze drying of the large volumes of 
aqueous extracts as described in Section 4.2.2.1.   
 
The preparation of methanol- and acetone extracts was performed in the same 
manner as aqueous extracts, with the only exception having been that the 
supernatants were decanted into clean, pre-weighed glass beakers which were 
then placed in a hot water bath at 40°C over night in a laminar air flow cabinet to 
allow the methanol and acetone to evaporate, as apposed to freeze drying as 
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was done for aqueous extracts.  After evaporation of the extractants, the glass 
beakers were weighed in order to determine the amount of crude methanol- and 
acetone extracts and percentage yield obtained, followed by storage at 4°C until 
required. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighing of fresh leaves and drying in an 
oven at 40°C overnight, followed by 
weighing of dry leaves the following 
morning.  
Forty ml distilled water 
(RT)/methanol/acetone to 
12.15 g dry A. afra leaves 
in pre-weighed 50 ml 
centrifuge tubes. 
Forty ml distilled water 
(RT)/methanol/acetone to 
4.47 g dry G. incanum 
leaves in pre-weighed 50 
ml centrifuge tubes. 
 
Forty ml distilled water 
(RT)/methanol/acetone to 
12.46 g dry A. absinthium 
leaves in pre-weighed 50 
ml centrifuge tubes 
Shake tubes vigorously for 3 minutes and 
centrifuge at 1811 x g for 15 minutes, 
followed by decantation of supernatants 
into pre-weighed containers. 
Freezing at -20°C, freeze drying 
and weighing of aqueous extracts, 
followed by storage at room 
temperature in the dark. 
Evaporation of methanol and 
acetone in air flow cabinet at 40°C in 
hot water bath overnight, followed 
by weighing and storage of extracts 
at 4°C. 
Figure 4.5: Schematic representation of the preparation of aqueous-, methanol- and acetone 
extracts for antimicrobial screening. 
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4.2.3. Antimicrobial screening  
 
4.2.3.1. Culturing and maintenance of microbial test strains 
 
A Pro-Lab Diagnostics Microbank™ kit (Toronto, Canada) was supplied by the 
Department of Biomedical Technology of the NMMU, and utilised in the culturing 
and maintenance of the bacterial test strains.  The kit contained 5 different 
families of microbes, including S. aureus, C. albicans, E. coli, E. faecalis and P. 
aeruginosa. Ten strains of each of the 5 species of the aforementioned microbes 
were included in the kit. The first strain of each of the 5 families was from the 
American Type Culture Collection (ATCC), including C. albicans (ATCC 66027), 
E. coli (ATCC 35218), P. aeruginosa (ATCC 27853), E. faecalis (ATCC 29212) 
and S. aureus (ATCC 43300).  The remaining nine strains of each of the five 
respective microbial families were clinical isolates.  Each strain, except for the 
seventh strain of P. aeruginosa, which was not available at that time and 
subsequently excluded from the first round of antimicrobial screening, was 
inoculated onto porous colored beads contained in cryovials.  Furthermore, 4 
strains of B. cereus inoculated in agar deeps, including B. cereus (ATCC 10876) 
and 3 clinical isolates, were supplied by the Department of Biomedical 
Technology of the NMMU and used as a sixth microbial species for screening.   
 
For the culturing of the test organisms, one bead from each of the 49 respective 
cryovials was placed into 10 ml sterilised nutrient broth (Merck-Biolab, South 
Africa), while a small amount of each of the 4 strains of B. cereus was removed 
from the agar deeps and respectively inoculated into 10 ml sterile nutrient broths.  
The broths were then incubated at 37°C for 48 hours until turbid.  In order to 
determine the purity of the cultures, the nutrient broths containing S. aureus and 
E. faecalis were inoculated on blood agar plates, while nutrient broths containing 
strains of C. albicans were inoculated on Sabouraud Dextrose agar (Merck-
Biolab, South Africa).  The remaining strains of E. coli, P. aeruginosa and B. 
cereus were respectively inoculated on nutrient agar plates (Merck-Biolab, South 
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Africa).  The subcultured plates were then incubated at 37°C for 24 hours and 
examined for contamination.  
 
 
4.2.3.2. Agar dilution method  
  
An agar dilution method adapted from Alanis et al. (2005), Kumar et al. (2006), 
Tshikalange et al. (2004) and Weckesser et al. (in press), was employed in the 
screening of the microbes for sensitivity towards the infusions, aqueous-, 
methanol- and acetone extracts of G. incanum, A. afra and A. absinthium, 
respectively.  The first round of antimicrobial screening was done in August, 
2007.  The 12 crude extracts of the 3 plants were dissolved in dimethylsulfoxide 
(DMSO) (Merck-Saarchem, South Africa) and added to 12 separate aliquots of 
25 ml molten Mueller Hinton (MH) agar (Merck-Biolab, South Africa) in order to 
obtain a final concentration of 100 mg extract/ml agar.  Lin et al. (1999) found 
that the growth media used appeared to play a decisive role in the determination 
of antimicrobial activity.  When MH agar was used as growth medium, some 
extracts showed an increased capacity to inhibit the growth of S. aureus as 
apposed to when blood agar was used as growth medium.  Similar results were 
reported when potato dextrose agar and SS agar were used to evaluate the 
inhibitory activity of extracts towards C. albicans and Salmonella-Shigella spp., 
respectively (Lin et al., 1999).  In both cases, MH agar was found to be a more 
effective growth medium to use for the assessment of antimicrobial activity. 
 
Due to variation in the solubility of the various extracts in DMSO, different 
amounts of DMSO were used to solubilise the different extracts.  Subsequently, 
different amounts of the respective extracts in DMSO had to be added to the 
agar in order to maintain a final concentration of 100 mg extract/ml agar.  
Variation also existed between the amounts of extracts retrieved during the three 
rounds of plant extractions, as is indicated in Section 5.2.1.  Thus the amount of 
DMSO used to dissolve any specific extract also varied during the three 
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respective rounds.  The maximum amount of DMSO used to dissolve any 
specific extract equaled 3.5 ml.  This was used, both in the first and second 
rounds of extract preparation, to dissolve the aqueous extract of A. absinthium.  
The minimum amount of DMSO used to dissolve any specific extract equaled 1 
ml.  This was used during all three rounds of extract preparation to dissolve the 
infusion extract of G. incanum.     
 
After addition of the dissolved extracts, the 12 aliquots of agar containing the 
respective plant extracts were poured into Petri plates and allowed to set.  A 
Mast Diagnostics® (UK) multipoint inoculator (Figure 4.6) was used to inoculate 
dilutions equivalent to 1 McFarland standard of each of the pure strains of the six 
families of test microbes onto the MH agar plates.  In order to establish whether 
any microbial susceptibility was due to the action of the respective extract being 
tested or merely a result of the DMSO used to dissolve the extract, 3 control 
plates were included in the screening.  The first control plate consisted of MH 
agar containing DMSO equivalent to the highest volume of DMSO-dissolved 
extract added to a plate for a specific round of screening.  For example, during 
the first round of screening, 3.5 ml DMSO was used to dissolve the aqueous 
extract of A. absinthium, and 702 µl of this extract in DMSO was added to 24.30 
ml MH agar to obtain a concentration of 100 mg/ml.  Thus, for the control, 702 µl 
of pure DMSO was added to 24.30ml MH agar. 
 
The second control plate consisted of MH agar containing DMSO equivalent to 
the average volume of DMSO-dissolved extract added to a plate for a specific 
round of screening.  For example, during the first round of screening, 2.26 ml 
DMSO was used to dissolve the acetone extract of A. absinthium, and 446 µl of 
this extract in DMSO was added to 24.55 ml MH agar to obtain a concentration of 
100 mg/ml.  Thus, for the control, 446 µl of pure DMSO was added to 24.55 ml 
MH agar. 
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The third control plate contained no DMSO.  Due to the fact that the amount of 
DMSO added to controls 1 and 2 was dependent on the highest and average 
amounts of extracts in DMSO added to agar, and the fact that the amount of any 
specific extract added to agar varied during the three rounds of screening in 
order to maintain a concentration of 100mg/ml, the amounts of DMSO added to 
controls 1 and 2 also varied during the three rounds of antimicrobial screening.  
However, control 1 always contained DMSO equivalent to the highest amount of 
extract in DMSO added to a plate, while control 2 always contained DMSO 
equivalent to the average amount of extract in DMSO added to a plate.  The 
control plates were inoculated with the various strains of the 6 species of 
microbes being tested, and incubated together with the test plates for 48 hours at 
37°C, followed by examination for inhibition of microbial growth.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The second- and third rounds of antimicrobial screening were done as described 
above, with some exceptions, during January 2008.  During the second round of 
screening, strains 5 and 6 of P. aeruginosa were found to be non-viable upon 
Figure 4.6: The Mast Diagnostics® multipoint inoculator. 
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subculture, and were subsequently excluded from the second and third rounds of 
screening.  Strain 7 of P. aeruginosa was available during the second and third 
rounds of screening, but was found to be contaminated with a Proteus organism.  
Thus any results pertaining to this strain were not taken into consideration.  
Finally, P. aeruginosa (ATCC 27853) was found to be infected with a 
bacteriophage during the third round of antimicrobial screening.  Results 
obtained during the third round of antimicrobial screening pertaining to this 
particular strain of P. aeruginosa were not taken into consideration.  Only those 
extracts showing activity, at least twice, out of the three sensitivity trials, against 
a specific microbe, were considered to have activity and the respective microbe 
was reported as being sensitive.     
 
 
4.3. Anticancer studies 
 
4.3.1. Collection and preparation of plant materials 
 
Unlike the antimicrobial screening, only one set of infusions and extracts were 
prepared for use in anticancer studies as this required significantly less extract 
than the antimicrobial activity screening.   
 
Fresh plant material was harvested and prepared for extract preparation during 
January 2008.  G. incanum plant material was obtained from the garden of Dr N. 
Smith, while fresh A. afra plant material was collected from the horticultural 
services of the NMMU.  Dr. M. van de Venter once again supplied fresh A. 
absinthium plant material from her garden.  The fresh leaves were separated 
from the stems of the respective plants and separately rinsed in distilled water in 
order to remove dust, soil and insects.  The fresh leaves were then allowed to dry 
at room temperature and separately weighed.  Leaves used in the preparation of 
infusions were extracted immediately, while the remaining leaves used in the 
preparation of aqueous-, methanol- and acetone extracts were dried in an oven 
at 40°C over night. 
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4.3.2. Extraction of plant materials 
 
4.3.2.1. Preparation of infusions  
 
The preparation of extracts for use in anticancer studies was slightly adapted 
from the method used during extract preparation for antimicrobial screening with 
regards to the amount of plant material used.  It was estimated that 60 mg of 
each of the crude infusion-, aqueous-, methanol- and acetone extracts of G. 
incanum, A. afra and A. absinthium, respectively, would be required for the 
completion of anticancer studies.  The amount of plant material used and the 
crude extract yields obtained during the preparation of extracts for antimicrobial 
screening was used to approximate the amount of plant material needed to 
obtain 60 mg of each of the respective extracts of the three plants for use in 
anticancer studies.   
 
Infusions of G. incanum were prepared according to an adapted traditional 
method described by Scott & Springfield (2004a, p.4).  Approximately 2.04 g of 
fresh leaves was added to 60.96 ml of boiling distilled water and left to infuse for 
ten minutes.  The infusion was then filtered using Whatman No 1 filter paper to 
remove residual plant material, the infused leaves were discarded, and the filtrate 
was taken to dryness in a laminar air flow cabinet (Labscheme Allchem®, South 
Africa) by evaporation in a hot water bath for 48 hours at 40°C.  The crude 
extract was then re-suspended in approximately 2 ml of distilled water and frozen 
at -20°C in clean, pre-weighed 2 ml microtubes (Axygen® Scientific, USA), 
followed by freeze drying and weighing of the microtubes in order to determine 
the amount of crude extract and to calculate the percentage yield.  
 
The infusion of A. afra was prepared according to an adapted traditional method 
described by Scott & Springfield (2004b, p.4).  Approximately 5.09 g of fresh 
leaves were added to 363.71ml of boiling distilled water and left to infuse until 
cool.  The infusion was then filtered using Whatman No 1 filter paper to remove 
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residual plant material, the infused leaves were discarded, and the filtrate was 
taken to dryness in a laminar air flow cabinet by evaporation in a hot water bath 
for 48 hours at 40°C.  The crude extract was then re-suspended in approximately 
2 ml of distilled water and frozen at -20°C in clean, pre-weighed 2 ml microtubes, 
followed by freeze drying and weighing of the microtubes in order to determine 
the amount of crude extract and percentage yield obtained from the fresh plant 
material of A. afra.  The infusion of A. absinthium was prepared in exactly the 
same manner, except that 5.03 g fresh leaves were added to 358.93 ml boiling 
distilled water for infusion.  
 
 
4.3.2.2. Preparation of aqueous-, methanol- and acetone extracts 
   
Water, methanol and acetone were once again used as extractants for the 
preparation of extracts of the three respective plants, which were prepared as 
described in Section 4.2.2.2., with a few exceptions.  The remaining fresh leaves 
of the three test plants were separately weighed, dried over night in an oven at 
40°C and weighed again the following morning in order to determine the 
percentage yield of dry plant material.   
 
One gram of dried G. incanum plant material was used in the preparation of 
aqueous- and methanol extracts, while 7.01 g dried plant material was used for 
the preparation of the acetone extract.  For the preparation of the aqueous- and 
methanol extracts of A. afra, 1 g of dried plant material was used, respectively, 
while 1.5 g of dried plant material was used in the preparation of the acetone 
extract.  One gram of dried A. absinthium plant material was used for the 
preparation of the aqueous-, methanol- and acetone extracts, respectively. 
 
The aqueous extracts of the three plants were prepared in the same manner as 
was done during extract preparation for antimicrobial screening (Section 
4.2.2.2.), except for different amounts of dried plant material used, and extracts 
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having been re-suspended in approximately 2 ml distilled water following 
evaporation in a hot water bath for 48 hours at 40°C and freezing of the extracts 
in pre-weighed 2 ml microtubes instead of 50 ml centrifuge tubes.  
 
The methanol- and acetone extracts of the respective plants were prepared in 
the same manner as the aqueous extracts, except that after centrifugation the 
respective supernatants were separately combined in clean, pre-weighed glass 
beakers and placed in a hot water bath at 40°C over night in a laminar air flow 
cabinet, allowing the extractants to evaporate.  The glass beakers were then 
weighed in order to determine the amount of crude methanol- and acetone 
extracts and percentage yields obtained from the dried leaves of the three 
respective plants. 
 
All crude extracts were re-dissolved in DMSO to a concentration of 2 mg/10 µl.  
Re-dissolved methanol- and acetone extracts were removed from the glass 
beakers and separately placed in clean, 2 ml microtubes.  These, together with 
the microtubes containing the respective re-dissolved aqueous extracts, were 
stored as stock solutions at -20°C in the dark until the day of testing. 
 
4.3.3. Maintenance of cell cultures 
 
The infusions, aqueous-, methanol- and acetone extracts of G. incanum, A. afra 
and A. absinthium were screened for anticancer activity against three cell lines, 
namely MCF-7, HT-29, and HeLa, which were obtained from the Department of 
Biochemistry and Microbiology at the NMMU.  Cells were routinely maintained by 
culturing in 10cm Cellstar® DNase- and RNase- free tissue culture dishes 
(Greiner Bio-one™, Germany) without antibiotics in BioWhittaker RPMI-1640 
medium (Lonza™, Switzerland), supplemented with 10% Gibco® heat 
inactivated fetal bovine serum (FBS) (Invitrogen™, UK).  Cells were incubated in 
a ThermoForma 310 (Labotec™, USA) direct heat humidified incubator with 5% 
CO2 at 37°C, and subcultured when 80% confluency was reached, which was 
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approximately every 72 hours.  Subculturing entailed the removal of old growth 
medium by vacuum suction, followed by washing the cells twice with phosphate 
buffered saline (PBS) lacking calcium and magnesium.  After removal of the 
PBS, 1 ml trypsin (10% in PBS containing ethylene diaminetetra-acetic acid 
[EDTA, 0.2 g/l]) was added to the cells and allowed to completely cover the 
monolayer.  The trypsin was then removed by vacuum suction, and the cells 
incubated at 37°C for approximately 10 minutes until complete dislodgement of 
the cells from the surface of the culture dish had occurred.  Cells were then 
diluted to the required concentration, usually 1:5 to 1:8, by the addition of RPMI-
1640 growth medium supplemented with 10% FBS, and subcultured in sterile cell 
culture dishes (Freshney, 2000, pp.1-7). 
 
 
 
4.3.4. Determination of plant extract toxicity towards cancer cells by means  
          of the MTT assay   
 
Mosmann (1983, pp.55-63) first described the MTT assay as a quantitative 
means of determining mammalian cell survival and proliferation in vitro.  
Dehydrogenase enzymes of viable cells convert 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide, a yellow tetrazoleum salt, to purple formazan 
crystals.  The amount of viable cells present following exposure to a test 
substance, in this case the plant extracts, is directly proportional to the amount of 
formazan formed, which can be measured spectrophotometrically.   
 
A method adapted from the MTT assay as described by Mosmann (1983, pp.55-
63), was utilised during this study to test for cell viability and cytotoxicity in vitro 
following exposure to the various plant extracts.  Cells were washed twice with 
PBS, trypsinised (10% trypsin in PBS with EDTA [0.2 g/l]), harvested and 
counted using a hemocytometer and the amount of viable cells present 
visualized using trypan blue.  The cell membrane of necrotic cells looses its 
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integrity and ability to exclude certain substances such as trypan blue.  
Microscopically, necrotic cells stained with trypan blue will appear blue, while 
viable cells remain unstained.  Cultured cells from a plate were used when the 
cell viabililty as counted with trypan blue exclusion was more than 90%.  Cells 
were seeded in Costar® polystyrene 96 well plates (Corning Incorporated, USA), 
each well containing 200 µL RPMI-1640 media supplemented with 10% heat 
inactivated FBS, using a Multipette Plus (Eppendorf®, Germany), at a density of 
5000 cells per 200 µL.  The tissue culture plates were incubated for 24 hours in 
relative humidity at 37°C with 5% CO2, followed by inspection of the wells for 
microbial contamination and removal of the media by vacuum.  Stock solutions (2 
mg extract/10 µL DMSO) of the plant extracts of G. incanum, A. afra and A. 
absinthium were serially diluted with RPMI-1640 media supplemented with 10% 
heat inactivated FBS, starting at 500 µg/ml (0.25% DMSO) diluted to 375 µg/ml, 
250 µg/ml, 125 ug/ml, 62.5 µg/ml, 25 µg/ml and 10 µg/ml.  Each set of dilutions of 
the various extracts were individually tested on all three cell lines, with wells 
containing 200 µL of the respective diluted extracts.  RPMI-1640 media 
supplemented with 10% heat inactivated FBS lacking any extract was added to 
the top and bottom peripheral wells of each plate, as extract blanks and negative 
controls.  All three cell lines were also treated with serial dilutions of cisplatin, a 
known anticancer agent which induces apoptosis.  Cisplatin was kindly donated 
by Professor J. du Preez of the Chemistry department of the NMMU.  The 
dilutions of cisplatin used ranged from a concentration of 30 μg/ml in RPMI-1640 
media supplemented with 10% heat inactivated FBS (0.25% DMSO) to 22.5 
μg/ml, 15 μg/ml, 7.5 μg/ml, 3.75 μg/ml and 1.5 μg/ml.  Since the extracts were 
dissolved in DMSO to a final concentration of 0.25% DMSO, this concentration of 
DMSO not being toxic to malignant cells (M. van de Venter, personal 
communication, January, 2008), a DMSO control was not included during 
screening.  Tissue culture plates were incubated for 48 hours in relative humidity 
at 37°C with 5% CO2 following addition of the diluted extracts and cisplatin. 
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After 48 hours the medium was 
removed and 200 µL of fresh RPMI-
1640 medium and 20 µL of MTT (4 
mg/ml in distilled water) was added to 
each well and the plate incubated a 
further 4 hours at 37°C.  Thereafter 
the medium was removed and 100 µL 
of DMSO was added to each well in 
order to solubilise the formazan 
crystals produced by viable cells.  
Following incubation at room 
temperature for 15 minutes, the 
optical densities of the formazan 
solution in each well was measured 
at 570 nm using a BioTek 
PowerWave XS™ photometer (Progen Scientific®, UK) (Figure 4.7).    
 
Screening of all the extracts on the three respective cell lines was done in 
triplicate, with cell viability, as well as inhibition of cell growth/cell death having 
been expressed as a mean percentage ± standard deviation (SD) of the mean 
negative control absorbance.  This data was analysed in GraphPad Prism® (San 
Diego, USA) and used to construct dose response curves of the various extracts 
on the respective cell lines.  Where extracts appeared to significantly inhibit cell 
growth or induce cell death, screening of the specific extract on the respective 
cell line was repeated using lower concentrations of the extract.  GraphPad 
Prism® was used to perform regression analysis in order to determine IC50 
values, the concentration of each extract, as well as cisplatin, at which 50% of 
the cells are inhibited.  When the coefficient of correlation (r2) was not ≥  0.95 for 
any of the regression analyses, the results were considered insignificant and 
screening of the specific extract on the relevant cell line was repeated.    
 
Figure 4.7: The BioTek PowerWave XS™ 
photometer. 
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4.3.5. Apoptotic and necrotic assay – fluorescence microscopy 
 
As discussed in Section 2.6.2., the two modes of cell death, being apoptosis and 
necrosis, are characterised by two different sets of morphological as well as 
biochemical changes in the cell.  By observing and identifying these two sets of 
cellular changes, it is possible to discern apoptotic cells from necrotic ones.  
Darzynkiewicz et al. (as cited in Bungu, 2005, p.50) describes various methods 
and assays having been developed for the identification of apoptotic parameters, 
including the activation of apoptotic caspases, as discussed in Section 2.6.2.1., 
the release of cytochrome c and AIF into the cytoplasm, as discussed in Section 
2.6.2.1.2., the formation of apoptotic bodies in individual cells and/or cell 
populations, and alterations in the integrity of the plasma membrane. 
 
As the induction of apoptosis in malignant cells is the mechanism of action of 
many anticancer agents, it would be desirable for a plant extract expressing 
toxicity towards malignant cells to induce apoptosis in these cells rather than 
necrosis.  During the current study, apoptotic body formation, nuclear chromatin 
condensation and loss of membrane integrity in necrotic cells were used as 
parameters for the detection of apoptotic- and necrotic cells.  This was 
accomplished by separately exposing malignant cells treated with a plant extract 
to two fluorescent dyes, being 4',6-diamidino-2-phenylindole dihydrochloride 
(DAPI) and propidium iodide (PI), and observing any morphological changes 
under a fluorescence microscope.  
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4.3.5.1. DAPI and PI exclusion staining 
 
The principle of this assay exploits the phenomenon of apoptotic cells 
maintaining the integrity and functions of their plasma membranes, unlike 
necrotic cells, in which case integrity of the plasma membrane is compromised.  
While the intact cell membrane of live- and apoptotic cells selectively exclude 
various substances, including cationic dyes such as PI and trypan blue, others 
are transported into the cell, such as DAPI.  In necrotic cells, having lost their cell 
membrane integrity, cationic dyes such as PI and trypan blue are able to 
penetrate into the cytosol of the cell, staining cellular structures. 
 
DAPI is a fluorescent indole dye which is capable of penetrating the cell 
membrane of viable- and apoptotic cells, where it forms fluorescent complexes 
with natural double stranded DNA in the nucleus, which appears blue during 
fluorescence microscopy.  According to Darzynkiewicz et al. (as cited in Bungu, 
2005, p.50), one of the trademarks of apoptotic cells is nuclear chromatin 
condensation.  Apoptotic cells generally fluoresce brighter than non-apoptotic 
cells when stained with a nuclear fluorescence dye such as DAPI.  DAPI has an 
excitation wavelength of 340 nm and an emission wavelength of 488 nm in 
aqueous solution.  When dying or dead cells are exposed to PI, which has an 
excitation wavelength of 488nm and an emission wavelength of 560-680nm, the 
dye enters the cell and forms fluorescent complexes with double stranded nucleic 
acids, rendering a red color to the nucleus during fluorescence microscopy 
(DAPI, 2007; Bungu, 2005, p.50).     
 
DAPI and PI staining of cells was performed using a combined, modified method 
of Moongkarndi et al. (2004), Bungu (2005, p. 51) and Botha (2003, p. 80).  For 
the purpose of this study, it was decided to investigate the mechanism of toxicity 
of the plant extract exhibiting the highest degree of toxicity to a specific cell line 
(Table 5.9).  Cells were counted using trypan blue exclusion and seeded on 
sterile 13mm glass coverslips in Cellstar® DNAase- and RNAase- free 6-well 
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tissue culture  plates (Greiner Bio-one™, Germany), each well containing 5 ml 
RPMI-1640 media supplemented with 10% heat inactivated FBS, at a density of 
5000 cells per 200 µL.  The tissue culture plates were incubated for 24 hours in 
relative humidity at 37°C with 5% CO2.  The stock solution of the extract (2 mg 
extract/10 µL DMSO) was diluted with RPMI-1640 media supplemented with 10% 
heat inactivated FBS, to the extract’s IC50 value for the particular extract as 
indicated in Section 5.3.2., and 5 ml of this dilution was added to the first and 
second wells. As a negative control, 5 ml RPMI-1640 media supplemented with 
10% heat inactivated FBS lacking any extract was added to the third and fourth 
wells, while 5 ml RPMI-1640 media supplemented with 10% heat inactivated FBS 
containing cisplatin at a concentration of 10 µM (0.25% DMSO) was added to 
each of the remaining two wells of the first plate.  This served as a positive 
control for the induction of apoptosis.  To two wells of the second tissue culture 
plate, 5 ml RPMI-1640 media supplemented with 10% heat inactivated FBS 
lacking any extract was added, which was used to establish the accuracy of the 
method by permeabilising and staining the cells in these two wells, as discussed 
in the following paragraph.  The tissue culture plates were then incubated for 48 
hours in relative humidity at 37°C with 5% CO2. 
 
After removal of the spent medium, wells were washed once with PBS lacking 
EDTA, calcium and magnesium, followed by the addition of 1 ml of ice cold 3:1 
methanol:acetic acid (Carnoy’s fixative) to each of the 6 wells of the first plate, 
and 1 ml ice cold permeabilising agent (1:1 methanol:acetone) to the remaining 
two wells of the second plate.  The fixative and permeabilising agent was 
removed after ten minutes incubation at room temperature.  All wells were once 
again washed with PBS and 1 µg/ml DAPI (made up in PBS lacking EDTA, 
calcium or magnesium) was added to one of each of the wells containing cells 
treated with plant extract, cisplatin, untreated cells and permeabilised cells.  To 
the remaining wells, 5 µg/ml PI was added.  Cells were then incubated for 30 
minutes in relative humidity at 37°C with 5% CO2, followed by the removal of the 
DAPI and PI solutions.  The coverslips were removed from the tissue culture 
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plate using a forceps and mounted upside down in PBS on microscope slides.  
An Olympus BX-60 fluorescent microscope (Olympus™, Japan) was used to 
examine each of the eight slides for cellular staining and the presence of 
apoptotic and necrotic morphological parameters, and photographs were taken 
using an Olympus camera.   
 
 
 
4.3.6. Determination of plant extract toxicity in peripheral blood  
          mononuclear cells  
 
The aim of modern cancer chemotherapy is to selectively destroy malignant cells 
while having as little effect as possible on the patient’s normal cell populations 
and general homeostatic balance.  Unfortunately, however, more often that not 
the chemotherapeutic agent being administered not only leads to the destruction 
of malignant cells, but also adversely affects various healthy cell populations in 
varying degrees, especially those types which replicate and divide faster, such as 
the haemopoietic stem cells, cells of the digestive tract, cells of the reproductive 
system as well as hair follicles (MedicineNet, 2004).  As stated earlier, the 
mechanism of action of many clinical anticancer agents is the induction of 
apoptosis in malignant cells.  A plant extract or compound isolated from such an 
extract exhibiting anticancer activity is not only required to induce apoptosis in 
malignant cells as opposed to necrosis; it also needs to do so selectively in 
malignant cells without affecting normal healthy cells. 
 
The degree of toxicity expressed by extracts of G. incanum, A. afra and A. 
absinthium on MCF-7 cells, HT-29 cells and HeLa cells, as well as the 
mechanism of cell death induced by the most toxic of these extracts in a specific 
cell line (apoptosis vs. necrosis) have been investigated and discussed in 
Sections 4.3.4. and 4.3.5., respectively.  Investigation into the possible 
expression of toxicity of the latter extract in normal, healthy human cells, having 
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been peripheral blood mononuclear cells (PBMC’s) for the purpose of this study, 
was judged the next logical step, and is discussed in Sections 4.3.6.1. and 
4.3.6.2. 
 
4.3.6.1. Isolation and preparation of PBMC’s 
 
The isolation of PBMC’s was performed according to a Ficoll™ (Amersham, 
USA) density gradient centrifugation protocol adapted from the Immune 
Tolerance Network (n.d.).  In order to obtain PBMC’s, venous blood was 
collected from a healthy, consenting adult male into 2 x 8 ml BD Vacutainer® 
CPT mononuclear cell preparation tubes (Becton Dickinson and Company, USA) 
containing a density gradient polymer gel, sodium heparin and Ficoll™ medium, 
and processed within half an hour of sample collection.  Both tubes were gently 
inverted 10 times, followed by centrifugation of the blood collection tubes at 1800 
x g for 30 minutes in an Eppendorf® 5810 centrifuge (Germany) at room 
temperature.  Plasma and PBMC’s were then aspirated and transferred to clean, 
15 ml Eppendorf® centrifuge tubes, which were gently inverted 10 times and 
centrifuged again at 300 x g for 15 minutes.  Following centrifugation, the plasma 
was aspirated and discarded, except for approximately 1 ml, which was used to 
re-suspend the cell pellet.  Ten millilitre of RPMI-1640 media supplemented with 
10% heat inactivated FBS was then added to the re-suspended cell pellet, and 
the suspension was centrifuged at 300 x g for 15 minutes, followed by aspiration 
of the supernatant and re-suspension of the cell pellet in approximately 4 ml 
RPMI-1640 media supplemented with 10% heat inactivated FBS.   
 
 
 
4.3.6.2. The CellTiter-Blue® cell viability assay 
 
The CellTiter-Blue® Cell Viability Assay (Promega, USA) is a flourometric 
method for the estimation of the amount of viable cells present in a sample, and 
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is based upon the principle of viable cells being able to reduce the indicator dye 
resazurin, which is dark blue in color and possessing very little intrinsic 
fluorescence, to the highly fluorescent resorufin, which is pink in color.  The 
amount of fluorescence present after completion of the assay is directly 
proportional to the number of viable cells present in the sample. 
 
The CellTiter-Blue® assay was performed according to the method as outlined in 
the Promega Technical Bulletin (2006).  For the purpose of the assay, screening 
of the extract against PBMC’s was done in triplicate, while three different controls 
were simultaneously run, each control having been performed in duplicate.  
Following the re-suspension of the PBMC pellet in 4 ml RPMI-1640 medium 
supplemented with 10% heat inactivated FBS, viable cells were counted using 
trypan blue exclusion and seeded in the first 33 wells of a Costar® polystyrene 
96 well plate (Corning Incorporated, USA).  Eleven serial dilutions of the extract 
were made in RPMI-1640 media supplemented with 10% heat inactivated FBS 
and screened against PBMC’s, ranging between 500µg/ml (0.25% DMSO) and 
2.65µg/ml (0.25% DMSO).  The respective dilutions were added to the 33 wells 
containing the seeded cells to a final volume of 100 µl per well at a cell density of 
100 000 cells per well.  The first control consisted of 22 wells containing cells at a 
density of 100 000 cells per well in 100 µl RPMI-1640 media supplemented with 
10% heat inactivated FBS only.  The fluorescence obtained from cells treated 
with the extract was expressed as a percentage of the fluorescence of these 
untreated cells in order to determine the percentage cell viability of cells exposed 
to the extract.  As a second control, 22 wells were filled with 100 µl of RPMI-1640 
medium supplemented with 10% heat inactivated FBS only, which served as a 
negative control for the determination of possible background fluorescence.  As a 
third control, the eleven respective extract dilutions mentioned above were added 
to 22 wells at a final volume of 100 µl, which served to rule out fluorescence of 
the extract itself or possible interference of the extract with the chemistry of the 
assay reagent.  The tissue culture plates were then incubated for 48 hours in 
relative humidity at 37°C with 5% CO2.  
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All wells were visually inspected for bacterial contamination after 48 hours, 
followed by the addition of 20 µl of the CellTiter-Blue® reagent to each well and 
further incubation for 4 hours in relative humidity at 37°C with 5% CO2.  After 4 
hours of incubation, a Flouroskan Ascent® fluorometer (Thermo Labsystems, 
Finland) (Figure 4.8) was used to record the fluorescence at an excitation 
wavelength of 544 nm and an emission wavelength of 590 nm.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fluorescence and possible interference of the extract itself was excluded by 
subtracting the mean values of any fluorescence emitted by each of the eleven 
extract dilutions from the third control from the fluorescence readings obtained 
from the three triplicate sets of wells containing PBMC’s treated with the 
respective eleven dilutions of the extract.  The percentage of PBMC viability, as 
well as the percentage cell death was determined by expressing the final 
fluorescence values of the wells containing PBMC’s treated with the extract as a 
mean percentage ± standard deviation (SD) of the mean fluorescence readings 
recorded for the wells containing untreated cells (control 1).  This data was 
Figure 4.8: The Flouroskan Ascent® 
fluorometer.  
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recorded in GraphPad Prism® (San Diego, USA) and used to construct a dose 
response curve of the extract for PBMC’s.  GraphPad Prism® was also used to 
perform regression analysis in order to determine the IC50 of the extract for 
PBMC’s.  When the coefficient of correlation (r2) was not ≥ 0.95, the results were 
considered insignificant and the assay repeated to confirm the results.    
 
 
4.3.7. Analysis of the effects of the most toxic extract on the cell cycle of  
          the most sensitive cells by means of flow cytometry 
 
As stated under Section 2.6.1.2.1., the development of malignancy is usually the 
result of aberrations in the regulatory mechanisms of the cell cycle, allowing for 
uncontrolled proliferation of undifferentiated cells.  The final step in the current 
investigation was to determine whether the most toxic extract, as indicated in 
Table 5.9, could in fact alter the cell cycle of the most sensitive cell line of the 
three lines tested, in such a manner as to decrease or completely halt 
proliferation of these cells.  This was done by analyzing the cell cycle of the cells 
following treatment with the extract, lysis of the cells and staining of the DNA with 
PI using flow cytometric analysis, a quantitative technique with the ability to 
rapidly measure large amounts of cells.  The assay is based on the principle that 
PI is able to bind to double stranded DNA, which emits fluorescence.  By 
measuring the fluorescence, which is directly proportional to the amount of DNA 
present, it is possible to establish during which phase of the cell cycle a specific 
cell is, proportional to its DNA content (Beckman Coulter Technical Bulletin, 
2003).  
Cell cycle analysis was performed in triplicate.  Cells were seeded in three sets 
of three Cellstar® DNAase- and RNAase- free 10 cm tissue culture plates, each 
at a density of 3x106 cells/ml in RPMI-1640 medium supplemented with 10% 
heat inactivated FBS, and incubated for 24 hours in relative humidity at 37°C with 
5% CO2.  Following 24 hour incubation, the growth medium was removed by 
vacuum from each of the tissue culture dishes, and each dish was washed twice 
 126 
with PBS lacking EDTA, calcium and magnesium.  To three of the dishes 
cisplatin was added at a concentration of 10 µM (0.25% DMSO) in RPMI-1640 
media supplemented with 10% heat inactivated FBS.  This served as a positive 
control.  To the second set of three plates, fresh RPMI-1640 medium 
supplemented with 10% heat inactivated FBS lacking cisplatin or extract was 
added, which served as a negative control.  To the last three plates, the most 
toxic extract was added to a final concentration of its IC50 (0.25% DMSO) for the 
most sensitive cell line (Table 5.9) in RPMI-1640 medium supplemented with 
10% heat inactivated FBS.  After a further 24 hour period of incubation in relative 
humidity at 37°C with 5% CO2, the medium, extract and cisplatin was removed 
from the plates by vacuum, and each plate was rinsed twice with PBS containing 
EDTA (0.2 g/l).  Cells were trypsinised by the addition of 1 ml trypsin (10% in 
PBS containing EDTA [0.2 g/l]) to each plate, which was allowed to cover the 
plate surface before removal by vacuum and incubation of the plates in relative 
humidity at 37°C with 5% CO2 for 15 minutes to facilitate trypsinisation.  
Following trypsinisation, 1 ml RPMI-1640 media supplemented with 10% heat 
inactivated FBS was added to each of the respective plates in order to create cell 
suspensions.  The suspensions were aspirated and placed into separate 5 ml 
Beckman Coulter™ FC 500 cytometer sample tubes and centrifuged at 500 x g 
for 5 minutes, followed by discarding 900 µl of the respective supernatants.  To 
each sample tube, 100 µl of lysis buffer, which was included in the Coulter® DNA 
Prep™ Reagents Kit used for this study, was added.  Trout red blood cells (NPE 
Systems, USA) were used as a DNA reference calibrator.  Two drops of trout red 
blood cells were added to a separate clean cytometer sample tube together with 
100 µl lysis buffer, which was left together with the other cell samples to incubate 
for 5 minutes at room temperature.  Following incubation, 1 ml PI, also included 
in the Coulter® DNA Prep™ Reagents Kit, was added to each of the sample 
tubes and incubated for 15 minutes in relative humidity at 37°C with 5% CO2 in 
the dark.  Samples were subsequently loaded into a Beckman Coulter™ FC 500 
cytometer for analysis, and the percentages of cells present in each respective 
phase of the cell cycle of cells treated with the extract was compared to the 
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percentages of cells occurring in the corresponding phases of the cell cycles for 
cells treated with cisplatin as well as cells which remained untreated.     
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CHAPTER 5 
RESULTS 
 
5.1. Introduction 
 
The current chapter discusses the results obtained during the present study, 
including the percentage yields obtained after fresh leaves were dried, the  
infusion- and extract yields obtained from the respective plants, as well as 
descriptions of the infusions and crude extracts obtained after freeze drying and 
evaporation.  The results obtained during antimicrobial screening studies, as well 
as results obtained during anticancer screening studies, are also given. 
 
 
5.2. Antimicrobial activity studies 
 
5.2.1. Percentage yields of dried plant material obtained, and the  
          percentage yields of infusions and crude extracts obtained from  
          G. incanum, A. afra and A. absinthium  
 
Infusions as well as aqueous-, methanol- and acetone extracts were prepared as 
discussed in Sections 4.2.2.1. and 4.2.2.2., respectively.  The percentage yields 
of plant material obtained after drying, used in the preparation of aqueous-, 
methanol- and acetone extracts for antimicrobial screening, is shown in Table 
5.1. 
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Table 5.1: Percentage yields of plant material obtained after drying, used in the 
preparation of aqueous-, methanol- and acetone extracts for antimicrobial 
screening. 
 
Plant Weight of fresh plant 
material before drying 
(gram) 
Weight of dried 
plant material (gram) 
Percentage yield of dried 
plant material (%) 
G. incanum 52.6 13.4 25.5 
A. afra 169.2 36.4 21.5 
A. 
absinthium 
196.9 37.4 19.0 
 
 
Weighing of dried G. incanum plant material indicated a reduction in weight to the 
amount of 39.2 g.  Water constituted approximately 74.5% of the weight of fresh 
G. incanum plant material.  Weighing of dried A. afra plant material indicated a 
reduction in weight of 132.7 g.  Water constituted approximately 78.5% of the 
weight of fresh A. afra plant material.  The weight of A. absinthium plant material 
was reduced by 159.5 g during the drying of fresh plant material, indicating a 
water content of approximately 81.0% in fresh A. absinthium plant material.                         
 
After freeze drying of infusions and aqueous extracts, and evaporation of 
methanol- and acetone extracts, respectively, the pre-weighed containers 
containing the crude extracts of G. incanum, A. afra and A. absinthium were 
weighed again in order to determine the weight of crude extracts obtained.  
Tables 5.2, 5.3 and 5.4 indicate the percentage yields of extracts obtained for 
each of the three respective rounds of infusion and extract preparation for 
antimicrobial screening.  The weights of the fresh and dried plant materials used 
as well as the weights of extracts after freeze drying (infusions and aqueous 
extracts) and evaporation (methanol- and acetone extracts) are indicated in 
Tables 1, 2 and 3 in Appendix I, respectively. 
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Table 5.2: Percentage yields of extracts obtained after the initial round of extract  
preparation for antimicrobial screening, June 2007 (winter). 
 
 
Table 5.3: Percentage yields of extracts obtained after the second round of 
extract preparation for antimicrobial screening, September 2007 (spring). 
 
Table 5.4: Percentage yields of extracts obtained after the third round of extract  
preparation for antimicrobial screening, January 2008 (summer). 
 
 
Extract Geranium 
 incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Yield % (w/w) Yield % (w/w) Yield % (w/w) 
Infusion (Fresh leaves used) 5.4 2.9 2.4 
Aqueous extract (Dry leaves used) 8.6 9.9 9.0 
Methanol extract (Dry leaves used) 9.0 11.9 10.0 
Acetone extract (Dry leaves used)  1.3 6.9 
 
8.1 
Extract Geranium 
 incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Yield % (w/w) Yield % (w/w) Yield % (w/w) 
Infusion (Fresh leaves used) 1.7 3.7 4.6 
Aqueous extract (Dry leaves used) 5.6 5.1 7.6 
Methanol extract (Dry leaves used) 6.3 7.6 7.7 
 
Acetone extract (Dry leaves used)  0.9 
 
5.5 
 
6.0 
Extract Geranium 
 incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Yield % (w/w) Yield % (w/w) Yield % (w/w) 
Infusion (Fresh leaves used) 7.2 
 
10.1 
 
6.3 
 
Aqueous extract (Dry leaves used) 13.2 
 
7.7 
 
10.4 
 
Methanol extract (Dry leaves used) 3.2 
 
7.4 
 
9.9 
 
Acetone extract (Dry leaves used)  5.8 
 
6.8 
 
6.4 
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The previous three tables clearly indicate variation in the extract yields obtained 
after each of the three respective rounds of plant extractions.  Generally, the 
second round of extractions (September 2007, spring) appears to have produced 
the lowest yields in all but four of the twelve respective infusion and extract 
preparations, including: 
 
• The methanol extracts of G. incanum and A. afra, in which case the lowest 
yields were obtained during the third round of extraction (January 2008, 
summer).  
• The infusions of A. afra and A. absinthium, in which case the lowest yields 
were obtained during the first round of extraction (June 2007, winter). 
 
The first round of extractions (June 2007, winter) produced the highest yields in 6 
of the 12 extracts prepared, including the aqueous extract of A. afra, the 
methanol extracts of G. incanum, A. afra and A. absinthium as well as the 
acetone extracts of A. afra and A. absinthium, respectively.  The remaining six 
highest yields were obtained during the third round of extraction (January 2008, 
summer), including the infusions of G. incanum, A. afra and A. absinthium, the 
aqueous extracts of G. incanum and A. absinthium as well as the acetone extract 
of G. incanum. 
 
The greatest variation in extract yield obtained occurred between the second 
(September 2007, spring) and third (January 2008, summer) aqueous extracts of 
G. incanum, with 0.3g (57.5%) less extract having been obtained during the 
second round (September 2007, spring).   
 
The least amount of variation in extract yield obtained occurred between the first 
(June 2007, winter) and third (January 2008, summer) methanol extracts of A. 
absinthium, with only 0.03g (0.9%) less extract having been obtained during the 
third round (January 2008, summer).  
 
 132 
5.2.2. Description of crude infusions and extracts obtained after freeze  
          drying and evaporation, used in antimicrobial screening 
 
A marked variability in the physical appearances of the crude infusions and 
aqueous extracts obtained after freeze drying, as well as the crude methanol- 
and acetone extracts obtained after evaporation for G. incanum, A. afra and A. 
absinthium, respectively, was observed.  Crude extracts and infusions differed in 
volume, texture, color and degree of dryness.  Table 5.5 gives brief descriptions 
of the physical appearances of crude infusions and extracts of G. incanum, A. 
afra and A. absinthium, respectively.   
 
Table 5.5: Descriptions of the physical appearances of crude infusions and 
extracts of G. incanum, A. afra and A. absinthium.  
 
Infusion/Extract Physical appearance 
G. incanum  
Infusion Completely dehydrated, fluffy and very light brown in color 
Aqueous extract Completely dehydrated, fluffy and slightly darker than infusion in color 
Methanol extract Smooth, solid, glassy and speckled appearance, being a light green-
brown in color 
Acetone extract Smooth, solid, glassy and wispy in appearance, being yellow-green to 
black in appearance 
A. afra  
Infusion Very viscous, sticky consistency, being toffee brown in color 
Aqueous extract Very viscous, sticky consistency, slightly crumbly, being darker than 
infusion in color 
Methanol extract Very viscous, semi dehydrated appearance, being dark green in color 
Acetone extract Smooth, solid and glassy appearance, being a light toffee-brown in color  
A. absinthium  
Infusion Dry and sticky consistency, being dark brown in color 
Aqueous extract Very viscous, sticky consistency, being dark brown in color 
Methanol extract Very viscous, semi dehydrated appearance, being dark green in color 
Acetone extract Very viscous, sticky consistency, being golden-green in color 
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Figure 5.1: G. incanum 
infusion (left) and aqueous 
extract (right) after freeze 
drying. 
Figure 5.2: G. incanum methanol- (left) 
and acetone extract (right) after 
evaporation of extractants. 
Figure 48: A. afra infusion 
(left) and aqueous extract 
(right) after freeze drying. 
Figure 5.4: A. afra methanol- (left) and 
acetone extract (right) after evaporation of 
extractants. 
Figure 5.3: A. afra infusion (left) 
and aqueous extract (right) after 
freeze drying. 
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All crude extracts were re-dissolved in DMSO after having been taken to 
dryness, either in vacuo as was the case with infusions and aqueous extracts, or 
through evaporation of the extractant in a laminar air flow cabinet using a hot 
water bath at 40°C over night.  Due to variation in the solvating capability of 
DMSO on the various extracts, different amounts of DMSO had to be used, 
depending on the solvability of the respective extracts in DMSO.  As indicated in 
Section 5.2.1., variation also existed between the amounts of extracts retrieved 
during the three rounds of plant extractions.  Thus the amount of DMSO used to 
dissolve any specific extract also varied during the three respective rounds.  The 
aqueous extract of A. absinthium proved to be the least soluble in DMSO, while   
the infusion extract of G. incanum was the most soluble in DMSO. 
 
 
Figure 5.5: A. absinthium infusion 
(left) and aqueous extract (right) 
after freeze drying. 
Figure 5.6: A. absinthium methanol- (left) 
and acetone extract (right) after 
evaporation of extractants. 
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Figure 5.7: DMSO- dissolved extracts of G. incanum.   
From left to right: infusion extract, aqueous extract, methanol extract, acetone extract. 
Figure 5.8: DMSO- dissolved extracts of A. afra.   
From left to right: Infusion extract, aqueous extract, methanol extract, acetone extract. 
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5.2.3. Inhibition of the growth of various strains of C. albicans, E. coli,  
          P. aeruginosa, E. faecalis, S. aureus and B. cereus by infusions,                
          aqueous-, methanol- and acetone extracts of G. incanum, A. afra  
          and A. absinthium 
 
Infusions, aqueous-, methanol- and acetone extracts of G. incanum, A. afra and 
A. absinthium, respectively, were screened for inhibition of growth of ATCC 
strains and various clinical isolates of Candida albicans, Escherichia coli, 
Pseudomonas aeruginosa, Enterrococcus faecalis, Staphylococcus aureus and 
Bacillus cereus, using the agar dilution method.  All extracts were screened at a 
final concentration of 100 mg extract/ml agar. Three control plates were 
concomitantly run with each round of screening as discussed in Section 4.2.3.2.  
Table 5.6 indicates the final results obtained in the screening of infusions, 
Figure 5.9: DMSO-dissolved extracts of A. absinthium.   
From left to right: Infusion extract, aqueous extract, methanol extract, acetone extract. 
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aqueous-, methanol- and acetone extracts for growth inhibition of various strains 
of C. albicans, E. coli, P. aeruginosa, E. faecalis, S. aureus and B. cereus.  
Where a specific strain of any one of the test organisms was found to be 
resistant to an extract for two out of the three rounds of screening, that specific 
strain was reported as being resistant to inhibition of growth by the relevant 
extract.  Likewise, where a specific strain of any one of the test organisms was 
found to be inhibited by an extract for two out of the three rounds of screening, 
that specific strain was considered to be susceptible to growth inhibition.  
 
During the initial round of antimicrobial screening (August, 2007), strain 7 of P. 
aeruginosa was unavailable, and subsequently omitted from this round.  During 
the second round of screening (January, 2008), strains 5 and 6 of P. aeruginosa 
were found to be non-viable upon subculture, and were subsequently excluded 
from the second and third rounds of screening.  Strain 7 of P. aeruginosa was 
available during the second and third rounds of screening, but was found to be 
contaminated with a Proteus organism.  Thus any results pertaining to this strain 
were not taken into consideration.  Finally, P. aeruginosa (ATCC 27853) was 
found to be infected with a bacteriophage during the third round of antimicrobial 
screening (January, 2008).  It was, however, found to be resistant to inhibition of 
growth by any one of the 12 extracts during the first and second rounds of 
screening, and was subsequently reported in the final results as such.  
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Table 5.6: Susceptibility to growth inhibition of various strains of C. albicans, 
E. coli, P. aeruginosa, E. faecalis, S. aureus and B. cereus to infusions,   
aqueous-, methanol- and acetone extracts of G. incanum, A. afra and A. 
absinthium.  
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C. albicans  
ATCC 66027  + + + + - - + + - - - - - - - 
Clinical 
isolate 2 + + + + - - - + - - - - - - - 
Clinical 
isolate 3 + + + + - - - + - - - - - - - 
Clinical 
isolate 4 + + + + - - - + - - - - - - - 
Clinical 
isolate 5 + + + + - - - + - - - - - - - 
Clinical 
isolate 6 + + + + - - - + - - - - - - - 
Clinical 
isolate 7 + + + + - - - + - - - - - - - 
Clinical 
isolate 8 + + + + - - - + - - - - - - - 
Clinical 
isolate 9 + + + + - - - + - - - - - - - 
Clinical 
isolate 10 + + + + - - - + - - - - - - - 
E. coli  
ATCC 35218 - - - - - - - - - - - - - - - 
Clinical 
isolate 2 - - - - - - - - - - - - - - - 
Clinical 
isolate 3 - - - - - - - - - - - - - - - 
Clinical 
isolate 4 - - - - - - - - - - - - - - - 
Clinical 
isolate 5 - - - - - - - - - - - - - - - 
Clinical 
isolate 6 - - - - - - - - - - - - - - - 
Clinical 
isolate 7 - - - - - - - - - - - - - - - 
Clinical 
isolate 8 - - - - - - - - - - - - - - - 
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E. coli  
Clinical 
isolate 9 - - - - - - - - - - - - - - - 
Clinical 
isolate 10 - - - - - - - - - - - - - - - 
P. 
aeruginosa 
 
ATCC 27853 - - - - - - - - - - - - - - - 
Clinical 
isolate 2 - - - - - - - - - - - - - - - 
Clinical 
isolate 3 - - - - - - - - - - - - - - - 
Clinical 
isolate 4 - - - - - - - - - - - - - - - 
Clinical 
isolate 8 - - - - - - - - - - - - - - - 
Clinical 
isolate 9 - - - - - - - - - - - - - - - 
Clinical 
isolate 10 - - - - - - - - - - - - - - - 
E. faecalis  
ATCC 29212 - - - - - - - - - - - - - - - 
Clinical 
isolate 2 - - - - - - - - - - - - - - - 
Clinical 
isolate 3 - - - - - - - - - - - - - - - 
Clinical 
isolate 4 - - - - - - - - - - - - - - - 
Clinical 
isolate 5 - - - - - - - - - - - - - - - 
Clinical 
isolate 6 - - - - - - - - - - - - - - - 
Clinical 
isolate 7 - - - - - - - - - - - - - - - 
Clinical 
isolate 8 - - - - - - - - - - - - - - - 
Clinical 
isolate 9 - - - - - - - - - - - - - - - 
Clinical 
isolate 10 - - - - - - - - - - - - - - - 
 140 
M
ic
ro
bi
al
 s
tr
ai
n G. incanum A. afra A. absinthium Controls 
In
fu
si
on
 
A
qu
eo
us
  
M
et
ha
no
l  
A
ce
to
ne
  
In
fu
si
on
 
A
qu
eo
us
  
M
et
ha
no
l  
A
ce
to
ne
  
In
fu
si
on
 
A
qu
eo
us
  
M
et
ha
no
l  
A
ce
to
ne
  
C
on
tr
ol
 1
 
C
on
tr
ol
 2
 
C
on
tr
ol
 3
 
S. aureus  
ATCC 43300 + + + - + - + + - - + + - - - 
Clinical 
isolate 2 + + + - + - + + - - + + - - - 
Clinical 
isolate 3 + + + - + - + + - - + + - - - 
Clinical 
isolate 4 + + + - + - + + - - + + - - - 
Clinical 
isolate 5 + + + - + - + + - - + + - - - 
Clinical 
isolate 6 + + + - + - + + - - + + - - - 
Clinical 
isolate 7 + + + - + - + + - - + + - - - 
Clinical 
isolate 8 + + + - + - + + - - + + - - - 
Clinical 
isolate 9 + + + - + - + + - - + + - - - 
Clinical 
isolate 10 + + + - + - + + - - + + - - - 
B. cereus  
ATCC 10876 + + + - + - + + - - + + - - - 
Clinical 
isolate 2 + + + - + - + + - - + + - - - 
Clinical 
isolate 3 + + + - + - + + - - + + - - - 
Clinical 
isolate 4 + + + - + - + + - - + + - - - 
 
+: Inhibition of growth; - : No growth inhibition 
 
Growth inhibition by plant extracts was observed mainly in strains of C. albicans, 
S. aureus and B. cereus, as reflected in Table 5.6.  Strains of S. aureus and B. 
cereus were the most susceptible to inhibition, and had similar inhibition patterns.  
C. albicans consistently exhibited sensitivity to growth inhibition by the G. 
incanum extracts, but was not sensitive to other extracts, with the exception of 
the A. afra acetone extract.   
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All ten strains of C. albicans were sensitive to the infusion, aqueous-, methanol- 
and acetone extracts of G. incanum.  C. albicans ATCC strain 66027 was 
inhibited by the methanol extract of A. afra, while all ten strains were inhibited by 
the A. afra acetone extract.  No inhibition of C. albicans was observed for the 
infusion or aqueous extract of A. afra or for any of the A. absinthium extracts.   
 
All ten strains of S. aureus were sensitive to growth inhibition by eight of the 
twelve extracts tested, including the infusions of G. incanum and A. afra, the 
aqueous extract of G. incanum, the methanol extracts of G. incanum, A. afra and 
A. absinthium and the acetone extracts of A. afra and A. absinthium.  None of the 
S. aureus strains tested exhibited any sensitivity to the acetone extract of G. 
incanum, the aqueous extracts of A. afra and A. absinthium or the infusion of A. 
absinthium.   
 
The four strains of B. cereus exhibited sensitivity to the same extracts as the 
strains of S. aureus.  All four B. cereus strains were sensitive to the infusions of 
G. incanum and A. afra, the aqueous extract of G. incanum, the methanol 
extracts of G. incanum, A. afra and A. absinthium and the acetone extracts of A. 
afra and A. absinthium.  None of the B. cereus strains exhibited any sensitivity to 
the acetone extract of G. incanum, the aqueous extracts of A. afra and A. 
absinthium or the infusion of A. absinthium.   
 
All strains of the test organisms grew on both Control 1 and Control 2 during all 
three rounds of screening and were not inhibited by the addition of DMSO.  
Furthermore, all organisms grew on Control 3, which did not contain any DMSO 
or extract, as expected.  It was noted during the second round of testing 
(January, 2008) that all P. aeruginosa colonies were significantly larger than 
colonies of other organisms on the agar plate containing the A. afra acetone 
extract.  The same observation was made during the second round of testing of 
the effect of the aqueous extract of A. absinthium on S. aureus and B. cereus 
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strains. Bacterial colonies of all the strains of S. aureus and B. cereus appeared 
larger than surrounding colonies on the agar plate containing the A. absinthium 
aqueous extract.  During the third round of screening (January, 2008), P. 
aeruginosa colonies on agar plates containing infusions of A. afra and A. 
absinthium as well as those on the agar plate containing the A. absinthium 
aqueous extract appeared larger than the surrounding colonies.  These results 
were not observed consistently during all three rounds of screening, and were 
thus not considered significant.  However, the possibility of stimulation of growth 
of the various organisms by the corresponding extracts as mentioned above can 
not be excluded. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.10: Inhibition of C. albicans 
by G. incanum infusion (Left: negative 
control, no DMSO; Right: extract). 
Figure 5.11: Inhibition of C. albicans by G. 
incanum aqueous extract (Left: negative 
control, no DMSO; Right: extract).  
Figure 5.12: Inhibition of C. albicans by G. 
incanum methanol extract (Left: negative 
control, no DMSO; Right: extract). 
Figure 5.13: Inhibition of C. albicans by A. 
afra acetone extract (Left: negative control, no 
DMSO; Right: extract). 
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Figure 5.15: Inhibition of S. aureus and B. 
cereus by G. incanum aqueous extract 
(Left: negative control, no DMSO; Right: extract). 
Figure 5.14: Inhibition of S. aureus and 
B. cereus by G. incanum infusion (Left: 
negative control, no DMSO; Right: extract). 
Figure 5.16: Inhibition of S. aureus 
and B. cereus by G. incanum 
methanol extract (Left: negative control, 
no DMSO; Right: extract). 
Figure 5.17: Inhibition of S. aureus and 
B. cereus by A. afra infusion (Left: negative 
control, no DMSO; Right: extract). 
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Figure 5.18: Inhibition of S. aureus and 
B. cereus by A. afra methanol extract 
(Left: negative control, no DMSO; Right: 
extract). 
Figure 5.19: Inhibition of S. aureus and 
B. cereus by A. afra acetone extract 
(Left: negative control, no DMSO; Right: 
extract). 
Figure 5.20: Inhibition of S. aureus and B. 
cereus by A. absinthium acetone extract 
(Left: negative control, no DMSO; Right: extract). 
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5.3. Anticancer activity studies 
 
5.3.1. Percentage yields of dried plant material obtained, and the  
          percentage yields of infusions and crude extracts obtained  
          from G. incanum, A. afra and A. absinthium  
 
The preparation of extracts for use in anticancer studies was slightly adapted 
from the method used during extract preparation for antimicrobial screening with 
regards to the amount of plant material used.  It was estimated that 60 mg of 
each of the crude infusion-, aqueous-, methanol- and acetone extracts of G. 
incanum, A. afra and A. absinthium, respectively, would be required for the 
completion of anticancer studies.  The amount of plant material used and the 
crude extract yields obtained during the preparation of extracts for antimicrobial 
screening was used to approximate the amount of plant material needed to 
obtain 60 mg of each of the respective extracts of the three plants for use in 
anticancer studies.   
 
Preparation of infusions, as well as aqueous-, methanol- and acetone extracts for 
anticancer studies was done as described in Sections 4.3.2.1. and 4.3.2.2., 
respectively.  Table 5.7 reflects the weights of fresh plant material of G. incanum, 
A. afra and A. absinthium, harvested for anticancer studies, as well as the 
weights of plant material after drying and the percentage yields of dried plant 
material obtained.  
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Table 5.7: Percentage yields of plant material obtained after drying, used in the 
preparation of aqueous-, methanol- and acetone- extracts for anticancer studies, 
January 2008 (summer). 
 
Plant Weight of fresh plant 
material before drying 
(gram) 
Weight of dried 
plant material (gram) 
Percentage yield of dried 
plant material (%) 
G. incanum 52.1 16.7 32.2 
A. afra 101.3 26.1 25.8 
A. 
absinthium 
160.6 40.1 25.0 
 
 
Weighing of dried G. incanum plant material indicated a reduction in weight to the 
amount of 35.3 g.  Water constituted approximately 67.9% of the weight of fresh 
G. incanum plant material.  Weighing of dried A. afra plant material indicated a 
reduction in weight of 75.2 g.  Water constituted approximately 74.2% of the 
weight of fresh A. afra plant material.  The weight of A. absinthium plant material 
was reduced by 120.4 g during the drying of fresh plant material, indicating a 
water content of approximately 75.0% in fresh A. absinthium plant material.  After 
freeze drying of infusions and aqueous extracts, and evaporation of methanol- 
and acetone extracts, respectively, the pre-weighed microtubes and glass 
beakers containing the crude extracts of G. incanum, A. afra and A. absinthium 
were weighed again in order to determine the weight of crude extracts obtained.  
Table 5.8 reflects the percentage yields of extracts obtained during the 
preparation of extracts used in anticancer studies.  The weights of the fresh and 
dried plant materials used as well as the weights of extracts after freeze drying 
(infusions and aqueous extracts) and evaporation (methanol- and acetone 
extracts) are indicated in Table 4 in Appendix I. 
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Table 5.8: Percentage yields of extracts obtained after the extract preparation for 
anticancer studies, January 2008. 
 
 
The results presented in Table 5.8. clearly indicate variation in the percentage 
yields of G. incanum extracts obtained during preparation for antimicrobial 
screening compared to the percentage yields of G. incanum extracts obtained 
during preparation for anticancer studies.  The greatest variation exists in the 
percentage yield of methanol extract obtained during the third round of extract 
preparation for antimicrobial screening (January 2008, summer) compared to that 
obtained during extract preparation for anticancer studies (January 2008, 
summer), with an increase of 83.9% extract having been obtained during the 
latter.  Similar results were observed for the methanol extracts prepared during 
the second (September 2007, spring) and first rounds (June 2007, winter) of G. 
incanum extract preparation for antimicrobial screening as compared to the 
methanol extract prepared for anticancer studies (January 2008, summer).  An 
increase of 67.7% of methanol extract obtained was observed during preparation 
for anticancer studies compared to the second round of extract preparation for 
antimicrobial studies (September 2007, spring), while an increase of 53.7% in G. 
incanum methanol extract obtained was observed for extract preparation for 
anticancer studies compared to the initial round of extract preparation for 
antimicrobial screening (June 2007, winter).      
 
The least variation was observed between the third round of acetone extract 
preparation for antimicrobial screening (January 2008, summer) compared to 
Extract Geranium 
 incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Yield % (w/w) Yield % (w/w) Yield % (w/w) 
Infusion (Fresh leaves used) 8.4 3.8 2.4 
Aqueous extract (Dry leaves used) 15.0 11.5 
 
41.9 
Methanol extract (Dry leaves used) 19.5 15.5 28.6 
Acetone extract (Dry leaves used)  4.8 8.0 11.6 
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extract preparation for anticancer studies (January 2008, summer), with 17.4% 
less extract having been obtained during the latter.   
 
Variation also existed in the percentage yields of A. afra extracts obtained during 
preparation for antimicrobial screening compared to the percentage yields of A. 
afra extracts obtained during preparation for anticancer studies.  Interestingly, 
this variation once again occurred mainly between the methanol extracts of A. 
afra, as was the case with G. incanum.  Increases of 23.3%, 50.7% and 52.5% of 
A. afra methanol extract obtained during extract preparation for anticancer 
studies was observed, compared to amounts obtained for initial (June 2007, 
winter), second (September 2007, spring) and third rounds (January 2008, 
summer) of antimicrobial screening extract preparation, respectively.  The least 
variation was observed during the second round of A. afra infusion preparation 
(September 2007, spring) for antimicrobial screening compared to A. afra 
infusion preparation for anticancer studies (January 2008, summer), with an 
increase of only 1.6% extract obtained during the latter.   
 
Overall, the greatest variation in the amount of extracts obtained was observed 
for the aqueous- and methanol extracts of A. absinthium.  Increases of 78.6%, 
81.9% and 75.1% of A. absinthium aqueous extract, as well as increases of 
65.1%, 73.2% and 65.2% of A. absinthium methanol extract obtained during 
extract preparation for anticancer studies was observed (January 2008, 
summer), compared to amounts obtained for initial (June 2007, winter), second 
(September 2007, spring) and third rounds (January 2008, summer) of 
antimicrobial screening extract preparation, respectively.  The least variation was 
observed for the first round of A. absinthium infusion preparation for antimicrobial 
screening (June 2007, winter) compared to A. afra infusion preparation for 
anticancer studies (January 2008, summer), with a decrease of only 2.9% extract 
obtained during the latter.   
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Figure 5.21 is a graphical representation of the variation in extract yields 
obtained during the first (June 2007, winter), second (September 2007, spring) 
and third rounds (January 2008, summer) of extract preparation for antimicrobial 
screening, referred to as the first, second and third rounds respectively, as well 
as extract preparation for anticancer studies, referred to as the fourth round of 
extract preparation (January 2008, summer).   
 
Variation in the % extract yields obtained during the various rounds of 
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Figure 5.21:  Variation in the percentage extract yields obtained during the 
three rounds of extract preparation for antimicrobial screening, referred to as 
the first, second and third rounds, respectively, and extract preparation for 
anticancer studies, referred to as the fourth round. 
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5.3.2. Cytotoxicity of various extracts in MCF-7, HT-29 and HeLa cell  
          lines  
           
For the purpose of the current study, infusions, aqueous-, methanol- and acetone 
extracts of G. incanum, A. afra and A. absinthium were prepared and screened 
against MCF-7 cells, HT-29 cells and HeLa cells at concentrations ranging from 
500 μg/ml (0.25% DMSO) to as little as 0.781 μg/ml (0.25% DMSO) for toxicity or 
inhibition of growth towards the aforementioned cell lines.  The MTT assay, as 
described in Section 4.3.4., was used to determine the percentage cell viability 
after cells were treated with the various extracts for 48 hours.  All three cell lines 
were exposed to cisplatin, constituting the positive control.  Screening of all the 
extracts on the three respective cell lines was done in triplicate, with cell viability, 
as well as inhibition of cell growth/cell death being expressed as a mean 
percentage ± standard deviation (SD) of the mean negative control absorbance.  
This data was analysed using GraphPad Prism® (San Diego, USA) and used to 
construct dose response curves of the various extracts on the respective cell 
lines.  Where extracts appeared to significantly inhibit cell growth or induce cell 
death, screening of the specific extract on the respective cell line was repeated 
using lower concentrations of the extract. GraphPad Prism® was used to perform 
regression analysis for each of the extracts as well as the positive control on the 
three cell lines in order to determine IC50 values, the concentration of each 
extract as well as cisplatin, at which 50% of the cells were inhibited.  When the 
coefficient of correlation (r2) was not ≥ 0.95 for any of the regression analyses, 
the results were considered insignificant and screening of the specific extract on 
the relevant cell line was repeated.    
 
Three different sets of graphs were constructed with the data obtained from the 
aforementioned procedures.  Firstly, graphs comparing the serially diluted 
infusions, aqueous-, methanol- and acetone extracts of each of the respective 
three plants against each of the three respective cell lines were constructed in 
order to visually determine which extract of each of the respective plants 
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exhibited the strongest inhibitory activity against each of the three cell lines.  A 
second set of graphs individually comparing only one serially diluted extract of 
each of the three respective plants on all three of the cell lines was constructed in 
order to visually determine which of the three cell lines was most susceptible to 
inhibition by a specific extract.  Thirdly, a graph comparing serially diluted 
cisplatin against all three cell lines was constructed in order to visually determine 
which cell line was most susceptible to inhibition by cisplatin. 
 
 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.22 indicates G. incanum acetone extract to be considerably less toxic 
towards MCF-7 cells than the infusion, aqueous- or methanol extracts of the 
same plant (Figure 5.22, blue plot versus orange-, green- and purple plots, 
respectively).  The latter three extracts exhibited a similar degree of toxicity in 
MCF-7 cells, however, in order to determine their respective IC50 values, 
regression analysis was done, and the results are presented in Table 5.9. 
 
 
Figure 5.22: Comparison of inhibitory activity of G. incanum 
infusion, aqueous-, methanol- and acetone- extracts in MCF-7 
cells.   
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Figures 5.23 and 5.24 allow the comparison of the toxicity of the four G. incanum 
extracts on HT-29 cells and HeLa cells, respectively.  The infusion and aqueous 
extract of G. incanum appeared to be more toxic in HT-29 cells, with the aqueous 
extract showing the highest degree of toxicity (Figure 5.23, orange plot), as 
Figure 5.23: Comparison of inhibitory activity of G. incanum infusion, 
aqueous-, methanol- and acetone extracts in HT-29 cells.   
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Figure 5.24: Comparison of inhibitory activity of G. incanum infusion, 
aqueous-, methanol- and acetone extracts in HeLa cells.   
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compared to the methanol- and acetone extracts (Figure 5.23, blue- and purple 
plots, respectively), which both had higher IC50 values and thus less toxicity 
(Table 5.9).  With regard to toxicity in HeLa cells, the methanol extract of G. 
incanum showed the highest degree of toxicity (Figure 5.24, blue plot), followed 
by the aqueous extract (Figure 5.24, purple plot).  The infusion was slightly less 
toxic to HeLa cells (Figure 5.24, green plot), with HeLa cells being the least 
susceptible to toxicity by the acetone extract (Figure 5.24, red plot).  IC50 values 
were calculated using nonlinear regression analysis, and the results are 
presented in Table 5.9, showing this trend. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.25: Comparison of inhibitory activity of A. afra infusion 
and aqueous extract in MCF-7 cells.   
 
Figure 5.26: Comparison of inhibitory activity of A. afra methanol- 
and acetone extracts in MCF-7 cells.   
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Figures 5.25 and 5.26 respectively show the toxicities of A. afra infusion (Figure 
5.25, blue plot) and aqueous extract (Figure 5.25, red plot), as well as the 
toxicities of A. afra methanol- and acetone extracts in MCF-7 cells (Figure 5.26, 
green- and blue plots, respectively).  The two graphs were not combined to allow 
the various plots to be distinguishable from each other.  Compared to the infusion 
and aqueous extract (Figure 5.25), the methanol- and acetone extracts of A. afra 
were significantly more toxic to MCF-7 cells (Figure 5.26), with IC50 values of the 
methanol- and acetone extracts being between 0 µg/ml and 25 µg/ml, while the 
IC50 values of the infusion and aqueous extract were between 50 µg/ml and 100 
µg/ml (Table 5.9). 
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Figure 5.27: Comparison of inhibitory activity of A. afra infusion and 
aqueous extract in HT-29 cells.   
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Figures 5.27 and 5.28 respectively show the toxicities of A. afra infusion (Figure 
5.27, green plot) and aqueous extract (Figure 5.27, pink plot), as well as the 
toxicities of A. afra methanol- and acetone extracts in HT-29 cells (Figure 5.28, 
turquoise- and orange plots, respectively).  The two graphs were not combined to 
allow the various plots to be distinguishable from each other.  Compared to the 
infusion and aqueous extract (Figure 5.27), the methanol- and acetone extracts 
of A. afra were significantly more toxic (Figure 5.28), as was the case with MCF-7 
cells.  IC50 values of the methanol- and acetone extracts ranged between 0 µg/ml 
and 25 µg/ml, while the IC50 values of the infusion and aqueous extract ranged 
between 50 µg/ml and 100 µg/ml (Table 5.9). 
 
 
 
 
 
 
 
Figure 5.28: Comparison of inhibitory activity of A. afra methanol- and 
acetone extracts in HT-29 cells.   
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Figure 5.29: Comparison of inhibitory activity of A. afra infusion and 
aqueous extract in HeLa cells. 
 
Figure 5.30: Comparison of inhibitory activity of A. afra methanol- and 
acetone extracts in HeLa cells.   
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Figures 5.29 and 5.30 respectively show the toxicities of A. afra infusion (Figure 
5.29, green plot) and aqueous extract (Figure 5.30, red plot), as well as the 
toxicities of A. afra methanol- and acetone extracts in HeLa cells (Figure 5.30, 
maroon- and purple plots, respectively).  The A. afra methanol- and acetone 
extracts showed a significantly higher degree of toxicity in HeLa cells (Figure 
5.30), as was the case with MCF-7 cells (Figure 5.26) and HT-29 cells (Figure 
5.28).  Of the four A. afra extracts, the acetone extract appeared to have the 
highest degree of toxicity in HeLa cells, with the lowest IC50, followed by the 
methanol extract (Table 5.9).  The infusion showed the third highest degree of 
toxicity in HeLa cells, with the aqueous extract having been the least toxic of the 
four (Table 5.9).  In general, it would appear that the methanol- and acetone 
extracts of A. afra are more toxic in all three cell lines tested as compared to the 
infusion and aqueous extract, with the acetone extract being the most toxic.  
MCF-7 cells appear to be the most susceptible to toxicity by the acetone extract, 
having had the lowest IC50 of the three cell lines tested (Table 5.9).   
 
 
 
 
 Figure 5.31: Comparison of inhibitory activity of A. absinthium infusion 
and aqueous extract in MCF-7 cells.   
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Figures 5.31 and 5.32 respectively show the toxicities of A. absinthium infusion 
(Figure 5.31, green plot) and aqueous extract (Figure 5.31, blue plot), as well as 
the toxicities of A. absinthium methanol- and acetone extracts in MCF-7 cells 
(Figure 5.32, green- and blue plots, respectively).  The A. absinthium methanol- 
and acetone extracts showed a degree of toxicity towards MCF-7 cells, with IC50 
values occurring between 0 µg/ml and 25 µg/ml (Table 5.9), which was more 
significant than that shown by the infusion and aqueous extract, which had IC50 
values between 25 µg/ml and 250 µg/ml (Table 5.9). 
 
 
 
 
 
 
 
 
 
Figure 5.32: Comparison of inhibitory activity of A. absinthium 
methanol- and acetone- extracts in MCF-7 cells.   
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Figures 5.33 and 5.34 respectively show toxicity of the four A. absinthium 
extracts on HT-29 cells and HeLa cells.  The methanol- and acetone extracts 
showed the highest degree of toxicity in both HT-29 cells (Figure 5.33, purple- 
and green plots, respectively) and HeLa cells (Figure 5.34, purple- and green 
plots, respectively), as was the case with the A. afra methanol- and acetone 
extracts in all three cell lines (Figures 5.26, 5.28 and 5.30), as well as the A. 
Figure 5.33: Comparison of inhibitory activity of A. absinthium infusion, 
aqueous-, methanol- and acetone- extracts in HT-29 cells.   
 
Figure 5.34: Comparison of inhibitory activity of A. absinthium infusion, 
aqueous-, methanol- and acetone- extracts in HeLa cells. 
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absinthium methanol- and acetone extracts in MCF-7 cells (Figure 5.32, green- 
and blue plots, respectively).  Thus it would appear that all three cell lines are 
more susceptible to the methanol- and acetone extracts of A. afra and A. 
absinthium as compared to their respective infusions and aqueous extracts.  With 
regard to the A. absinthium extracts screened against HT-29 cells, the acetone 
extract showed the highest degree of toxicity with the lowest IC50, followed by the 
methanol extract with a higher IC50 (Table 5.9).  The aqueous extract showed a 
higher degree of toxicity in HT-29 cells as compared to the infusion, which 
appeared to have been the least toxic (Table 5.9).  With regard to the effects of 
A. absinthium extracts in HeLa cells, the methanol extract showed the highest 
degree of toxicity with the lowest IC50, followed by the acetone extract with a 
slightly higher IC50 (Table 5.9).  The infusion showed a higher degree of toxicity in 
HT-29 cells as compared to the aqueous extract, which appeared to have been 
the least toxic with the highest IC50 value (Table 5.9).  Figures 5.35 to 5.46 are 
comparisons of the serially diluted individual extracts of each of the three plants 
against all three cell lines, which were prepared in order to visually determine 
which of the three cell lines was most susceptible to inhibition by a specific 
extract.  
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Figure 5.35: Comparison of the toxicity of G. incanum infusion in 
MCF-7, HT-29 and HeLa cells. 
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Figure 5.37: Comparison of the toxicity of G. incanum methanol 
extract in MCF-7, HT-29 and HeLa cells. 
Figure 5.36: Comparison of the toxicity of G. incanum aqueous 
extract in MCF-7, HT-29 and HeLa cells. 
Toxicity of G. incanum aqueous extract on MCF-7, HT-29 & HeLa
0 100 200 300 400 500 600
0
10
20
30
40
50
60
70
80
90
100
110
MCF-7
HT-29
HeLa
Concentration (ug/ml)
Pe
rc
en
ta
ge
 c
el
l v
ia
bi
lit
y
(%
)
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Figures 5.35 to 5.38 show the susceptibility of MCF-7 cells, HT-29 cells and 
HeLa for the infusion, aqueous-, methanol- and acetone extract of G. incanum, 
respectively.  In each of the four cases the HeLa cell line consistently showed the 
highest sensitivity for each of the four G. incanum extracts (Figure 5.35, green 
plot; Figure 5.36, brown plot; Figure 5.37, orange plot; Figure 5.38, purple plot), 
having the lowest IC50 values as compared to those for MCF-7 cells and HeLa 
cells (Table 5.9).  MCF-7 cells appeared to have had the second highest degree 
of sensitivity for each of the four G. incanum extracts (Figure 5.35, orange plot; 
Figure 5.36, blue plot; Figure 5.37, green plot; Figure 5.38, blue plot), while HT-
29 cells appeared to have been the least sensitive of the three cell lines for any 
of the four G. incanum extracts (Figure 5.35, blue plot; Figure 5.36, maroon plot; 
Figure 5.37, blue plot; Figure 5.38, green plot). 
Figure 5.38: Comparison of the toxicity of G. incanum acetone extract 
in MCF-7, HT-29 and HeLa cells. 
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Figure 5.39: Comparison of the toxicity of A. afra infusion in MCF-7, 
HT-29 and HeLa cells. 
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Figure 5.40: Comparison of the toxicity of A. afra aqueous extract in 
MCF-7, HT-29 and HeLa cells. 
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Figure 5.41: Comparison of the toxicity of A. afra methanol extract in 
MCF-7, HT-29 and HeLa cells. 
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Figure 5.42: Comparison of the toxicity of A. afra acetone extract in 
MCF-7, HT-29 and HeLa cells. 
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Figures 5.39 to 5.42 show the susceptibility of MCF-7 cells, HT-29 cells and 
HeLa cells towards the infusion, aqueous-, methanol- and acetone extract of A. 
afra, respectively.   
 
Unlike the case with G. incanum extracts (Figure 5.35, orange plot; Figure 5.36, 
blue plot; Figure 5.37, green plot; Figure 5.38, blue plot), MCF-7 cells appeared 
to show the highest sensitivity towards each of the four A. afra extracts (Figure 
5.39, pink plot; Figure 5.40, blue plot; Figure 5.41, blue plot; Figure 5.42, green 
plot), having the lowest IC50 values as compared to those for HT-29 cells and 
HeLa cells (Table 5.9).  In the case of the A. afra infusion, HeLa cells (Figure 
5.39, orange plot) were more susceptible to growth inhibition as compared to HT-
29 cells (Figure 5.39, yellow plot), with the infusion showing a lower IC50 for HeLa 
cells compared to HT-29 cells (Table 5.9).  In the case of the A. afra aqueous 
extract, HT-29 cells (Figure 5.40, purple plot) were significantly more susceptible 
to growth inhibition compared to HeLa cells (Figure 5.40, orange plot), with the 
aqueous extract showing an IC50 for HeLa cells approximately double that 
showed for HT-29 cells (Table 5.9).   
 
HT-29 cells also showed a lower IC50 when treated with the A. afra methanol 
extract (Figure 5.41, yellow plot) as compared to HeLa cells (Figure 5.41, purple 
plot), indicating HT-29 cells to be more sensitive to growth inhibition by the 
methanol extract than HeLa cells (Table 5.9).  Finally, HeLa cells showed an IC50 
after treatment with the A. afra acetone extract (Figure 5.42, purple plot) which 
was only slightly lower than the IC50 showed for HT-29 cells (Figure 5.42, yellow 
plot), indicating HeLa cells to be slightly more sensitive to growth inhibition by the 
acetone extract than HT-29 cells (Table 5.9).  
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Figure 5.43: Comparison of the toxicity of A. absinthium infusion in 
MCF-7, HT-29 and HeLa cells. 
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Figure 5.44: Comparison of the toxicity of A. absinthium aqueous 
extract in MCF-7, HT-29 and HeLa cells. 
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Figure 5.45: Comparison of the toxicity of A. absinthium methanol 
extract in MCF-7, HT-29 and HeLa cells. 
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Figure 5.46: Comparison of the toxicity of A. absinthium acetone 
extract in MCF-7, HT-29 and HeLa cells. 
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Figures 5.43 to 5.46 show the susceptibility of MCF-7 cells, HT-29 cells and 
HeLa cells towards the infusion, aqueous-, methanol- and acetone extract of A. 
absinthium, respectively. 
 
MCF-7 cells appeared to exhibit the highest sensitivity towards three of the four 
A. absinthium extracts, being the infusion (Figure 5.43, red plot), methanol- 
(Figure 5.45, green plot) and acetone extracts (Figure 5.46, blue plot).  In the 
case of the aqueous extract, HT-29 cells (Figure 5.44, turquoise plot) showed the 
highest degree of sensitivity as compared to MCF-7 cells (Figure 5.44, blue plot) 
and HeLa cells (Figure 5.44, red plot).  HT-29 cells showed the second highest 
degree of sensitivity towards the infusion of A. absinthium (Figure 5.43, green 
plot), with an IC50 lower than that for HeLa cells, indicating the latter to be the 
least sensitive to the infusion (Table 5.9).  MCF-7 cells showed the second 
highest degree of sensitivity towards the aqueous extract of A. absinthium 
(Figure 5.44, blue plot), with an IC50 lower than that for HeLa cells, indicating 
HeLa cells to be the least sensitive to inhibition by the aqueous extract (Table 
5.9). 
 
With respect to the methanol extract of A. absinthium, HeLa cells (Figure 5.45, 
purple plot) showed the second highest degree of sensitivity with an IC50 lower 
than that for HT-29 cells (Figure 5.45, orange plot), which appeared to be the 
least sensitive of the three cell lines to growth inhibition by the A. absinthium 
methanol extract (Table 5.9).  Finally, in the case of the A. absinthium acetone 
extract, HT-29 cells (Figure 5.46, pink plot) showed the second highest degree of 
sensitivity with an IC50 lower than that for HeLa cells (Figure 5.46, orange plot), 
which appeared to be the least sensitive of the three cell lines to growth inhibition 
by the A. absinthium acetone extract (Table 5.9). 
 
        
 
 
 169 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.47 shows the comparison of the toxicity of serially diluted cisplatin, a 
known anticancer agent, in MCF-7 cells, HT-29 cells and HeLa cells.  Cisplatin 
showed a similar degree of toxicity in both HT-29 cells (Figure 5.47, purple plot) 
and HeLa cells (Figure 5.47, orange plot), with IC50 values ranging between 0 
µg/ml and 10 µg/ml (Figure 5.47).  MCF-7 cells, on the other hand, appeared to 
be slightly less susceptible to cisplatin toxicity (Figure 5.47, turquoise plot), with 
an IC50 occurring in the range of 10 µg/ml to 20 µg/ml (Figure 5.47). 
 
Table 5.9 is a summary of the various IC50 values calculated using nonlinear 
regression analysis of the toxicity of the infusions, aqueous-, methanol- and 
acetone extracts of G. incanum, A. afra and A. absinthium in MCF-7 cells, HT-29 
cells and HeLa cells.  The IC50 for the extract of each of the respective plants 
which exhibited the strongest inhibitory activity against a specific cell line is 
indicated with a * symbol, while the IC50 for the cell line most susceptible to each 
one of the four extracts of each plant is indicated with a # symbol.    
 
 
 
 
Figure 5.47: Toxicity of Cisplatin on MCF-7, HT-29 and HeLa cells. 
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Table 5.9: IC50 values as determined by nonlinear regression analysis of the 
MCF-7 cells, HT-29 cells and HeLa cells after respective treatment with the 
infusions, aqueous-, methanol- and acetone- extracts of G. incanum, A. afra and 
A. absinthium for 48 hours.  The standard deviation, r2 value and 95% confidence 
interval for each IC50 is also indicated. 
 
Pl
an
t 
ex
tr
ac
t 
Cells 
MCF-7 HT-29 HeLa 
IC50  ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
IC50  ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
IC50 ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
G. 
incanum 
infusion 
66.25± 
1.03 
r2=0.99; 
60.95 to 
72.02 
77.97± 
1.06 
r2=0.96; 
69.12 to 
87.95 
#26.74± 
1.07 
r2=0.96; 
23.03 to 
31.05 
G. 
incanum 
aqueous 
extract 
27.11± 
1.11 
r2=0.96; 
20.82 to 
35.29 
*53.38± 
1.06  
r2=0.95; 
46.75 to 
60.96 
#17.87± 
1.07  
r2=0.96; 
15.55 to 
20.53 
G. 
incanum 
methanol 
extract 
*19.16± 
1.10  
r2=0.95; 
15.25 to 
24.07 
147.70± 
1.08  
r2=0.95; 
123.9 to 
176.10 
*#13.71± 
1.06  
r2=0.96; 
12.04 to 
15.61 
G. 
incanum 
acetone 
extract 
183.30± 
1.08  
r2=0.96; 
155.50 to 
216.00 
198.50± 
1.11  
r2=0.95; 
156.70 to 
251.50 
#127.80± 
1.06 
r2=0.96; 
111.40 to 
146.60 
 
A. afra 
infusion 
54.81± 
1.11 
r2=0.95; 
43.64 to 
68.84 
90.47± 
1.11 
r2=0.98; 
71.56 to 
114.40 
#38.31± 
1.10 
r2=0.97; 
29.80 to 
49.24 
A. afra 
aqueous 
extract 
#87.69± 
1.09  
r2=0.95; 
72.04 to 
106.70 
136.6± 
1.09 
r2=0.95; 
109.70 to 
170.10 
272.80± 
1.04 
r2=0.95; 
249.40 to 
298.50 
A. afra 
methanol 
extract 
#8.36± 
1.08 
r2=0.97; 
7.08 to 
9.88 
15.80± 
1.04 
r2=0.97; 
14.43 to 
17.30 
16.68± 
1.06 
r2=0.97; 
14.60 to 
19.04 
A. afra 
acetone 
extract 
*#2.65± 
1.05 
r2=0.97; 
2.39 to 
2.94  
*6.98± 
1.06  
r2=0.99; 
6.07 to 
8.02 
*6.54± 
1.06 
r2=0.96; 
5.79 to 
7.38 
A. 
absinthium 
infusion 
#37.33± 
1.04 
r2=0.98; 
34.03 to 
40.95 
54.65± 
1.05 
r2=0.97; 
49.01 to 
60.93 
95.98± 
1.06 
r2=0.95; 
84.83 to 
108.60 
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Pl
an
t 
ex
tr
ac
t 
Cells 
MCF-7 HT-29 HeLa 
IC50  ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
IC50  ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
IC50 ± 
Standard 
Deviation 
(µg/ml) 
r2; 95% 
confidence 
interval 
(µg/ml) 
A. 
absinthium 
aqueous 
extract 
244.90± 
1.03 
r2=0.98; 
230.20 to 
260.60 
#37.82± 
1.36 
r2=0.97; 
18.31 to 
78.14 
285.30± 
1.03 
r2=0.97; 
265.80 to 
306.20 
A. 
absinthium 
methanol 
extract 
#14.31± 
1.05 
r2=0.97; 
12.74 to 
16.08 
33.16± 
1.02 
r2=0.99; 
31.50 to 
34.92 
*20.96± 
1.07 
r2=0.96; 
18.10 to 
24.28 
A. 
absinthium 
acetone 
extract 
*#6.11± 
1.10 
r2=0.95; 
5.00 to 
7.45 
*12.29± 
1.05 
r2=0.97; 
10.96 to 
13.78 
26.86± 
1.07 
r2=0.96; 
22.99 to 
31.38 
 
*: IC50 for the extract of a specific plant exhibiting the strongest inhibitory activity 
against a specific cell line. 
#: IC50 for the cell line most susceptible to each individual extract of the three test 
plants.  
 
 
 
Figure 5.48 is a graphical representation of the IC50 values and their respective 
SD values as indicated in Table 5.9. 
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IC50 values of the extracts of G. incanum, A. afra  and A. 
absinthium  for MCF-7 cells, HT-29 cells and HeLa cells
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Of the four G. incanum extracts used, the methanol extract appeared to have had 
the highest degree of toxicity in MCF-7 cells (Figure 5.48, G. incanum methanol 
green plot), with the lowest IC50 at 19.16 ± 1.10 µg/ml (Table 5.9).  The aqueous 
extract showed the second highest degree of toxicity towards MCF-7 cells 
(Figure 5.48, G. incanum aqueous green plot), with an IC50 of 27.11 ± 1.11 µg/ml 
(Table 5.9), followed by the infusion (Figure 5.48, G. incanum infusion green 
plot).  It would seem that the acetone extract showed the lowest degree of 
toxicity towards MCF-7 cells (Figure 5.48, G. incanum acetone green plot), with 
an IC50 of 183.30 ± 1.08 µg/ml, which is considerably higher than that obtained 
for the previous three extracts (Table 5.9).  
Figure 5.48: Graphical representation of the differences between IC50 
values of the different plant extracts for MCF-7 cells, HT-29 cells and 
HeLa cells. 
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The degree and order of toxicity of the four G. incanum extracts changed 
considerably in the HT-29 cells, compared to MCF-7 cells (Figure 5.48).  The 
aqueous extract showed the highest degree of toxicity in HT-29 cells (Figure 
5.48, G. incanum aqueous orange plot), with an IC50 of 53.38 ± 1.06 µg/ml (Table 
5.9), followed by the infusion (Figure 5.48, G. incanum infusion orange plot), with 
an IC50 of 77.97 ± 1.06 µg/ml (Table 5.9).  The methanol extract showed the third 
highest degree of toxicity (Figure 5.48, G. incanum methanol orange plot), with 
an IC50 of 147.70 ± 1.08 µg/ml (Table 5.9), followed by the lowest degree of 
toxicity showed by the acetone extract (Figure 5.48, G. incanum acetone orange 
plot), as was the case with MCF-7 cells, at an IC50 of 198.50 ± 1.11 µg/ml (Table 
5.9).   
 
The same toxicity pattern was observed in the case of HeLa cells as was seen 
with MCF-7 cells (Figure 5.48).  The methanol extract of G. incanum showed the 
highest degree of toxicity towards HeLa cells (Figure 5.48, G. incanum methanol 
blue plot), with an IC50 of 13.71 ± 1.06 µg/ml (Table 5.9), followed by the aqueous 
extract (Figure 5.48, G. incanum aqueous blue plot), with an IC50 of 17.87 ± 1.07 
µg/ml (Figure 5.48).  The infusion showed the third highest degree of toxicity in 
HeLa cells (Figure 5.48, G. incanum infusion blue plot), followed by the acetone 
extract (Figure 5.48, G. incanum acetone blue plot) with the lowest IC50 (Table 
5.9).  The methanol extract of G. incanum had the highest degree of toxicity in 
two of the three cell lines, being MCF-7 cells and HeLa cells (Figure 5.48, G. 
incanum methanol green- and blue plots, respectively), with the lowest overall 
IC50 occurring for HeLa cells treated with the methanol extract (Table 5.9).  The 
aqueous extract showed the second highest degree of toxicity in two of the three 
cell lines, once again MCF-7 cells and HeLa cells (Figure 5.48, G. incanum 
aqueous green- and blue plots, respectively).  The infusion showed the third 
highest degree of toxicity in the case of MCF-7 cells and HeLa cells (Figure 5.48, 
G. incanum infusion green- and blue plots, respectively), while being the second 
most toxic extract tested against HT-29 cells (Figure 5.48, G. incanum infusion 
orange plot).  The acetone extract of G. incanum appeared to show the lowest 
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degree of toxicity in all three cell lines, as compared to the other three extracts 
(Figure 5.48).  Of the MCF-7 cells, HT-29 cells and HeLa cells screened, the 
latter showed the highest degree of susceptibility to toxicity induced by the G. 
incanum infusion, aqueous-, methanol- and acetone extracts (Figure 5.48).   
 
Of the four A. afra extracts used, the acetone extract appeared to have had the 
highest degree of toxicity in MCF-7 cells, HT-29 cells and HeLa cells.  In the case 
of MCF-7 cells (Figure 5.48, A. afra acetone green plot), the acetone extract 
showed an IC50 of 2.65 ± 1.05 µg/ml (Table 5.9).  In the case of HT-29 cells 
(Figure 5.48, A. afra acetone orange plot) the acetone extract had an IC50 of 6.98 
± 1.06 µg/ml (Table 5.9), and an IC50 of 6.54 ± 1.06 µg/ml (Table 5.9) was 
calculated in the case of HeLa cells (Figure 5.48, A. afra acetone blue plot).  The 
methanol extract showed the second highest degree of toxicity towards all three 
cell lines, with an IC50 of 8.36 ± 1.08 µg/ml for MCF-7 cells, 15.80 ± 1.04 µg/ml for 
HT-29 cells and 16.68 ± 1.06 µg/ml for HeLa cells (Table 5.9), followed by the 
infusion and aqueous extracts showing the third and fourth highest degrees of 
toxicity, in that order (Figure 5.48).  In summary, the acetone extract produced 
the highest degree of toxicity in all three cell lines screened, followed by the 
methanol extract, infusion and aqueous extract, in that order.  Of the MCF-7 
cells, HT-29 cells and HeLa cells screened, HeLa cells showed the highest 
degree of susceptibility to toxicity induced by the A. afra infusion, while MCF-7 
cells showed the highest degree of susceptibility to toxicity by the aqueous-, 
methanol- and acetone extracts.   
 
Of the four A. absinthium extracts screened, the acetone extract appeared to 
have had the highest degree of toxicity in MCF-7 cells (Figure 5.48, A. 
absinthium acetone green plot), with the lowest IC50 at 6.11 ± 1.10 µg/ml (Table 
5.9).  The methanol extract showed the second highest degree of toxicity in 
MCF-7 cells (Figure 5.48, A. absinthium methanol green plot), with an IC50 of 
14.31 ± 1.05 µg/ml (Table 5.9), followed by the infusion (Figure 5.48, A. 
absinthium infusion green plot) with an IC50 of 37.33 ± 1.04 µg/ml (Table 5.9).  
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The aqueous extract showed the lowest degree of toxicity in MCF-7 cells (Figure 
5.48, A. absinthium aqueous green plot), with an IC50 of 244.90 ± 1.03 µg/ml 
(Table 5.9), which is considerably higher than that obtained for the previous three 
extracts.  
 
As was the case with G. incanum extracts, the degree and order of toxicity 
shown by the four A. absinthium extracts varied in HT-29 cells, as compared to 
MCF-7 cells.  The acetone- and methanol extracts once again showed the 
highest and second highest degrees of toxicity in HT-29 cells (Figure 5.48, A. 
absinthium methanol and acetone orange plots, respectively), with IC50 values of 
12.29 ± 1.05 µg/ml and 33.26 ± 1.02 µg/ml, respectively (Table 5.9).  However, 
unlike as was the case with MCF-7 cells, the aqueous extract of A. absinthium 
showed the third highest degree of toxicity in HT-29 cells (Figure 5.48, A. 
absinthium aqueous orange plot), with an IC50 of 37.82 ± 1.36 µg/ml (Table 5.9), 
followed by the infusion being the least toxic in HT-29 cells (Figure 5.48, A. 
absinthium infusion orange plot), with an IC50 of 54.65 ± 1.05 µg/ml (Table 5.9).   
 
Finally, in the case of HeLa cells, the A. absinthium methanol extract showed the 
highest degree of toxicity of the four A. absinthium extracts tested (Figure 5.48, 
A. absinthium methanol blue plot), with an IC50 of 20.96 ± 1.07 µg/ml (Table 5.9), 
followed by the acetone extract showing the second highest degree of toxicity 
(Figure 5.48, A. absinthium acetone blue plot), with an IC50 of 26.86 ± 1.07 µg/ml 
(Table 5.9).  The infusion and aqueous extract respectively showed the third and 
fourth highest degrees of toxicity in HeLa cells (Figure 5.48, A. absinthium 
infusion and aqueous blue plots, respectively).  In summary, the acetone extract 
of A. absinthium showed the highest degree of toxicity in two of the three cell 
lines, being MCF-7 cells and HT-29 cells (Table 5.9).  The methanol extract 
showed the second highest degree of toxicity in two of the three cell lines, once 
again MCF-7 cells and HT-29 cells (Table 5.9), while showing the highest degree 
of toxicity in one cell line, being HeLa cells (Table 5.9).  MCF-7 cells were the 
most susceptible to three of the four A. absinthium extracts screened, being the 
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infusion, methanol- and acetone- extracts, while HT-29 cells appeared to be the 
most susceptible to toxicity induced by the aqueous extract (Table 5.9).     
 
 
 
5.3.3. Determination of the mode of cell death induced by A. afra  
          acetone extract in MCF-7 cells by means of fluorescence microscopy 
 
 
As previously mentioned, the induction of apoptosis in malignant cells is the 
mechanism of action of many anticancer agents.  Thus it would be desirable for a 
plant extract showing toxicity in malignant cells to induce apoptosis in these cells 
rather than necrosis. 
 
For the purpose of this study, it was decided to investigate the mechanism of cell 
death, i.e. apoptosis versus necrosis, of that plant extract which showed the 
highest degree of toxicity towards a specific cell line, in this case the toxicity of 
the A. afra acetone extract in MCF-7 cells, by exposing MCF-7 cells for 48 hours 
to the IC50 of the A. afra acetone extract for MCF-7 cells (2.65 ± 1.05 µg/ml), as 
discussed in Section 4.3.5.1.  MCF-7 cells treated with cisplatin at a 
concentration of 10 µM for 48 hours, and MCF-7 cells grown in RPMI-1640 
media lacking extract or cisplatin, served as positive- and negative controls, 
respectively, while MCF-7 permeabilised with 1:1 methanol:acetone dilution was 
used to establish method validity and accuracy.  Two fluorescent dyes, DAPI and 
PI, were used separately to stain MCF-7 cells treated with the A. afra acetone 
extract, as well as the MCF-7 cells of the positive control, negative control and 
method validation control, as described in Section 4.3.5.1.  Fixed and 
permeabilised cells were finally observed under a fluorescent microscope for 
staining patterns morphological characteristics consistent with apoptosis or 
necrosis, as mentioned in Section 2.6.2.    
 
Figure 5.49 shows the morphological changes observed in MCF-7 cells following 
48 hour treatment with cisplatin and the A. afra acetone extract, respectively, 
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followed by staining with DAPI.  As mentioned in Section 2.6.2., chromatin 
condensation (Figure 5.49; Aa, arrow 3) and nuclear fragmentation (Figure 5.49; 
Ab, arrow 4) leading to the formation of apoptotic bodies, are hallmarks of cells 
undergoing apoptosis.  Variation in the intensity of fluorescence between 
apoptotic cells and non-apoptotic cells due to chromatin condensation in the 
former, has also been observed (Figure 5.49; A[a-c] and B[a-c], arrow 2) for cells 
treated with cisplatin as well as the A. afra acetone extract.  Non-apoptotic cells 
are indicated in Figure 5.49 (A[a-c] and B[a-c], arrow 1).  Untreated MCF-7 cells 
were also stained with DAPI and observed during fluorescence microscopy for 
any morphological changes indicative of apoptosis, however, neither apoptotic 
cells nor nuclear fragmentation was observed, as was expected.  Similarly, MCF-
7 cells were also stained with PI in order to rule out the possibility of cell death 
through induction of necrosis.  Staining with PI was not observed for cells treated 
with cisplatin or A. afra acetone extract, indicating that neither of the two induced 
significant necrosis during the treatment period.  Furthermore, necrotic cells were 
not observed amongst the MCF-7 cells cultured in media lacking any cisplatin or 
extract.  Permeabilised cells stained with DAPI as well as PI, however, indicating 
that the method was accurate. 
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Results obtained from the MTT assay (Section 5.3.2.) performed as described in 
Section 4.3.4. showed the A. afra acetone extract to be toxic in MCF-7 cells.  The 
reasonable correlation in the DAPI staining pattern of MCF-7 cells treated with 
cisplatin, which is known to induce apoptosis in cancer cells, and the A. afra 
  
  
  
B 
a a 
b b 
c c 
Figure 5.49: Morphological changes in MCF-7 cells after 48 hours exposure to 
cisplatin [A(a-c)] and A. afra acetone extract [B(a-c)], followed by DAPI staining.  
1→: normal cells; 2→: apoptotic cells; 3→: chromatin condensation; 4→: nuclear 
fragmentation. 
A 
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acetone extract (Figure 5.49), respectively, suggests the A. afra acetone extract 
to induce apoptosis in MCF-7 cells, rather than necrosis.  The observation of 
certain cellular morphological characteristics in MCF-7 cells treated with the A. 
afra acetone extract, for example variation in the intensity of fluorescence 
between apoptotic cells and non-apoptotic cells due to chromatin condensation in 
the former (Figure 5.49; A[a-c] and B[a-c], arrow 2), and the absence of PI 
staining of MCF-7 cells treated with the plant extract, further supports this notion. 
   
 
5.3.4. Determination of the degree of toxicity of the A. afra acetone  
          extract in PBMC’s, compared to MCF-7 cells, utilising the  
          CellTiter-Blue® assay 
 
A number of anticancer drugs currently employed in the clinical setting have 
been derived from botanical sources, and examples of these have been given in 
Section 2.6.4.  Nonetheless, an anticancer drug that is safe, economic to develop 
and site-specific is still elusive (Srivastava et al., 2005).  Thus far it has been 
shown that the A. afra acetone extract inhibits the growth of C. albicans, S. 
aureus and B. cereus, as well as showing toxicity in HT-29 cells, HeLa cells and 
MCF-7 cells, and inducing apoptosis in the latter.  However, as stated earlier, a 
plant extract or compound isolated from such an extract showing anticancer 
activity is not only required to induce apoptosis in malignant cells as opposed to 
necrosis, it also needs to do so selectively in malignant cells without affecting 
normal healthy cells. 
 
In order to determine the degree of toxicity of the A. afra acetone extract in 
normal human cells, PBMC’s were isolated from a healthy adult male and treated 
at various concentrations of the extract for 48 hours, as described in Section 
4.3.6.  The CellTiter-Blue® assay, a flourometric method for the estimation of the 
amount of viable cells present in a sample after exposure to a test compound, 
was used to determine the percentage cell viability and percentage cell death of 
 180 
PBMC’s following exposure to the A. afra acetone extract.  Screening of the 
extract, which totaled eleven dilutions and ranged in concentration between 500 
µg/ml and 2.65 µg/ml, was performed in triplicate, while three different controls 
were simultaneously run in duplicate, the first control having consisted of PBMC’s 
in media only, the second having consisted of media without extract or cells and 
acting as a background fluorescence control, and the third control having 
consisted of the eleven extract dilutions in media lacking PBMC’s, which acted as 
a test compound control to rule out any fluorescence of the extract itself which 
might have interfered with the assay.   
 
It should be mentioned here that during analysis of the raw fluorometric data 
obtained from the assay, it was noted that fluorescence values for the test 
compound control, which consisted of medium and serial dilutions of the extract 
and lacking PBMC’s, were slightly increased at an extract concentration of 500 
µg/ml and gradually decreased with a decrease in extract concentration, to the 
final concentration of 2.65 µg/ml, as compared to the values obtained for the 
background fluorescence control, which remained consistent.  This was 
indicative of either the extract itself possessing fluorescent properties, or the 
extract interfering with the chemistry of the assay reagent.   
 
As the aim of the assay was to measure the amount of fluorescence emitted after 
exposure of the PBMC’s to the extract, with the amount of fluorescence being 
directly proportional to the amount of living PBMC’s present, any fluorescence 
due to the extract or any sources other than the reduction of resazurin to 
resorufin by PBMC’s would produce elevated fluorometric readings.  Thus, in 
order to exclude fluorescence of the extract itself, the mean fluorescence values 
of each of the duplicate sets of the eleven extract dilutions in the test compound 
control were subtracted from each of the three corresponding extract dilution 
fluorescence readings obtained from the three triplicate sets of PBMC’s treated 
with the respective extract dilutions.  The percentage of PBMC viability, as well 
as the percentage cell death was determined by expressing the final 
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fluorescence values of the extract dilutions containing PBMC’s as a mean 
percentage ± standard deviation (SD) of the mean fluorescence readings 
recorded for the untreated cell control representing 100% cell viability. 
 
 
   
  
  
 
 
   
 
 
 
 
 
 
 
Figure 5.50 allows for the comparison of the toxicity shown by the A. afra 
acetone extract towards MCF-7 cells and PBMC’s, respectively.  Both PBMC’s 
(Figure 5.50, blue plot) and MCF-7 cells (Figure 5.50, red plot) showed a similar 
degree of sensitivity for the extract up to an extract concentration of 
approximately 2.65 µg/ml.  PBMC’s, however, appeared to be less sensitive to 
extract concentrations ranging between 2.65 µg/ml and 15 µg/ml, compared to 
MCF-7 cells, which were more sensitive and showed lower levels of cell viability 
in this extract concentration range.  Regression analysis showed an IC50 of 4.54 ± 
1.07 µg/ml with a 95% confidence interval between 3.96 µg/ml and 5.21µg/ml 
(r2= 0.98) for PBMC’s treated with the A. afra acetone extract, compared to MCF-
7 cells, which had an IC50 of 2.65 ± 1.05 µg/ml with a 95% confidence interval 
between 2.39 µg/ml and 2.94 µg/ml (r2= 0.97) (Table 5.9).  Thus, although MCF-
7 were more sensitive to the extract at higher concentrations as compared to 
Figure 5.50: Comparison of the toxicity of A. afra acetone extract in 
MCF-7 cells and PBMC’s. 
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PBMC’s, it was only marginally so, indicating the extract to be toxic in both 
malignant cells, in this case MCF-7 cells, and normal human cells, in this case 
PBMC’s.  
 
 
5.3.5. Flow cytometry analysis of the effects of A. afra acetone extract on   
          the cell cycle of MCF-7 cells 
 
The effect of the A. afra acetone extract on the cell cycle of MCF-7 cells was 
investigated in order to determine during which phase of the cell cycle the extract 
exerts its effects.  MCF-7 cells separately treated with 2.65 μg/ml of the extract, 
10 μM of cisplatin (positive control), as well as untreated cells (negative control), 
were lysed and stained with PI as described in Section 4.3.7.   
 
 
 Figure 5.52: Percentages MCF-7 cells 
exposed to cisplatin (positive control) 
present during the different stages of the 
cell cycle. C: apoptotic cells; D: G1/G0 
phase; E: S phase; F: G2/M phase.   
 
Figure 5.51: Percentages untreated 
MCF-7 cells (negative control) present 
during the different stages of the cell 
cycle. C: apoptotic cells; D: G1/G0 phase; 
E: S phase; F: G2/M phase.   
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Figures 5.51 to 5.53 indicate the percentages of MCF-7 cells present in the G1/G0 
phase of the cell cycle (D), the S phase of the cycle (E) and the G2/M phase (F) 
for untreated cells, cells exposed to cisplatin and cells exposed to the A. afra 
acetone extract, respectively.  The percentages of apoptotic cells present in each 
of the cell samples are also indicated (C), with Figure 5.54 being a summary of 
Figures 5.51, 5.52 and 5.53.  Considerably more apoptotic cells were present in 
the cell sample exposed to the extract (10.9%) (Figure 5.53) compared to that 
present in the sample exposed to cisplatin (1.5%) (Figure 5.52) and untreated 
cells (1.2%) (Figure 5.51).  Of the 3 cell samples, cells exposed to the extract 
showed the highest percentage of cells present in the G1/G0 phase of the cycle 
(34.3%) (Figure 5.53), followed by untreated cells (33%) (Figure 5.51) and cells 
exposed to cisplatin (27.6%) (Figure 5.52).  The cell sample exposed to cisplatin 
contained the highest percentage of cells present in the S phase (27.2%) (Figure 
5.52), while cells exposed to the extract showed the second highest percentage 
Figure 5.54: Variation in the percentage MCF-7 
cells present in each phase of the cell cycle 
between untreated cells, cells exposed to 
cisplatin and cells exposed to the A. afra acetone 
extract.   
Comparison of the percentage MCF-7 cells 
present in each stage of the cell cycle, as well as 
apoptotic cells, for the Negative Control, Cisplatin 
and A. afra  acetone extract
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Figure 5.53: Percentages MCF-7 cells 
exposed to the A. afra acetone extract 
present during the different stages of the 
cell cycle. C: apoptotic cells; D: G1/G0 
phase; E: S phase; F: G2/M phase.   
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of cells in the same phase (23.7%) (Figure 5.53), followed by untreated cells 
(18.6%) (Figure 5.51).  Finally, the untreated cell sample contained the highest 
percentage of cells in the G2/M phase of the cell cycle (16%) (Figure 5.51), 
followed by cells exposed to cisplatin (7.5%) (Figure 5.52) and cells exposed to 
the extract (5.4%) (Figure 5.53).  The fact that considerably more apoptotic cells 
were present in the sample exposed to the extract as compared to that present in 
the sample exposed to cisplatin, could signify A. afra acetone extract to be more 
active in MCF-7 cells in an anticancer capacity than cisplatin.  The finding of the 
extract’s toxicity in normal PBMC’s (Section 5.3.4.), however, indicates that A. 
afra may be unsuitable for the treatment of breast cancer due to non-selective 
toxicity.   
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CHAPTER 6 
DISCUSSION & CONCLUSION 
 
 
Mankind has been turning to Nature and, more specifically, its botanical 
resources to fulfill its most basic needs, including food, shelter, clothing and 
medicines for thousands of years, and will most probably continue doing so 
indefinitely.  As mentioned in the first chapter, the human race has recognised 
and has been using plants for their medicinal properties for at least the last 60 
millennia.     
 
An increasing interest in traditional medicines has been witnessed in recent 
years, largely due to the fact that conventional medicines are often ineffective 
and cause serious side effects.  Furthermore, the inaccessibility to conventional 
drugs by a large proportion of the global population and the belief that natural 
products are safe, also contribute to the popularity of traditional medicine.  
However, the emergence of new diseases, the development of drug resistance 
and the existence of pathologies for which no effective treatment has been 
developed as yet, has now necessitated the exploration of natural resources, 
especially botanical in kind, for the discovery of novel chemotherapeutic agents 
more than ever before (Cragg, Newman & Snader, 1997, p.57-58).   
 
With over 30 000 flowering plant species, which constitutes more or less one 
tenth of the global higher plant species (Stafford et al., 2005), and of which 3000 
to 4000 of these plant species are used for their medicinal properties by 
approximately 27 million South Africans (Fennell et al., 2004; Mulholland & 
Drewes, 2004), South Africa’s rich botanical biodiversity and resources 
possesses the potential to partially fulfill the need for novel chemotherapeutic 
agents in the ongoing fight against ailments for which no safe and effective 
treatment currently exists.       
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The present study sought to fulfill two main aims, which included: 
 
1. Scientifically determining the antimicrobial properties of the two medicinal 
plants G. incanum and A.  afra, and comparing the antimicrobial properties of 
A. afra to those of its European counterpart, A. absinthium, and  
2. Scientifically determining the anticancer properties of G. incanum and A. afra, 
and comparing the anticancer properties of A. afra to those of A. absinthium. 
 
 
Using the correct extractant plays an important role in the retrieval and isolation 
of biologically active compounds from plant materials.  The literature reports on 
various extractants used to extract biologically active compounds from plants.  
There appears to be relative variation in the amount of active compounds 
extracted when different extractants are used.  Water is reported to be routinely 
used by traditional healers in the extraction process (Lin et al., 1999; Shale et al., 
1999).  Other solvents which have been used in various studies, with varying 
degrees of success mostly surpassing that of water, include ethanol, methanol, 
hexane, chloroform, petroleum ether, methylene dichloride, ethyl acetate and 
methanol-chloroform-water mixture (Eloff, 1998; Eloff, 1999; George et al., 2001; 
Lin et al., 1999; Martini & Eloff, 1998; Shale et al., 1999).  Shale et al. (1999) 
found methanol and water extracts to possess higher antimicrobial activity than 
hexane extracts, while Lin et al. (1999) found methanol extracts to show the most 
potent antimicrobial activity.  In his study, Which extractant should be used for 
the screening and isolation of antimicrobial components from plants, Eloff (1998) 
reports that acetone was the best extractant, followed by methanol-chloroform-
water mixture, methylene dichloride, methanol, ethanol and finally water.  
However, this does not necessarily indicate water to be an ineffective extractant 
for the preparation of traditional medicines.  Shale et al. (1999) report that a 
dosage of traditional medicine for adults may be up to 4 cups a day.  Considering 
this dosage, water may very well be an effective extractant to use in the 
preparation of a traditional remedy.  A four cup dosage of e.g. methanol- or 
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hexane extracts would be more concentrated and potentially dangerous.  In 
addition, methanol and hexane may extract higher concentrations of other 
potentially toxic compounds.  Ultimately, the choice of solvent should depend on 
the purpose for which the extract is to be used.  If all the chemical constituents of 
an extract are to be evaluated, solvents with increasing dielectric constants 
should be used.  If the extract is to be used in antimicrobial screening, it is 
important that the solvent is not toxic to and does not inhibit the bioassay itself.  
However, if the aim is simply to isolate chemical compounds without any 
bioassays, toxicity of the solvent is irrelevant, as the solvent can be removed 
from the extract before isolation of compounds (George et al., 2001).   
 
Regarding the use of fresh vs. dried plant material being used in the preparation 
of extracts, Eloff (1998) stated that dried plant material is preferred by most 
scientists for the following reasons: 
 
• Fewer problems occur with the large scale extraction of dried plant material. 
• Differences in the water content of fresh plant material may affect the 
solubility or separation of compounds by liquid-liquid extraction. 
• Secondary plant metabolites need to be stable, especially if employed in 
antimicrobial screening. 
• Dried plant material is often used by traditional healers. 
 
The above information having been considered, it was decided to use distilled 
water, methanol and acetone as extractants and dried plant material as opposed 
to fresh plant material in the preparation of extracts of G. incanum, A. afra and A. 
absinthium.  
 
Screening of G. incanum, A. afra and A. absinthium for possible antimicrobial 
activity was performed in triplicate, and for each respective round of screening, a 
new set of extracts, including infusions, aqueous-, methanol- and acetone 
extracts of each plant was made during June 2007, September 2007 and 
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January 2008, respectively.  Since the anticancer studies performed required 
significantly less crude extract than the antimicrobial activity screening, only one 
set of infusions and extracts of the respective test plants was prepared for use in 
anticancer studies, the plant materials having been harvested and extracts 
prepared during January 2008. 
 
It was interesting to note variation in the percentage yield of crude extracts 
obtained amongst the three rounds of extract preparation for antimicrobial 
screening.  Generally, the second round of extractions, which was performed 
during September 2007 (spring), appears to have produced the lowest yields in 
all but four of the twelve respective infusion and extract preparations, as 
compared to yields obtained during the first (June 2007, winter) and thirds rounds 
(January 2008, summer).  On comparing the type of extractant used and yields 
obtained relative to the month of extract preparation, the use of boiling water as 
an extractant in the form of an infusion produced the highest yield in extract 
obtained for all three plants during January, 2008 (summer).  A similar pattern 
was observed when cold water was used as extractant in the form of a decoction.  
The highest yields of aqueous extract for G. incanum and A. absinthium were 
obtained during January 2008 (summer), although the A. afra aqueous extract 
produced the highest yield during June, 2007 (winter).   
 
A pattern also existed between the percentage crude extract obtained when 
methanol was used as the extractant and the month during which extraction was 
performed.  In all three of the plants, methanol as extractant produced the 
highest percentage crude extract yield during June, 2007 (winter).  The use of 
acetone as extractant produced similar results, with the highest percentage 
extract yield for A. afra and A. absinthium having been obtained during June 
2007 (winter).  However, the highest percentage extract yield obtained for G. 
incanum with acetone as extractant occurred during January, 2008 (summer).  In 
general, it would appear that water, having been used in the form of either an 
infusion or decoction, produced the highest percentage extract yields during 
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summer (January, 2008), while both methanol and acetone produced the highest 
percentage extract yields during winter (June, 2007).  One possible explanation 
for this might be the fact that plants do not consistently produce the same 
chemicals in the same quantities.  According to Prance (as cited in Buwa and 
Van Staden, 2007), various factors including internal biochemical factors, plant 
part extracted and external environmental factors such as climate, location, 
season and growth conditions all influence the effectiveness of medicinal plants.  
This may, for example, explain why the aqueous extract of A. afra produced a 
higher percentage extract yield during June 2007 compared to other times of the 
year when cold water was used as extractant (Figure 5.21).  Furthermore, it was 
also noted that when cold water was used as an extractant, for example, it 
produced the highest percentage extract yield for A. afra during June 2007, 
compared to G. incanum and A. absinthium, for which the highest respective 
yields were obtained during January 2008, with cold water as the extractant.  The 
finding of a particular extract, for example cold water, extracting different amount 
of phytochemicals from different plant species during different times of the year 
emphasises the importance of using the most appropriate extractant for a 
specific plant at the most appropriate time of year in order to obtain a maximum 
percentage extract yield.     
   
Previous studies have also shown variation in the amount of bioactive 
phytochemicals produced by plants depending on the age of the plant, the nature 
of the soil and processing of plant material (Buwa and Van Staden, 2007).  
Except for G. incanum, both A. afra and A. absinthium were harvested from the 
same location for each round of extract preparation for antimicrobial screening.  It 
is not known, however, if plants were exposed to fertiliser or other chemicals 
during this time, which could also have possibly influenced the amount of 
bioactive compounds produced by the plant.  The fact that harvesting and 
extraction occurred during three seasons for each round of extraction, could very 
well have influenced the quantity of phytochemicals produced by the plants.   
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Another possible explanation for the variation in the amount of plant extract 
yielded for each respective plant relative to the time at which it was extracted, 
could be the actual extractant used.  The literature reports on various extractants 
used with relative variation in the amount of active compounds extracted, as 
discussed above.  The possibility that one extractant could extract different 
quantities of phytochemicals produced by a plant depending on the season can 
thus not be overlooked.   
 
In order to investigate the antimicrobial properties of G. incanum, A. afra and A. 
absinthium, various ATCC strains and clinical isolates of C. albicans, E. coli, P. 
aeruginosa, E. faecalis, S. aureus and B. cereus were treated with the infusions, 
aqueous-, methanol- and acetone extracts of the three respective plants, using 
an agar dilution method as described in Section 4.2.3.2.  Extracts were tested at 
a concentration of 100 mg/ml.  It should be mentioned here that the solubility of 
the extracts in DMSO varied, and was not a factor of the type of extractant used.  
For example, the G. incanum infusion and aqueous extract were quite soluble, 
while the aqueous extracts of both A. afra and A. absinthium were considerably 
less so.  The same occurred when methanol and acetone were used as 
extractants.  It would appear that the solubility of the extract rather depended on 
the plant extracted and the method employed in taking the extracts to dryness, 
i.e. freeze drying vs. evaporation of the extract. 
 
Growth inhibition by plant extracts was observed mainly in strains of C. albicans, 
S. aureus and B. cereus, while inhibition of E. coli, P. aeruginosa and E. faecalis 
was not observed.  Strains of S. aureus and B. cereus were the most susceptible 
to inhibition, and had similar inhibition patterns.  All of the C. albicans strains 
screened consistently showed sensitivity to growth inhibition by all the G. 
incanum extracts.  A. study conducted by Scott et al. (2004, p.198) found that an 
aqueous extract of G. incanum showed no growth inhibition of C. albicans, unlike 
the findings of this study.  A possible explanation for this could once again be the 
variation in biologically active compounds produced by plants as a function of 
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internal and external factors.  The use of different scientific methods in the 
determining of microbial susceptibility producing a variation in results should also 
not be overlooked. Scott et al. (2004, p.187) made use of a disc diffusion assay 
to screen for antimicrobial activity, while an agar dilution assay was used during 
the present study (Section 4.2.3.2.).  A third possible explanation for this 
discrepancy could be the use of different strains of C. albicans by Scott et al. 
(2004, p.198) showing different susceptibility patterns compared to the strains 
used in this study.  C. albicans ATCC 10231 was tested for sensitivity to G. 
incanum in the study by Scott et al. (2004, p.195), while C. albicans ATCC 66027 
and nine other clinical isolates were used in the present study (Section 4.2.3.1.).    
 
C. albicans was not sensitive to any of the other plant extracts tested, with the 
exception of the A. afra acetone extract, the acetone possibly having extracted 
active compounds from the plant to which C. albicans was sensitive, while water 
and methanol might not have been able to extract the same compounds.  The C. 
albicans ATCC strain was also noted to be inhibited by the A. afra methanol 
extract.  Gundidza (as cited in Herbal Africa, n.d.) found C. albicans to be 
sensitive to inhibition by the essential oils of A. afra.  This seems to support the  
present findings as essential oil might very well have been present in the 
acetone- and methanol extracts of the plant.  The absence of inhibition of any of 
the C. albicans strains by any of the A. absinthium extracts in the present study 
also seems to be partially supported by a study conducted by Uzun et al. (2004).  
This study found an absence of inhibition of C. albicans growth when treated with 
ethanol- and petroleum ether extracts of A. absinthium.       
 
None of the E. coli, P. aeruginosa or E. faecalis strains showed sensitivity for any 
extract of the three respective plants.  Scott et al. (2004, p.198) reported similar 
results regarding the sensitivity of P. aeruginosa to an aqueous extract of G. 
incanum, while Uzun et al. (2004) reported the absence of growth inhibition of E. 
coli and P. aeruginosa following exposure to ethanol- and petroleum ether 
extracts of A. absinthium.  The failure of methanol- and acetone extracts of A. 
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absinthium to inhibit growth of E. coli and Pseudomonas fluorescens has been 
reported by Endoğrul (2002, p.271).  However, Williamson (2003, p.459) found E. 
coli to be inhibited by a methanol extract of A. absinthium, while Wilson (2004, 
p.51) found various strains of P. aeruginosa and Pseudomonas species to be 
inhibited by decoctions, aqueous-, methanol- and acetone extracts of A. afra.  
Variation in biologically active compounds produced by plants as a function of 
internal and external factors, the use of different scientific methods in the 
determination of microbial susceptibility as well as the use of different strains of 
E. coli and P. aeruginosa in these respective studies, could once again be 
possible explanations for the variation in findings amongst different studies.  
 
All ten strains of S. aureus were sensitive to growth inhibition by eight of the 
twelve extracts tested.  The infusion, aqueous- and methanol extracts of G. 
incanum inhibited growth of all the S. aureus strains, which is in part supported 
by the findings of Scott et al. (2004, p.192) that included inhibition of S. aureus by 
an aqueous extract of G. incanum.  Of the A. afra extracts screened, the infusion, 
methanol- and acetone extracts, with the exception of the aqueous extract, 
inhibited the growth of all the S. aureus strains.  An aqueous extract of A. afra 
was also ineffective in the inhibition of S. aureus when screened by McGaw et al. 
(2000), while Rabe and Van Staden (1997, p.84) found a methanol extract of A. 
afra to effectively inhibit S. aureus.  This, in part, supports the aforementioned 
findings.  It was expected that both the infusion and aqueous extract would have 
the same inhibition patterns since water was used as extractant in both cases.  
However, it could be possible that, since boiling water was used to prepare the 
infusion as apposed to cold water used for the aqueous extract, the boiling water 
was able to lyse plant cells and release bioactive compounds more efficiently 
than cold water.   
 
Of the A. absinthium extracts screened, only the methanol- and acetone extracts 
showed any inhibitory activity for S. aureus.  A study conducted by Uzun et al. 
(2004) found absence of growth inhibition of S. aureus when treated with 
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ethanol- and petroleum ether extracts of A. absinthium.  It is quite possible that 
methanol and acetone are able to extract compounds inhibitory to the growth of 
S. aureus which ethanol and petroleum ether can not.  This does not, however, 
explain the lack of inhibition of S. aureus following exposure to methanol- and 
acetone extracts of A. absinthium as reported by Endoğrul (2002, p.271).  Once 
again, the internal and external factors influencing the production of bioactive 
compounds by the plant must also be taken into account, as an extract might be 
able to extract active compounds from one plant of a species which is inhibitory 
to S. aureus growth, while the same compounds may not be present in another 
plant of the same species subjected to different intrinsic and extrinsic influences.         
 
The four strains of B. cereus showed sensitivity to the same extracts as the 
strains of S. aureus.  The infusion, aqueous- and methanol extracts of G. 
incanum inhibited growth of all four strains of B. cereus.  Literature appears to be 
rather limited in research conducted on the antimicrobial properties of G. 
incanum, and no previous research could be found to support these results.  The 
infusion, methanol- and acetone extracts of A. afra inhibited growth of all four B. 
cereus strains.  McGaw et al. (2000) has reported the inhibition of Bacillus 
subtilis by an ethanol extract of A. afra, while Mangena and Muyima (1999, 
p.294) found the essential oil of A. afra to be only slightly inhibitory to the growth 
of B. cereus.  Only the methanol- and acetone extracts of A. absinthium inhibited 
all four strains of B. cereus, thus it could be deduced that water is not an effective 
extractant of phytochemicals inhibiting the growth of B. cereus, and that acetone 
or methanol should rather be used instead.  None of the B. cereus strains 
showed any sensitivity to the acetone extract of G. incanum, the aqueous 
extracts of A. afra and A. absinthium or the infusion of A. absinthium.   
 
Evidence indicating the use of G. incanum, A. afra or A. absinthium in the 
treatment of specific microbial infections could not be found in the literature.  In 
general, all three plants are employed in the treatment of diseases in which 
microbial contamination could be a complication, or in the treatment of diseases 
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which could have been caused by any number of microbes.  A select number of 
the above findings might, however, support the use of the three plants in the 
treatment of certain ailments to an extent.  It must be stated here that traditionally 
the plants are extracted using water in some form or the other, instead of 
acetone or methanol, which might be toxic.  For this reason only the inhibition of 
an organism by the infusions and/or aqueous extracts of the plants can be 
interpreted as possibly supporting the traditional use of the plants for their 
medicinal properties.  Inhibition of C. albicans by the infusion and aqueous 
extract of G. incanum supports the traditional use of the plant in the treatment of 
urinary tract infections in females, of which C. albicans is occasionally the 
causative agent (Jensen et al., 1997, p.489).  Inhibition of B. cereus by the 
infusion and aqueous extract of G. incanum might also support the traditional use 
of the plant in treating diarrhea/gastroenteritis, provided the condition is caused 
by a B. cereus infection, which might occasionally be the case (Jensen et al., 
1997, p.273).  The traditional use of A. afra in the treatment of pimples and boils, 
of which S. aureus is often a causative agent, is supported by the inhibition of the 
organism by the infusion of the plant.       
 
In general, amongst the micro-organisms tested, the Gram positive organisms, 
with the exception of E. faecalis, showed a higher degree of sensitivity to 
inhibition by the plant extracts compared to the Gram negative organisms.  A 
possible explanation for this might be the presence of a lipopolysaccharide layer 
covering the peptidoglycan layer of the cell wall in Gram negative bacteria, which 
may render the cell considerably less permeable and consequently less 
susceptible to antimicrobial compounds as opposed to Gram positive organisms, 
which do not possess a lipopolysaccharide layer (Kumar et al., 2006).        
 
Although literature reporting on the traditional use of G. incanum, A. afra and A. 
absinthium being used in the treatment of cancer could not be found, various 
extracts of these three plants showed anticancer activity to one or more cancer 
cell line in variable degrees.  General anticancer activity of the infusions, 
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aqueous-, methanol- and acetone extracts of G. incanum, A. afra and A. 
absinthium were screened for at concentrations ranging between 500 µg/ml and 
10 µg/ml using the MTT assay, MCF-7 cells, HT-29 cells and HeLa cells (Section 
4.3.4.).  Cisplatin, a known anticancer agent which induces apoptosis in 
malignant cells, was used throughout as a positive control.  Cisplatin (Cl2H6N2Pt) 
acts by cross linking two nucleotide bases on a DNA molecule following the 
removal of two chloride ions.  The damaged DNA attracts HMG-1 and other DNA 
repair proteins which bind irreversibly to the distorted DNA molecule, making 
repair impossible and initiating apoptosis in the cell (Cisplatin, 2008).  Cisplatin is 
clinically used in the treatment of a wide array of neoplasms, including 
carcinomas, lymphomas, sarcomas and germ cell tumours, and was selected as 
a positive control for this study based on this information.   
 
Of the four G. incanum extracts tested against MCF-7 cells, the methanol extract 
showed the strongest inhibitory/cytotoxic activity with an IC50 of 19.16 ± 1.10 
µg/ml, followed by the aqueous extract, infusion and acetone extract, in order of 
decreasing activity.  HT-29 cells showed the highest degree of susceptibility to 
the aqueous extract of G. incanum with an IC50 of 53.38 ± 1.06 µg/ml, followed by 
the infusion, methanol- and acetone extracts, in order of decreasing activity.  The 
same toxicity pattern was observed in the case of HeLa cells as was seen with 
MCF-7 cells, with HeLa cells having shown the highest degree of susceptibility to 
the methanol extract of G. incanum with an IC50 of 13.71 ± 1.06 µg/ml, followed 
by the aqueous extract, infusion and acetone extract, in order of decreasing 
activity.  The finding that the aqueous extract showed the highest degree of 
toxicity in HT-29 cells as apposed to the methanol extract, as was the case with 
MCF-7 cells and HeLa cells, could be explained by the possibility that water in 
the form of an aqueous extract was able to extract a phytochemical or 
phytochemicals synergistically being more toxic towards HT-29 cells than to 
MCF-7 cells or HeLa cells.  It should also be taken into account that the 
metabolism of HT-29 cells could differ from that of MCF-7 cells and HeLa cells, 
and that an aqueous extract of G. incanum could possibly contain compounds 
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which activate the apoptotic- or cell death pathway signals in HT-29 cells at sites 
different to and more susceptible to influence by phytochemical compounds 
present in the aqueous extract, as compared to MCF-7 cells and HT-29 cells, in 
which case the methanol extract could have contained compounds affecting 
different points in the apoptotic pathway more susceptible to influence as 
compared to compounds present in the aqueous extract.  Cytotoxicity shown by 
an aqueous extract of G. incanum in HeLa cells has been reported previously 
(Treurnicht, as cited in Scott et al., 2004, p.208), though it was not indicated 
whether this was compared to the cytotoxic effects of other extracts of the plant.  
 
An interesting pattern was observed in the screening of the A. afra extracts for 
toxicity in all three cell lines.  The acetone extract produced the highest degree of 
toxicity in all three cell lines screened, followed by the methanol extract, infusion 
and aqueous extract.  In the case of MCF-7 cells, the acetone extract showed an 
IC50 of 2.65 ± 1.05 µg/ml.  In the case of HT-29 cells, the acetone extract showed 
an IC50 of 6.98 ± 1.06 µg/ml, while an IC50 of 6.54 ± 1.06 µg/ml was obtained for 
the acetone extract in HeLa cells.  Marginal variation was observed between the 
IC50 values of the three cell lines after exposure to the methanol extract, 
however, this variation increased significantly for cell lines treated with the 
infusion and aqueous extract, respectively.  This might be due to water not being 
able to extract the same compounds which showed such high levels of toxicity  
compared to when acetone and methanol are used as extractants.  The 
consistent pattern of toxicity amongst the three cell lines with regard to the 
different extracts is strongly indicative of a common biochemical mechanism of 
action of a compound(s) present in the respective extracts, amongst each of the 
three cell lines.  Thus the active compound(s) in e.g. the acetone extract of A. 
afra probably affect the same or similar site(s) in all three cell lines, indicating the 
possibility that the compound(s) could be used in the treatment of various 
malignancies as opposed to only one or two types.  Inhibition of growth of HeLa 
cells by an aqueous extract of A. afra has been reported previously (SA Health 
Info, as cited in Mukinda & Syce, in press; Treurnicht, as cited in Scott et al., 
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2004, p.210), and supports the inhibition of HeLa cells by the aqueous extract as 
found in this study. 
 
Unlike the case of susceptibility of MCF-7 cells, HT-29 cells and HeLa cells for 
the extracts of A. afra, no pattern in the toxicity of A. absinthium extracts in the 
three cell lines could be distinguished.  In the case of MCF-7 cells, the acetone 
extract of A. absinthium showed the highest degree of toxicity with an IC50 of 6.11 
± 1.10 µg/ml, followed by the methanol extract, infusion and aqueous extract, in 
order of decreasing activity.  As was the case with G. incanum extracts, the 
degree and order of toxicity shown by the four A. absinthium extracts varied with 
regard to HT-29 cells, compared to MCF-7 cells.  The acetone extract showed 
the highest degree of toxicity in HT-29 cells, with an IC50 of 12.29 ± 1.05 µg/ml, 
followed by the methanol extract, aqueous extract and infusion, in order of 
decreasing activity.  In the case of HeLa cells, the methanol extract showed the 
highest degree of toxicity with an IC50 of 20.96 ± 1.07 µg/ml, followed by the 
acetone extract, infusion and aqueous extract, in order of decreasing activity.  
 
It was noticed that the acetone- and methanol extracts, respectively, showed the 
highest and second highest degrees of toxicity in two of the three cell lines, with 
the exception of the methanol extract having showed the highest degree of 
toxicity, followed by the acetone extract, in HeLa cells.  This might suggest that 
methanol and acetone either extract the active compound(s) in larger quantities 
or more effective combinations as opposed to water, or that they are able to 
extract compounds which are considerably more toxic to malignant cells as 
opposed to the compounds extracted by water. 
 
It was interesting to note that a pattern of susceptibility existed in the cell lines 
most susceptible to each of the four G. incanum extracts.  Of the MCF-7 cells, 
HT-29 cells and HeLa cells, the latter was consistently the most sensitive to 
toxicity of each of the G. incanum extracts, followed by the MCF-7 cells and HT-
29 cells, in order of decreasing sensitivity.  The results possibly indicate that, if 
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used to treat malignancy, G. incanum would probably give more favorable results 
in the treatment of cervical cancer as opposed to breast cancer or colon cancer. 
 
Concerning the cell line most susceptible to any one of the four A. afra extracts 
screened, it was found that HeLa cells showed the highest degree of 
susceptibility to the A. afra infusion compared to MCF-7 cells and HT-29 cells, 
while MCF-7 cells showed the highest degree of susceptibility to the aqueous-, 
methanol- and acetone extracts.  Of the three cell lines, HT-29 cells were the 
least sensitive to any of the four A. afra extracts, as was the case with all four of 
the G. incanum extracts.  With regard to cisplatin, however, it was noted that not 
HT-29 cells but rather MCF-7 cells appeared to be the least sensitive cisplatin, 
while HT-29 cells and HeLa cells showed a similar sensitivity pattern (Figure 
5.47). 
 
With regard to the four A. absinthium extracts screened, MCF-7 cells were the 
most susceptible to three of the four extracts, namely the infusion, methanol- and 
acetone extracts, while HT-29 cells appeared to be the most susceptible to the 
aqueous extract.  The fact that, apart from the aqueous extract of A. absinthium, 
HT-29 cells were consistently the least sensitive to all the other extracts 
screened, could indicate that the aqueous extract of A. absinthium probability 
contained compounds more toxic to HT-29 cells than to MCF-7 cells and HeLa 
cells, compared to the other extracts.  
 
Another interesting observation was that certain extracts appeared to stimulate 
rather than inhibit the growth of the malignant cells against which they were 
screened, at lower concentrations of the respective extracts.  Based on the MTT 
assay, the G. incanum acetone extract stimulated the growth of MCF-7 cells at 
concentrations of 25 µg/ml and less (Figure 5.22), while the aqueous extract 
stimulated the growth of HT-29 cells at the same extract concentrations (Figure 
5.23).  The A. afra infusion and methanol extract both promoted the growth of 
HT-29 cells at the respective concentrations of 25 µg/ml and less (Figure 5.27) 
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and 6.25 µg/ml and less (Figure 5.28), while the A. afra infusion, aqueous extract 
and methanol extract all promoted the growth of HeLa cells at the respective 
concentrations of 25 µg/ml and less (Figure 5.29), 125 µg/ml and less (Figure 
5.29) and 3.125 µg/ml and less (Figure 5.30).  The A. absinthium infusion 
stimulated the growth of HT-29 cells at a concentration of 31.25 µg/ml and less 
(Figure 5.33), while the infusion, aqueous extract and acetone extract all 
promoted the growth of HeLa cells at the respective concentrations equal to or 
less than 31.25 µg/ml, 125 µg/ml and 6.25 µg/ml (Figure 5.34).  The implication 
of these results is that, although none of the above extracts are reported for 
traditional use in the treatment of malignancy, growth of breast cancer, colon 
cancer and cervical cancer could be promoted rather than inhibited should the 
above extracts be used, at the low concentrations, stimulating malignant growth.  
As previously mentioned, traditional healers aim to restore balance and a general 
sense of well being of a patient on both a mental and physiological level.  For this 
reason a combination of plants are usually prescribed to patients by traditional 
healers. This is because it is believed that the synergistic or additive effects of 
the correct combination of plants will be more successful in treating a patient 
than would be a single drug (Gurib-Fakim, 2006).  The possibility therefore exists 
that a person taking a traditional preparation containing one or more of the above 
extracts at a concentration which stimulates malignant cell growth could 
unknowingly contribute to growth of a known or underlying malignancy.  The 
above results are those of in vitro testing, however, and in vivo testing needs to 
be conducted to determine the promotion of malignant cell growth by these 
extracts at their respective concentrations.  
 
For the purpose of this study, it was decided to investigate the mechanism of 
toxicity of the plant extract showing the highest degree of toxicity, namely that of 
the A. afra acetone extract in MCF-7 cells (IC50 of 2.65 µg/ml).   MCF-7 cells were 
separately treated with cisplatin at a concentration of 10 µM which served as a 
positive control, as well as with the A. afra acetone extract at a concentration of 
2.65 µg/ml.  The negative control consisted of untreated MCF-7 cells.  Treated 
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and untreated cells were stained with DAPI and PI as discussed in Section 
4.3.5.1. and observed during fluorescence microscopy for the presence of 
apoptotic and necrotic cells.  
   
As previously mentioned, chromatin condensation and nuclear fragmentation 
leading to the formation of apoptotic bodies are both hallmarks of cells 
undergoing apoptosis.  Both these hallmarks were observed for cells treated with 
cisplatin.  Cells exposed to cisplatin did not stain with PI, indicating that necrotic 
cells were not present.  Untreated MCF-7 cells did not stain with either DAPI or 
PI, respectively, indicating that neither apoptosis nor necrosis occurred amongst 
these cells, which was expected.   
 
MCF-7 cells exposed to the A. afra acetone extract and stained with DAPI 
showed signs of chromatin condensation and fluoresced considerably brighter 
(Figure 5.49; B[a-c], arrow 2) than non-apoptotic cells which were also present 
(Figure 5.49; B[a-c], arrow 1).  Staining with PI was not observed for cells treated 
with the A. afra acetone extract, indicating that the decrease in cell viability as a 
result of exposure to the extract observed during the MTT assay was not due to 
necrosis being induced in the cells.  It is possible, however, that the extract could 
be toxic to MCF-7 at higher concentrations and induce necrosis as apposed to 
apoptosis.  Optimal dosage concentrations are still to be established.   
 
The reasonable correlation in the DAPI staining pattern of MCF-7 cells, treated 
with cisplatin and the A. afra acetone extract, respectively, the observation of 
apoptotic cells fluorescing brighter than non apoptotic cells amongst the MCF-7 
cells treated with the plant extract, and the absence of PI staining of MCF-7 cells 
treated with the plant extract, are all indicative of apoptosis being the mode of 
cell death induced in MCF-7 cells treated with the A. afra acetone extract, as 
apposed to necrosis.  
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The toxicity of the A. afra acetone extract in normal, differentiated human cells 
was investigated by exposing PBMC’s to different concentrations of the extract, 
which varied between 500 µg/ml and 2.65 µg/ml, for 48 hours using the CellTiter-
Blue® assay as described in Section 4.3.6.   
 
Both PBMC’s and MCF-7 cells showed a similar degree of sensitivity for the 
extract up to an extract concentration of approximately 2.65µg/ml.  PBMC’s 
appeared to be less sensitive to extract concentrations ranging between 2.65 
µg/ml and 15 µg/ml as compared to MCF-7 cells.  MCF-7 cells were more 
sensitive and expressed lower levels of cell viability in this extract concentration 
range, however.  Regression analysis indicated an IC50 of 4.54 ± 1.07 µg/ml with 
a 95% confidence interval between 3.96 µg/ml and 5.21 µg/ml (r2= 0.98) for 
PBMC’s treated with the A. afra acetone extract, compared to MCF-7 cells, which 
had an IC50 of 2.65 ± 1.05 µg/ml with a 95% confidence interval between 2.39 
µg/ml and 2.94 µg/ml (r2= 0.97).  Thus, although MCF-7 cells were more 
sensitive to the extract at higher concentrations as compared to PBMC’s, it was 
only marginally so, indicating the extract to be toxic in both malignant cells, in this 
case MCF-7 cells, and normal human cells, in this case PBMC’s.  Mukinda 
(2005, p.122) conducted a study on the toxicity of an aqueous extract of A. afra 
administered via both the oral route and intraperitoneal route in rats and mice, 
and concluded that acute doses of A. afra aqueous extract are relatively non-
toxic in mice, while chronic doses are safe when administered to rats.   
 
In the final part of this study, the effect of the A. afra acetone extract on the cell 
cycle of MCF-7 cells was analysed and compared to that of cisplatin, as well as 
untreated cells.  MCF-7 cells exposed to the extract showed more apoptosis 
(10.9%) compared to cells exposed to cisplatin (1.5%) and untreated cells 
(1.2%).  Cells in the sample exposed to the extract also showed the highest 
percentage of cells in the G1/G0 phase of the cell cycle (34.3%), compared to 
cells exposed to cisplatin (27.6%) and untreated cells (33%).  A small difference 
was seen in the percentage of cells present in the S phase for cells exposed to 
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cisplatin (27.2%), compared to cells exposed to the extract (23.7%), while 
untreated cells showed the lowest percentage of cells in the S phase (18.6%).  
Untreated cells showed the highest percentage cells in the G2/M phase (16%), 
which was significantly more than for cells exposed to cisplatin (7.5%) and cells 
exposed to the extract (5.4%).  The G2/M phase of the cell cycle is characterised 
by cellular growth and proliferation through mitosis,  This is inhibited by cisplatin 
and the A. afra acetone extract through the induction of apoptosis in MCF-7 cells 
(Section 5.3.3.).  It was to be expected that the untreated cell sample would have 
relatively more cells undergoing mitosis compared to cells exposed to cisplatin 
and the extract, respectively.  The correlation in the percentage cells in the S 
phase of the cell cycle of cells exposed to cisplatin (27.2%) and cells exposed to 
the extract (23.7%), could indicate that the extract exerts its inhibitory effect(s) 
during or just prior to the S phase of the cell cycle.  This is further supported by 
the relatively small percentage of cells present in the G2/M phase for cells, 
respectively, exposed to cisplatin and the extract, compared to untreated cells.  
The fact that considerably more apoptotic cells were present in the sample 
exposed to the extract compared to that present in the sample exposed to 
cisplatin, could signify A. afra acetone extract to be more active in MCF-7 cells in 
an anticancer capacity than cisplatin.   
 
The aims of this study included investigating the antimicrobial properties of G. 
incanum and A. afra, and comparing the antimicrobial activity of the latter to that 
of A. absinthium, as well as investigating the anticancer properties of G. incanum 
and A. afra, and comparing the anticancer activity of the latter to that of A. 
absinthium.  Results obtained from antimicrobial screening indicated that all three 
plants possess antimicrobial properties for certain microbes, with activity being 
largely dependent on the extract used.  In general, Gram positive organisms 
were more susceptible to inhibition than Gram negative organisms, with the 
exception of E. faecalis.  A. afra and A. absinthium showed relative similarity in 
their inhibition patterns of certain microbes, especially in the case of the 
methanol- and acetone extracts.   
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All of the extracts of G. incanum, A. afra and A. absinthium possessed anticancer 
activity in MCF-7 cells, HT-29 cells and HeLa cells to varying extents, which 
varied with the extract and cell line screened.  A. afra and A. absinthium showed 
similar inhibitory patterns, with the methanol- and acetone extracts being the 
most potent inhibitors of each of the respective cell lines in general, compared to 
the infusions and aqueous extracts.  The acetone extract of A. afra proved to be 
the most effective inhibitor with the lowest IC50 having been expressed in MCF-7 
cells.  Fluorescence microscopy indicates that the acetone extract of A. afra 
induces apoptosis in MCF-7 cells as apposed to necrosis, and the results are 
comparable to those obtained from cells exposed to cisplatin.   
 
The A. afra acetone extract proved to be toxic to human PBMC’s, with PBMC’s 
only marginally less susceptible to toxicity by the extract compared to MCF-7 
cells at the same extract concentrations.  Cell cycle analysis of MCF-7 cells 
exposed to the IC50 of the A. afra acetone extract indicated that the extract 
induced apoptosis in considerably more cells compared to cells exposed to 
cisplatin.  A correlation existed in the percentage MCF-7 cells in the S phase of 
the cell cycle of cells exposed to cisplatin and cells exposed to the extract.  This, 
in conjunction with the relatively small percentage of cells present in the G2/M 
phase of the cell cycle for cells exposed to cisplatin and the extract compared to 
untreated cells in which cellular growth and mitosis could continue unhampered 
during the G2/M phase, suggests that the A. afra acetone extract probably exerts 
its inhibitory effect(s) during or just prior to the S phase of the cell cycle.     
 
It is thus concluded that G. incanum, A. afra and A. absinthium do possess 
antimicrobial and anticancer properties for at least certain microbes and 
malignant cell lines, respectively, and that this activity is largely dependent on the 
extract used.  It is further concluded that A. afra and A. absinthium are similar in 
their inhibitory patterns against, at least, the micro-organisms and malignant cells 
screened during this study, and that this is once again a factor of the extract 
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used.  However, further studies are required in order to gain more clarity as to 
the specificity and biochemical mechanisms responsible for the antimicrobial and 
anticancer properties of these three plants.  As mentioned previously, the 
phytochemical profile of a plant may vary from one specimen to another, and is 
largely dependent on internal- and external influences.  A standardised protocol 
for plant collection and preparation needs to be established in order to rule out 
any discrepancies in the activity of the plants due to internal- and external factors 
and different analytical assays used.  The variation in antimicrobial and 
anticancer activities between different extracts of a specific plant as was found in 
this study strongly suggests that different extractants extract bioactive 
compounds from plants in different ratios and combinations with possible 
antagonistic or synergistic effects, which could greatly affect its medicinal value.  
It is, therefore, of utmost importance that the extractant which produces the most 
effective combination of bioactive compounds for each of the three plants be 
identified, and that extraction procedures are standardised.  It is also possible 
that different antimicrobial and anticancer screening methods could produce 
different results, which should be taken into account when the current results are 
compared to previous findings.  The possible loss of volatile components present 
in the extracts during freeze drying and evaporation might have produced results 
different from those obtained in studies where other methods of extract drying 
were employed. 
 
The bioactive compounds responsible for antimicrobial and anticancer activities 
of the three plants need to be identified and isolated, and it should be taken into 
account that it might possibly be the synergistic activity of two or more 
compounds responsible for the medicinal properties of the three plants.  It should 
also be taken into account that results obtained from in vitro assays may not 
necessarily be reproducible in vivo due to the metabolic processes of the test 
subject.  It is, therefore, suggested that the extracts which showed anticancer 
and antimicrobial activity during this study be tested in vivo, and that their toxicity 
patterns and mutation-inducing capacities be established.   
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With regards to the antimicrobial activities of the respective plant extracts, 
minimum inhibitory concentrations (MIC’s) of the various extracts which proved to 
have antimicrobial activity for the respective susceptible microbes need to be 
determined, the optimal dose concentrations established and the antimicrobial 
activity of the extracts for other pathogenic micro-organisms should be 
investigated.  With regard to the anticancer activity of the respective extracts, the 
optimal dosages of the extracts need to be determined, time controlled cell cycle 
analysis needs to be performed in order to establish the amount of time 
necessary of optimal inhibition of malignant cellular proliferation, the anticancer 
activities of the respective extracts in malignant cells other than those which were 
screened for in this study needs to be investigated, and the toxicity profiles of the 
extracts for human cells other than PBMC’s should be determined.   
 
To date, considerable progress has been made in the identification and isolation 
of bioactive phytochemicals which has proven to be of immeasurable value to 
mankind in its continuing fight against pathogens and disease.  The emergence 
of multiple drug resistant micro-organisms, the ever growing and threatening 
menace of diseases such as HIV/AIDS and malaria, unsanitary conditions and 
poverty in many countries across the globe and the unhealthy sedentary 
lifestyles adopted by many individuals in especially the First World countries 
have now, however, made it more important than ever to develop alternative, 
cheap yet effective and safe medicinal compounds for human consumption.  If 
done in a sustainable manner, mankind may be able to continue taking 
advantage of the wealth of medicinal compounds nature has to offer when our 
own devices fail.   
 
 
“The reasonable man adapts himself to the world; the unreasonable one persists 
in trying to adapt the world to himself.  Therefore, all progress depends on the 
unreasonable man” (Bernard Shaw).    
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APPENDIX 1 
 
 
Tables 1, 2 and 3 indicate the weights of plant materials used (fresh and dried), 
the weights of infusions and crude extracts after freeze drying and evaporation, 
as well as the percentage yields of extracts obtained for each of the three 
respective rounds of infusion and extract preparation for antimicrobial screening. 
 
Table 1: Weights of plant material used, weights of infusions and crude extracts 
after freeze drying and evaporation, and the percentage yields of extracts 
obtained after the initial round of extract preparation for antimicrobial screening, 
June 2007 
 
 
 
 
 
 
 
 
 
Extract Geranium 
incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Weight 
of 
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram)  
Yield % 
(w/w) 
Weight 
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Weight 
of leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Infusion 
(Fresh 
leaves 
used) 
6.012  0.326 5.42 14.000  0.402 2.87 14.000  0.342 2.44 
Aqueous 
extract 
(Dry leaves 
used) 
4.473  0.386 8.63 12.147  1.196 9.85 12.463  1.117 8.96 
Methanol 
extract 
(Dry leaves 
used) 
4.473  0.404 9.03 12.147 1.444 11.89 12.463  1.243 9.97 
Acetone 
extract 
(Dry leaves 
used)  
4.473  0.059 1.32 12.147  0.839 6.91 
 
12.463  1.003 8.05 
Table 2: Weights of plant material used, weights of infusions and crude extracts 
after freeze drying and evaporation, and the percentage yields of extracts 
obtained after the second round of extract preparation for antimicrobial 
screening, September 2007. 
 
Table 3: Weights of plant material used, weights of infusions and crude extracts 
after freeze drying and evaporation, and the percentage yields of extracts 
obtained after the third round of extract preparation for antimicrobial screening, 
January 2008.  
Extract Geranium 
incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Weight 
of 
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Weight  
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Weight  
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Infusion 
(Fresh 
leaves 
used) 
6.012  0.101 1.68 14.000  0.522 3.73 14.000 0.639 4.56 
Aqueous 
extract 
(Dry leaves 
used) 
4.473  0.251 5.61 12.147  0.619 5.10 12.463 0.944 7.57 
Methanol 
extract 
(Dry leaves 
used) 
4.473  0.282 6.30 12.147  0.928 7.64 12.463 0.956 7.67 
 
Acetone 
extract 
(Dry leaves 
used)  
4.473  0.040 0.89 
 
12.147 0.666 5.48 
 
12.463  0.743 5.96 
Extract Geranium 
incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Weight 
of 
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram)  
Yield 
% 
(w/w) 
Weight 
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram)  
Yield 
% 
(w/w) 
Weight 
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram)  
Yield 
% 
(w/w) 
Infusion 
(Fresh leaves 
used) 
6.012  0.434 7.22 
 
14.000  1.414 10.10 
 
14.000  0.878 6.27 
 
Aqueous 
extract (Dry 
leaves used) 
4.473  0.591 13.21 
 
12.147  0.937 7.71 
 
12.463  1.299 10.42 
 
Methanol 
extract (Dry 
leaves used) 
4.473  0.141 3.15 
 
12.147  0.894 7.36 
 
12.463  1.239 9.94 
 
Acetone 
extract (Dry 
leaves used)  
4.473  0.257 5.75 
 
12.147  0.829 6.83 
 
12.463  0.797 6.40 
 
Table 4 indicates the weights of plant materials used (fresh and dried), the 
weights of infusions and crude extracts after freeze drying and evaporation, as 
well as the percentage yields of extracts obtained during the preparation of 
extracts used in anticancer studies. 
 
Table 4: Weights of plant material used, weights of infusions and crude extracts 
after freeze drying and evaporation, and the percentage yields of extracts 
obtained after the extract preparation for anticancer studies, January 2008 
  
 
Extract Geranium 
incanum 
Artemisia 
afra 
Artemisia 
absinthium 
Weight 
of 
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram)  
Yield % 
(w/w) 
Weight 
of  
leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Weight 
of leaves 
used 
(gram) 
Weight 
of 
extract 
(gram) 
Yield % 
(w/w) 
Infusion 
(Fresh 
leaves 
used) 
2.036 0.171 8.40 5.092 0.193 3.79 5.025 0.119 2.37 
Aqueous 
extract (Dry 
leaves 
used) 
1.000 0.150 15.00 1.000 0.115 11.50 
 
1.000 0.419 41.90 
Methanol 
extract (Dry 
leaves 
used) 
1.000 0.195 19.50 1.000 0.155 15.50 1.000 0.286 28.60 
Acetone 
extract (Dry 
leaves 
used)  
7.010 0.333 4.75 1.500 0.120 8.00 1.000 0.116 11.60 
